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Abstract 
Myostatin (Mstn), a member of the transforming growth factor-β super 
family, is a potent negative regulator of skeletal muscle mass. Studies delineating 
the function of Mstn have identified multiple signal transduction pathways that 
convey the Mstn signal. Mstn has been shown to influence canonical TGF-β, 
mitogen activated protein kinase (MAPK) and the PI3K/AKT signal transduction 
cascades. The discovery in our laboratory of a novel splice variant of Mstn (MSV) 
that opposes Mstn and stimulates the proliferation of myoblasts provided the 
impetus for the investigations in this thesis. The splicing of MSV was restricted to 
the Cetartiodactyl clade of mammals, and MSV may represent an intragenic 
regulator of Mstn. Thus, the studies undertaken in this thesis were to delineate the 
signalling pathways used by Mstn and MSV in order to understand how their 
opposing roles in myoblasts regulate myogenesis.  
Initially, microarray analysis was used to investigate the transcriptional 
responses of ovine myoblasts following exposure to recombinant Mstn 
(eukaryotic) and MSV (prokaryotic) protein. Mstn treatment induced changes in 
number of transcripts, with changes consistent with previous investigations, for 
example increased interlukin-6 (IL6) and decreased MyoD. In addition, a novel 
transcriptional target of Mstn, the β1 subunit of the Na+-K+-ATPase was 
discovered. Treatment of ovine myoblasts with recombinant MSV induced a 
plethora of transcriptional responses. IPA analysis suggested a number of these 
were due to LPS (endotoxin) contamination, which could be attributed to the 
production of this protein in E. coli. This was confirmed using the Limulus 
amebocyte lysate assay. Phase separation using Triton-X 114 proved an effective 
method for the removal of LPS from the MSV preparation. 
Western blot analysis was performed following the treatment of ovine 
myoblasts with Mstn and purified MSV. Consistent with previous myoblast 
studies Mstn stimulated canonical TGF-β (Smad) signalling and the p38 and ERK 
components of the MAPK signalling cascade. In contrast to previous studies, 
Mstn also stimulated AKT signalling, with specific phosphorylation of serine 473 
(AKTS473). In addition, Mstn altered the abundance of multiple myogenic 
transcription factors (MyoD, Myf5, MRF4, Pax7 and Mef2) and the abundance 
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and/or the phosphorylation of targets that have a metabolic role in skeletal muscle 
(rps6, 4EBP1 and p70S6K). Treatment with MSV increased the abundance of 
Smad 3, Myf5, 4EBP1 and stimulated AKTS473 and 4EBP1 phosphorylation. 
These data provided the foundation for confirmation of these pathways targeted 
by MSV in C2C12 myoblasts that stably expressed MSV.  
C2C12 cells expressing MSV had an increased proliferative capacity and 
showed increased mitochondrial activity (EZ4U assay) as compared to controls. 
These cells showed an increased abundance of the MRFs MyoD, MRF4 and 
Myogenin and an increased abundance or phosphorylation of signalling targets 
involved in canonical TGF-β, MAPK and PI3K/AKT signalling cascades. In 
addition, cells expressing MSV had an increased abundance and phosphorylation 
of acetyl co-enzyme A carboxylase (ACC) and 4EBP1, which have established 
roles in regulating metabolism and the synthesis of protein 
The significant overlap of processes influenced by the Na+, K+ ATPase 
complex and Mstn prompted an investigation on how Mstn regulates the β1 
subunit of the Na+, K+ ATPase. This transcriptional response was found to be 
dependent on the Smad pathway. In addition, these studies also show that Na+ K+ 
ATPase activity plays a role in proliferation and differentiation of ovine 
myoblasts and suggest that Mstn inhibits ion flow controlled through the function 
of this enzyme complex. 
In conclusion, these studies show that Mstn and MSV share a number of 
common signalling targets. In contrast to previous studies of Mstn, the stable 
expression MSV increases the activation of AKT signalling and
 
increases the 
abundance of key myogenic transcription factors. In addition, MSV increases the 
abundance and phosphorylation of ACC and 4EBP1, molecules involved 
regulating the synthesis of protein and fatty acids. In addition, the β1 subunit of 
the Na+ K+ ATPase, was identified as a novel transcriptional target of Mstn, with 
this regulation controlled through a Smad dependant mechanism. These data 
confirm the postulate that Mstn and MSV have divergent signalling functions and 
suggest a role for MSV in the control of oxidative metabolism.  
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Chapter One 
1  Review of Literature 
This thesis investigates the signalling pathway(s) of a novel splice variant 
of myostatin (MSV), discovered in this laboratory. The following chapter will 
review the current literature on the structure of skeletal muscle in mammals, the 
process of myogenesis, and signal transduction in skeletal muscle. A detailed 
review of myostatin (Mstn) will follow, covering the discovery of the Mstn gene 
and its splice variant, the structure of the gene, signal transduction events 
associated with Mstn, and the function of Mstn in myogenesis and metabolism. A 
section covering the basic intermediary metabolism of skeletal muscle is also 
included. The chapter concludes with the aims to be addressed in this thesis. 
1.1 Skeletal muscle  
1.1.1 Structure  
The myofibril is the basic contractile structure responsible for the 
contraction of muscle fibres. The smallest functional unit of a myofibril is the 
sarcomere, which occur in repetitive units. Approximately 10,000 sarcomeres 
linked end to end constitute a single myofibril. Each muscle fibre can contain 
hundreds or thousands of myofibrils, which span the length of the fibre and are 
physically attached to the outer membrane (sarcolemma) of the muscle fibre 
(Martini 2001). Myofibrils are composed of protein filaments, predominantly 
actin (thin filaments) and myosin (thick filaments), and a dynamic interaction 
between these two proteins provides the mechanical basis for muscle contraction 
(Martini 2001) (discussed later). The sarcoplasmic reticulum (analogous to the 
endoplasmic reticulum in undifferentiated myoblasts) surrounds each myofibril, 
and in conjunction with the network of transverse-tubules (t-tubules), is 
responsible for the propagation of an action potential and the subsequent release 
of Ca2+ required to initiate the contraction of skeletal muscle (see 1.1.2). The t-
tubules are contiguous with the surface of the sarcolemma and provide the 
structural framework required to evenly distribute an action potential for the co-
ordinated contraction of skeletal muscle (Martini 2001). The membrane network 
provided by the t-tubule and sarcolemma contains numerous specialised 
membrane micro-domains such as caveolae (Lapidos, Kakkar et al. 2004) the 
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dystrophin sarcoglycan complex (Murphy, Mollica et al. 2009), and the 
neuromuscular junction (Hezel, de Groat et al. 2010). These domains are 
important for the innervation and structural integrity of skeletal muscle. In 
addition, these domains play a role in the regulation of numerous proteins and 
protein complexes critical for signal transduction, the regulation of ion flow and 
the control of metabolite entry into skeletal muscle fibres (Clausen 2003; Fecchi, 
Volonte et al. 2006; Hezel, de Groat et al. 2010).  
In individual muscles, multiple fibres are grouped into bundles, termed 
fascicles. The sarcolemma encases each fibre, which, in turn, is surrounded by a 
delicate layer of connective tissue called the endomysium that ties adjacent fibres 
together. The perimysium surrounds the muscle fascicles and contains collagen 
and elastic fibres. The perimysium provides structural support for the fascicles, in 
addition it supports the blood vessels and nerves required to fuel and innervate the 
muscle fibres. The final layer is the epimysium, which is composed of a dense 
layer of collagen fibres that encapsulate the muscle and separate it from 
surrounding tissues. The tendon connecting the muscle to bone is a blend of 
connective tissue fibres from the endo-, peri- and epimysium layers. Tendon 
fibres are interwoven with bone periosteum and continue into the bone matrix, 
providing the firm attachment required for muscle contraction to move the bone(s) 
(Martini 2001).  Figure 1.1 shows a pictorial representation of skeletal muscle and 
an individual muscle fibre. 
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1.1.2 Function 
The basic structural unit of vertebrate skeletal muscle is the muscle fibre, a 
single multinucleated cell capable of shortening to produce mechanical force and 
thereby providing the basis of vertebrate locomotion. A neuronal action potential 
initiates the contraction of skeletal muscle, via axons that innervate muscle fibres 
at the neuromuscular junction (Reger 1958). At the neuromuscular junction, the 
muscle fibre and nerve form a synaptic cleft, which allows for the propagation of 
an action potential through the nerve and into the muscle via the motor end plate 
(Martini 2001). Arrival of an action potential at the neuromuscular junction 
A 
B 
Figure 1.1: The structure of skeletal muscle. A, cartoon showing 
the basic structure of skeletal muscle, source (Scime, Caron et al. 2009). B, a 
3-dimentional rendering of an individual skeletal muscle fibre source 
(www.wikipedia.org).  
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induces the exocytotic release of acetylcholine from the axon terminal, which 
migrates across the cleft to bind receptors at the motor end plate, the result of 
which is increased permeability of the membrane to sodium ions. The influx of 
sodium ions (Na+) generates an action potential in the fibre that propagates across 
the membrane surface and through the t-tubule system, this occurs with an almost 
equal and immediate efflux of potassium ions (K+) (Martini 2001). The influx of 
sodium ions initiates the release of Ca2+ from the terminal cisternae of the 
sarcoplasmic reticulum, which binds troponin, freeing the contractile apparatus 
and allowing actin/myosin cross-bridges to form for muscle contraction to 
proceed (Huxley 1971). Uncoupling of the actin myosin cross-bridges is an ATP 
dependant process, and on activation, the head of the myosin molecule pivots, a 
motion known as the ‘power stroke’ and ADP is released along with a free 
phosphate molecule. To disengage the cross-bridge requires the binding of 
another ATP molecule, which generates the energy required to break the cross-
bridge in addition to re-cocking the myosin head for the cycle to start again 
(Martini 2001). Thus muscle activity is closely linked to the metabolic status of 
the cell.  
1.1.3 Muscle fibre type 
Mammalian skeletal muscle is composed of a number of different fibre 
types, the proportions of which define fast and slow twitch skeletal muscle. 
Identification of the different fibre types has been carried out using a number of 
techniques. Most commonly, fibre types are classified based on the myosin heavy 
chain (MHC) isoform(s) they express. Four major fibre types have been identified 
in the adult skeletal muscles of small mammals using the MHC classification 
system, with additional isoforms identified in embryonic, foetal and in the head 
muscles (Schiaffino and Reggiani 1996; Pette and Staron 2000).  The four main 
fibre types are; slow type I, which are suggested to originate from the primary 
fibres formed during myogenesis in the embryo, and fast type IIA, B and X. 
Functionally, these MHC isoforms have been correlated with shortening velocity. 
Studies indicate that type IIB fibres have the fastest shortening velocity, with IIX, 
IIA and I progressively slower. Different muscle fibre-types also display different 
metabolic profiles, primarily in terms of preferred energy substrate. In general, 
type I fibres are considered oxidative, with type II fibres becoming progressively 
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more glycolytic in the following order: type IIA<X<B (Schiaffino and Reggiani 
2011). Embryonic, foetal and adult cell populations contain myoblasts that have 
the capacity to form various fibre types. For example, clonal cultures of 
embryonic chicken and mouse are heterogeneous with respect to their MHC 
profile (Cho, Webster et al. 1993). This suggests that myoblasts may be 
committed to a specific fibre type and this commitment is retained in the progeny 
cells. However, studies on clonal human myoblasts, demonstrated that all cultures, 
although heterogeneous in their MHC profile, had the ability to express ‘slow’ 
MHC during differentiation. This work also  highlighted that extrinsic factors, 
such as innervation, growth factors the existing muscle structure are likely to  play  
a role in the acquisition of muscle fibre type (Cho, Webster et al. 1993). In 
addition to fibres expressing a single MHC isoform, intermediate fibres that co-
express two or more MHC isoforms also exist. The MHC isoforms have been 
shown to form up to seven myofibre hybrids. Notably, type I, IIC (type I and IIA 
hybrid), IIA, IIAX (type IIA and IIX hybrid), IIX, IIB and possibly, a IIXB based 
on their staining characteristics for antibodies to different MHC proteins (Picard, 
Duris et al. 1998; Zhang, Koishi et al. 1998; Greenwood, Tomkins et al. 2009). 
This plasticity in muscle fibre type is largely controlled by the external 
environment, in response to various stimuli such as neuromuscular or hormonal 
alterations, mechanical loading/unloading and aging (Schiaffino and Reggiani 
2011). In addition, calcium dependant signal transduction has been shown to play 
a significant role in the modulation of skeletal muscle fibre type (Tavi and 
Westerblad 2011). 
1.1.3.1 Origin of skeletal muscle 
The paraxial mesoderm in the embryo is the origin of vertebrate skeletal 
muscle. This tissue forms cellular spheres, termed somites (Christ and Ordahl 
1995). In mice, somite formation begins at about 8 days post coitum as the 
paraxial mesoderm on either side of the neural tube and notochord becomes 
segmented in a co-ordinated craino-caudal sequence. The somites provide a 
cellular reservoir for the formation of a number of specialised tissues including 
vertebrae, cartilage, tendon, skin and the skeletal muscle of the body and limbs. 
As somite development proceeds, specialised areas of the somite develop to form 
the dermomyotome (dorsal part of the somite) the myotome (underlying and 
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formed from the dermomyotome) and the sclerotome (dorsal part of the somite) 
(Buckingham, Bajard et al. 2003). Formation of these specialised regions requires 
the co-ordinated action of an array of genes. For the development of skeletal 
muscle development, important roles have been ascribed to the Pax3, MyoD and 
Mrf4 transcription factors in initial myotome formation, with Sonic hedgehog, 
Wnt and bone morphogenic protein signalling involved in the further segregation 
of the dermomyotome into epaxial (responsible for the formation of the back 
muscle) and hypaxial (responsible for the formation of diaphragm, body wall and 
limb muscle) regions (Buckingham, Bajard et al. 2003; Tzahor, Kempf et al. 
2003; Le Grand and Rudnicki 2007). There is heterogeneity in the populations of 
precursor cells present in these different spatial regions of the developing 
dermomyotome (Yokoyama and Asahara 2011), which is thought to define the 
distinct populations of myogenic precursors.  
1.1.3.2 Muscle progenitors in the developing embryo 
One clearly distinct population of muscle precursors are the Pax3 positive 
cells that develop in the ventrolateral lip of the dermomyotome. These cells 
undergo an epithelial to mesenchymal transition before delaminating and 
migrating to form the limb buds in the developing embryo (Buckingham 2007). 
Once this Pax3 positive population has migrated into the limb, expression of Pax3 
is reduced as the MRF family (discussed later) and associated transcription factors 
are induced to execute the myogenic program. The migration of progenitor cells 
into the limb bud requires a network of transcription factors (SIX1, SIX4, Eya1, 
Eya2, Myf5, Pax3 and Pitx3), in addition to genes with an ascribed role in the 
migration of the precursors (lbx1, c-met, CXCR4, HGF). Deletion of any of these 
genes impairs myogenesis in the limb buds (Buckingham, Bajard et al. 2003; 
Yokoyama and Asahara 2011).  
Most pertinent to this thesis, is a second population of muscle precursors that 
are present in, but are not necessarily derived from the central dermomyotome. 
These cells express the transcription factor Pax7 and not necessarily Pax3, are 
mitotically active and devoid of MRF expression. They persist throughout 
embryonic development and enter the myotome compartment as the preceding 
central dermomyotome disintegrates during development. Progenitor cells 
expressing Pax7 activate the myogenic program via the induction of Myf5 
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expression. This stimulates a second wave of myogenesis, providing additional 
cells to incorporate with existing primary muscle fibres during foetal 
development. A number of studies have identified this population as being 
responsible for the formation of the satellite cell pool in post-natal muscle, with 
~80% of satellite cells expressing Pax7 and Myf5 with or without Pax3 
(Buckingham, Bajard et al. 2003; Buckingham 2007).  
Satellite cells are defined based on their unique anatomical location 
between the basal lamina and the sarcolemma of multinucleated fibres. They are 
considered the major contributors to post-natal muscle growth and regeneration 
(Mauro 1961). They are also the major source of primary myoblasts isolated using 
enzymatic techniques (Rosenblatt, Lunt et al. 1995; Allen, Temm-Grove et al. 
1997; Partridge 1997). In mice, satellite cells are first seen in the limb muscles 
during mid- to late-gestation (embryonic day 15 in mice). In new-born mice, 
approximately 30% of the sub-laminar nuclei in muscles are satellite cells. 
However, this percentage decreases with age as the adult size of muscles is 
reached,  and at two months of age, the contribution of satellite cell nuclei to all 
sub-laminar nuclei is less than 5% (Gibson and Schultz 1983). Satellite cells have 
distinguishing morphological characteristics, such as a relatively high nuclear-to-
cytoplasmic ratio and increased nuclear heterochromatin and few organelles 
(Hawke and Garry 2001). In adults, satellite cells are normally in a state of mitotic 
quiescence. However, a range of stimuli can activate satellite cells, which induces 
the cells to re-enter the cell cycle to participate in myogenesis. These stimuli 
include muscle stretch, voluntary exercise, various forms of injury and electrical 
stimulation (Appell, Forsberg et al. 1988; Rosenblatt, Yong et al. 1994; Schultz 
and McCormick 1994). Activation of satellite cells induces myogenic gene 
expression and the myoblasts, termed myogenic precursor cells, differentiate and 
then fuse with existing myofibres or each other to form new or replacement 
myofibres (Sabourin and Rudnicki 2000). The absolute number of (quiescent) 
satellite cells stays relatively constant during adult life, and with repeated cycles 
of degeneration and regeneration (Gibson and Schultz 1983; Schultz and Jaryszak 
1985; Morlet, Grounds et al. 1989; Schultz 1996). This suggests that self-renewal 
maintains the satellite cell pool (Zammit and Beauchamp 2001), although other 
studies have demonstrated that other stem cell pools, for example pericytes, are 
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able to contribute to the satellite cell pool (Dellavalle, Maroli et al. 2011), and 
thus myogenesis. 
1.1.4 MRFs and control of myogenesis 
Myogenesis is an incremental process initiated with the commitment of a 
muscle precursor to the myogenic lineage. Once committed, myoblasts proliferate, 
differentiate into post-mitotic myocytes and finally fuse to form multinucleated 
myotubes, a process dependant on regulation of the cell cycle (see 1.1.5). This 
myogenic process is essentially the same in the embryo, post-natal muscle or in 
vitro, with the notable exception that the post-natal and in vitro precursors are, 
primarily, muscle satellite cells. Muscle-specific transcription factors control each 
stage of myogenesis, acting as the terminal effectors for multiple signalling 
cascades. These key transcription factors are responsible for the timely execution 
and maintenance of the myogenic program and have been well investigated and 
reviewed (Kuang, Kuroda et al. 2007; Knight and Kothary 2011). Figure 1.2 
outlines the key transcription factors involved in regulating myogenesis, and the 
stage of myogenesis in which they act.    
 
Figure 1.2: The key transcription factors involved in myogenesis. This figure 
depicts the key transcription factors involved in the regulation of myogenesis and 
indicates the stages of myogenesis at which they play a critical role.  Figure taken 
from (Knight and Kothary 2011). 
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Much of our knowledge of the process of myogenesis has come from the 
use transgenic models in which the roles of specific transcription factors have 
been defined. In addition, the use of cultured myoblasts has contributed to the 
understanding of the signalling events that regulate myogenesis (Sharples and 
Stewart 2011). The regulation of myogenesis relies on the ability of specific 
transcription factors to commit cells to the myogenic lineage, and to coordinate 
extra and intra-cellular signals to regulate the timely and stage-specific induction 
of transcripts responsible for the execution and maintenance of the myogenic 
program. The following section will focus on the major transcription factors that 
regulate myogenesis, including the myogenic regulatory factors (MRFs), Pax7 
and the MEF2 family.  
The MRFs are members of the basic helix-loop-helix (bHLH) superfamily. 
These transcription factors play critical roles in the specification, proliferation, 
differentiation and maintenance of the myogenic lineage. The MRF family of 
transcription factors consists of four members, MyoD, Myf5, myogenin and 
MRF4 (Braun, Buschhausen-Denker et al. 1989; Edmondson and Olson 1989; 
Rhodes and Konieczny 1989; Wright, Sassoon et al. 1989). Each shares structural 
similarities, containing both the DNA binding domain and the dimerisation 
domain (responsible for hetero-dimerisation) (Lassar, Buskin et al. 1989; Murre, 
McCaw et al. 1989; Arnold and Braun 1996). The most well defined mechanism 
of MRFs induced gene regulation is the ability of the MRFs to bind the 
ubiquitously expressed E proteins through their bHLH motif. The resulting 
heterodimer(s) interact with specific DNA sequences known as E-boxes. The 
consensus E-box sequence is 5’-CANNTG-3’ where N is any nucleotide. E-boxes 
are present in the promoters of numerous muscle specific genes and convey the 
ability to regulate gene expression in an MRF dependant manner (Arnold and 
Braun 1996; Sabourin and Rudnicki 2000). In vivo studies using knock-out 
models of the individual MRFs have provided great insight into specific MRF 
function, demonstrating a hierarchical relationship between the MRFs. Both 
MyoD and Myf5 are considered to be the primary MRFs with roles in myogenic 
determination, as evidenced by their functional and necessary roles in the 
establishment of epaxial (paraspinal and intercostal) and hypaxial (limb and 
muscle wall) muscle lineages, respectively, in the embryo (Arnold and Braun 
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1996; Yokoyama and Asahara 2011). Mice with both MyoD and Myf-5 deleted, 
are born completely devoid of skeletal muscle and die shortly after birth. The 
secondary MRFs, myogenin and MRF4 are thought to have critical roles in 
myogenic differentiation, with the most compelling evidence again from knock-
out models. Myogenin null mice die shortly after birth and display a large 
reduction in the mass of skeletal muscle, with a greatly reduced density of 
myofibres and a lack of myosin heavy chain and actin, both of which are 
structural markers of muscle differentiation (Arnold and Braun 1996). Deletion of 
MRF4 suggests a role in supporting Myf5 expression and, as with myogenin, 
influencing the expression of structural myogenic genes (Arnold and Braun 1996).  
Pax7 is an early transcription factor in the myogenic program and acts in 
concert with the MRFs to regulate myogenic gene expression. The importance of 
Pax7 to the myogenic program is best illustrated in the phenotype of the Pax7 null 
mouse. These animals have very few or no satellite cells (Seale, Sabourin et al. 
2000) , with those that are present characterised as prone to apoptosis, having cell 
cycle defects and demonstrate an impaired ability to both execute the myogenic 
program, and recruit stem cells to the myogenic lineage (Seale, Sabourin et al. 
2000; Relaix, Montarras et al. 2006; Lu, Cummins et al. 2008). Although at birth, 
Pax7 null animals appear normal, the postnatal growth of skeletal muscle is 
severely compromised and these animals die 2-3 weeks after birth (Lu, Cummins 
et al. 2008). One of the nine members of the Pax gene family, Pax7 contains a 
paired DNA binding domain and a homeodomain believed to regulate both DNA-
protein and protein-protein interactions (Chi and Epstein 2002; Buckingham and 
Relaix 2007). The critical role for Pax7 in the specification of the myogenic 
lineage, is thought to be mediated through the regulation of both MyoD and Myf5 
expression (Buckingham and Relaix 2007). Interestingly, it has also been reported 
that Pax7 can prevent the transcriptional activity of MyoD, thus preventing 
execution of the differentiation program. Pax7 has been shown to induce the 
expression of Id2 and Id3, direct inhibitors of MRF activity, as well as inducing 
the proteasome-dependant degradation of MyoD (Olguin and Pisconti 2012).  
Activation of muscle specific genes is also dependent on the functional 
interactions between the MRF proteins and the MEF2 family of MADS box 
transcription factors. MEF2 transcription factors are able to activate MRF protein 
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activity, however, they are unable to regulate myogenic activity alone (Molkentin, 
Black et al. 1995). Thus, it has been proposed that these two families form 
regulatory networks with critical roles in myogenesis (Olson and Klein 1994). 
Four vertebrate MEF2 genes have been identified. Mef2A, Mef2B and Mef2D are 
expressed ubiquitously, and Mef2C is expressed specifically in muscle, brain and 
spleen (Breitbart, Liang et al. 1993; Leifer, Krainc et al. 1993; Martin, Miano et 
al. 1994). The MEF2 factors all contain a MADS domain that is involved in 
dimerisation and binding DNA, and a MEF2 specific domain that influences 
dimerisation and cofactor interactions (Molkentin, Firulli et al. 1996). MADS box 
transcription factors bind to conserved A/T rich DNA sequences in many muscle 
specific genes to regulate their function (Molkentin, Firulli et al. 1996).  
The network of transcription factors that is described above, represent the 
major factors known to date that regulate myogenesis. As the control of 
myogenesis by this transcriptional network involves both the proliferation of 
myoblasts and their growth arrest to allow myoblast differentiation, their activity 
is also associated with control of the cell cycle.      
1.1.5 The cell cycle 
Control of the cell cycle is integral to the myogenic program, with 
significant roles in maintenance of proliferation as well as timely execution of the 
differentiation program. The following outlines mechanisms regulating the cell 
cycle program during myogenesis. Myogenesis involves the irreversible 
withdrawal of proliferating myoblasts from the cell cycle. This process involves 
the co-ordinated activation and control of muscle specific gene expression 
throughout myoblast proliferation, for cell cycle exit and for the formation of 
terminally differentiated myotubes (Lassar, Skapek et al. 1994). The cell cycle 
comprises of four stages; the DNA synthesis (S-phase) stage, mitosis (M-phase) 
and two gap phases (G1 and G2), which are between S- and M- phases. Cells can 
also exit the cell cycle at G1 into a state of quiescence known as G0 (Kitzmann and 
Fernandez 2001).  It is thought that the first gap phase (G1) plays a role in the 
decision to continue or withdraw from the cell cycle, and therefore, a number of 
the signalling pathways that regulate cell cycle progression are associated with the 
G1 phase (Grana and Reddy 1995; Kitzmann and Fernandez 2001).  
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Cell signalling pathways involved in the the cell cycle have a wide range 
of targets, including the retinoblastoma protein (Rb), the cyclins, cyclin-dependent 
kinases (CDKs) and cyclin dependent kinase inhibitors (CKIs).  The 
phosphorylation state of Rb serves as the major contributing factor in regulating 
exit from the cell cycle.  Inactive (hyperphosphorylated) Rb results in progression 
of the cell cycle, and the transition from G1 to S phase.  In contrast, active 
(hypophosphorylated) Rb is thought to stall the cell cycle at the G1 checkpoint. 
This is achieved through the binding to, and the inactivation of transcription 
factors responsible for the regulation of DNA synthesis (S-phase) genes, with E2F 
and DP1 genes providing good examples (Weinberg 1995; Wu, Zukerberg et al. 
1995; La Thangue 1996; Dyson 1998). Control of the cell cycle by Rb involves 
the CDKs and their obligate partners, the cyclins. Figure 1.3 provides an overview 
of cell cycle regulation.  
 
Figure 1.3: The eukaryotic cell cycle.  The figure showns the distinct phases 
of the cell cycle:  the first gap phase (G1), the DNA synthesis phase (S), the 
second gap phase (G2) and mitosis (M). Quiescent cells that exit the cell cycle 
are in the G0 phase. The progression through the cell cycle is regulated by the 
activity of the cyclin (triangles) and Cdk (squares) complexes, with complex 
activity also regulated by the Cdk inhibitors. Figure taken from (Coleman, 
Marshall et al. 2004). 
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The CKIs also play a major role in the control of the cell cycle. The CKIs 
are grouped into two families, based on their structure and target Cdks. The first 
family is the INK4 (inhibitors of Cdk4) family and includes; p15INK4b, p16INK4a, 
p18 INK4c and p19INK4d. The forced over-expression of INK4 family members 
results in a reduced rate of cell proliferation. They target both Cdk4 and 6, 
interfering with their binding to cyclin-D (Gu, Turck et al. 1993; Serrano, Hannon 
et al. 1993; Guan, Jenkins et al. 1994; Hannon and Beach 1994; Chen, Jackson et 
al. 1995; Grana and Reddy 1995; Hirai, Roussel et al. 1995). The second family is 
the Cip/Kip family, which and includes p21CIP1/WAF1, p27KIP1, and p57KIP2 (el-
Deiry, Tokino et al. 1993; Gu, Turck et al. 1993; Harper, Adami et al. 1993; 
Xiong, Hannon et al. 1993). The Cip/Kip family of proteins contain binding 
motifs that enable them to bind to both cyclin and CDK proteins.  These 
complexes which are present during the G1 phase, are inhibited by p21, p27 and 
p57.  In addition, this family also inhibits cyclin:Cdk interactions during DNA 
synthesis (Harper, Adami et al. 1993; Xiong, Hannon et al. 1993; Polyak, Kato et 
al. 1994; Lee, Reynisdottir et al. 1995). The association of Cdk4 with D-type 
cyclins is also thought to be promoted in a p21 dependant manner. This 
association occurs during periods of reduced p21 expression as seen in 
proliferating cells, conversely, an increased ratio of p21 to cyclin:Cdk results in 
the inactivation of cyclin:Cdk complexes (Zhang, Hannon et al. 1994; Sherr 1995; 
LaBaer, Garrett et al. 1997).  
The MRFs and other regulatory proteins play a role in exit from the cell 
cycle. MyoD is critical to the differentiation process, controlling the activation of 
cell cycle machinery involved in cell cycle withdrawal. MyoD has been shown to 
bind to and facilitate the homodimerisation of the CKIs p21, p27 and p57. These 
interactions result in the inhibition of the specific Cdks and ultimately exit from 
the cell cycle (Reynaud, Leibovitch et al. 2000; Guo, Wang et al. 1995; Halevy, 
Novitch et al. 1995; Parker, Eichele et al. 1995; Martelli, Cenciarelli et al. 1994). 
MyoD has also been shown to bind and enhance the expression of Rb protein 
(through preventing Rb phosphorylation), and induce p21 expression in 
differentiating myoblasts, two mechanisms promoting exit from the cell cycle 
(Gu, Schneider et al. 1993; Zhang, Zhao et al. 1999).  Thus, regulation of the cell 
cycle is critical for normal development and any defect in these mechanisms will 
14 
perturb myogenesis during foetal development, postnatal growth or in the 
regeneration of skeletal muscle in adults.  
1.1.6 General signal transduction in muscle 
At all stages of development, skeletal muscle responds to cues from an 
array of stimuli that includes: stretch, contraction, disuse, nutrient availability, pH, 
ion flow, growth factors, cytokines, mitogens, hormones, oxidative or heat stress, 
vitamins, toxins, and neuronal stimulation. In addition, skeletal muscle functions 
as an endocrine organ, secreting factors or ‘myokines’ that can elicit specific 
biological responses on muscle, or in other target tissues, this list includes: IL-6, 8 
and 15, BDNF, irisin, follistatin like 1, FGF21, Leukaemia inhibitory factor, FGF-
2, IGF-1 and Mstn (Pedersen and Febbraio 2008; Henriksen, Green et al. 2012). 
The architecture of skeletal muscle also plays a critical role in signal transduction, 
with muscle containing a number of specialised protein complexes and structures 
that play a critical role, including the neuromuscular junction, dystrophin 
sarcoglycan complex, caveolae, calthrin coated vesicles and t-tubules 
(Heydemann and McNally 2007; McMahon and Boucrot 2011; Staubach and 
Hanisch 2011; Takamori 2012). Specific signalling molecules are targeted to 
these discrete cellular locations, providing another means of regulating signal 
transduction, through the localisation of signalling intermediates. 
The ability of skeletal muscle and myoblasts to transduce a biological 
signal relies heavily on activation of a vast array of receptors. These are located 
throughout the cell, and, importantly in the cell membrane. Cell membrane 
receptors can be broadly classified into five major groups: the G-protein coupled 
receptors (GPCRs), tyrosine kinase receptors, cytokine receptors, ion channels 
and the TGF-β receptors (Jameson and DeGroot 2010). Activation of receptors 
involves binding of a secreted or introduced extracellular ligand to a surface 
receptor which results in conformational change. For secreted ligands, binding to 
receptors can occur in, (1) an endocrine manner (e.g. insulin produced in the 
pancreas acting on skeletal muscle), (2) paracrine manner (e.g. the release of 
acetylcholine at the neuromuscular junction), or (3), an autocrine manner. The 
receptor complex then transmits the signal into the cell, which can have both 
immediate and/or longer term consequences and can involve conjoint or different 
second messenger cascades (Jameson and DeGroot 2010).  
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Pertinent to this thesis is signal transfer through the simple and reversible 
process of phosphorylation, as occurs following the binding of Insulin-like growth 
factor (IGF-1) to the insulin-like growth factor receptor, or the binding of Mstn to 
the activin receptor type IIB (ACTRIIB) (Joulia-Ekaza and Cabello 2007; 
Laviola, Natalicchio et al. 2007; Elkina, von Haehling et al. 2011). It is notable 
that phosphorylation independent mechanisms to mediate receptor signalling also 
exist. For example, the signalling of the notch family of proteins, where ligand 
binding results in the cleavage and release of an intracellular C-terminal portion of 
the receptor, nuclear localisation of this C-terminal portion has been shown to 
directly participate in gene transcription (Oswald, Tauber et al. 2001). The 
regulation of GPCR signalling provides another example,  with the binding of a 
GPCR interacting protein GRK2 altering the interaction of the receptor with other 
signalling molecules to influence signal transduction (Ferguson 2007). 
The control of phosphorylation dependant signal transduction lies with a 
vast array of protein kinases, with over 500 identified so far in mice and humans. 
Protein kinases perpetuate the signal of a given stimulus via phosphorylation of 
signalling intermediates. Protein kinases can alter the activity, location and 
stability of many cellular proteins, coordinating and adapting critical cellular 
processes, including proliferation, differentiation, specification, cell death, 
metabolism, transcription and translation, often in a tissue or lineage specific 
context (Manning, Whyte et al. 2002). The major role of protein kinases in 
mammalian skeletal muscle development and regeneration has been recently 
reviewed (Knight and Kothary 2011). Most pertinent to this thesis are the 
phosphorylation events in the TGF-β and p38 (mitogen activated protein kinase 
(MAPK)) cascades (as described specifically for Mstn signalling (see 1.1.7.3-4)), 
and the ERK (MAPK) and Phosphatidylinositide 3-kinase (PI3K)/AKT signal 
transduction cascades.  
1.1.6.1 Extracellular regulated kinase (ERK) signalling 
In myoblasts, the events leading to ERK1/2 phosphorylation via RTK 
activation are well defined, a good example being ligand activation of fibroblast 
growth factor receptor (FGFR4). Following the binding of FGF, FGFR4 auto 
phosphorylates, which leads to the recruitment of Src homology 2 (SH2) domain-
containing proteins such as growth-factor receptor-bound 2 GRB2, the first step in 
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the formation of an adaptor complex. GRB2 interacts with the guanine-nucleotide 
exchange factor son of sevenless (SOS), the GRB2/SOS interaction allows 
activation of the plasma membrane bound GTPase, Ras. Ras activation requires 
SOS catalysed GTP exchange, with GTP bound Ras activating Raf and initiating 
the MAPK signal transduction cascade. In this pathway, Raf phosphorylates the 
MAP or ERK kinases (MEK), then ERK1/2.  To date MEK1/2 are the only known 
activators of ERK1/2 (Knight and Kothary 2011). Thus, pharmacological 
inhibitors of the ERK pathway generally prevent the phosphorylation of MEK, 
which disrupts the downstream signal transduction cascade. Activation of ERK 
signalling influences multiple cellular processes including proliferation, 
differentiation, protein synthesis, mitochondrial function and the maintenance of 
the fast glycolytic muscle fibres (Roux, Shahbazian et al. 2007; Shi, Scheffler et 
al. 2008; Shi, Scheffler et al. 2009; Knight and Kothary 2011; Wortzel and Seger 
2011). In addition, activation of the SOS/GRB-2/Ras/Raf/MEK pathway is 
common to other RTK, G protein-coupled receptors and the Na+ K+ ATPase 
(Schlessinger 2000; Hur and Kim 2002; Kotova, Al-Khalili et al. 2006).  
1.1.6.2 Phosphatidylinositol-3 Kinase (PI3K)/AKT 
The PI3K/AKT pathway has been studied in depth in skeletal muscle. 
Specifically, this pathway in conjunction with its downstream target mammalian 
target of rapamycin (mTOR) is a key regulator of growth and hypertrophy 
(Trendelenburg, Meyer et al. 2009). The principle activators of this pathway are 
insulin and IGF-1. The binding of IGF-1 to its receptor causes a conformational 
change in the receptor to induce the trans-phosphorylation and subsequent 
phosphorylation of insulin receptor substrate 1 (IRS-1). IRS-1 then activates the 
PI3K lipid kinases, which, in turn, phosphorylate phosphatidylinositol 4, 5 
bisphosphate (PIP2) to produce phosphatidylinositol 3, 4, 5 triphosphate (PIP3). 
PIP3 then recruits and phosphorylates phosphatidylinositol-dependant-kinase 
(PDK1), which in turn phosphorylates the serine/threonine kinase AKT. AKT 
then targets numerous intracellular targets including: mammalian target of 
rapamycin (mTOR), glycogen synthase kinase 3 (glycogen synthesis) and the 
fork-head box family of transcription factors (involved in the regulation of muscle 
atrophy related genes). Pertinent to this thesis is the phosphorylation/activation of 
targets downstream of mTOR which include p70 S6 kinase (p70S6K), which, in 
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turn, phosphorylates the ribosomal protein S6 (rpS6). The phosphorylation of 
rpS6 is suggested to increase the translational efficiency of a class of mRNA 
transcripts containing an oligopyrimidine tract. The mTOR complex also 
phosphorylates and inactivates 4EBP1, a repressor of the translation initiation 
factor eIF4E. When growth factor and nutrients are limiting 4EBP1 is hypo-
phosphorylated and is bound tightly with eIF4E which represses assembly of the 
translation initiation complex (Knight and Kothary 2011; Magnuson, Ekim et al. 
2012). Thus, the downstream activation of the PI3K pathway can have a direct 
influence on the cellular protein synthesis machinery.  
There is considerable crosstalk across signal transduction cascades, which 
involves specific intermediates. For example, ERK dependant activation of 
ribosomal S6 kinase (RSK) induces the phosphorylation of rpS6 on S234/236 
following ERK activation. PI3K signalling has also been shown to induce rpS6 
phosphorylation as mentioned earlier through p70S6K following activation by 
mTOR (Roux, Shahbazian et al. 2007; Won, Yang et al. 2012). This provides a 
mechanism for targeted crosstalk between MAPK and PI3K signal transduction, 
which converges on rpS6. Furthermore, crosstalk between MAPK and PI3K 
precedes the activation of ERK. For example, Grb2 possesses the ability to 
transduce signal down both MAPK and PI3K cascades (Won, Yang et al. 2012), 
an example of which is shown in Figure 1.3. Crosstalk through multiple signalling 
intermediates adds additional complexity to biological systems. This redundancy 
may play a substantial role in the ability of cells and tissues to ‘buffer’ a given 
stimulus, through preventing the saturation of a specific cascade. Regardless, 
signal transduction plays an indispensable role in all aspects of skeletal muscle 
function. 
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A 
B 
Figure 1.4: PI3K/AKT and MAPK crosstalk. A, Schematic diagram 
illustrating the how cross talk between PI3K/AKT and MAPK pathways can occur. 
4E-BP1 (eukaryotic initiation factor 4E-binding protein 1), KSR (kinase suppressor 
of Ras), mTORC1 (mTOR–raptor (regulatory associated protein of mTOR) 
complex), mTORC2 (mTOR–rictor (rapamycin-insensitive companion of mTOR) 
complex), PA (phosphatidic acid), PI (phosphatidylinositol), PP2A (protein 
phosphatase 2A), PS (phosphatidylserine), S (serine), S6RP (S6 ribosomal protein), 
SGK (serum- and glucocorticoid-induced protein kinase), T (threonine), Y  
(tyrosine). B, pictorial illustration of how the PI3K/AKT (orange lines) and 
Ras/MAPK (purple lines) signal transduction may interact with each other, source 
(Aksamitiene, Kiyatkin et al. 2012).  
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1.1.7 Myostatin (Mstn) 
The Mstn gene was identified in 1997 as growth and differentiation factor-
8 (GDF-8), a new member of the transforming growth factor-β (TGF-β) 
superfamily (McPherron, Lawler et al. 1997).  GDF-8 mRNA was found in 
developing and adult skeletal muscle, as well as the myotome compartment of the 
somites during early embryogenesis, this strongly suggested a role for GDF-8 in 
the development of skeletal muscle. Subsequently, the GDF-8 gene was 
inactivated by gene targeting in mice, wherein homozygous null mice display an 
increase in the mass of skeletal muscle, with an approximate 2-3 fold increase in 
the size of individual muscles (McPherron, Lawler et al. 1997). The increase in 
muscle size was attributed to a combination of muscle cell hyperplasia (increase 
in muscle fibre number) and hypertrophy (increase in muscle fibre size). These 
data strongly indicated that GDF-8 functioned specifically as a negative regulator 
of skeletal muscle growth. As a consequence, the authors named the new gene 
Mstn (McPherron, Lawler et al. 1997). 
1.1.7.1 Mutations and phenotypes of Mstn. 
Following its discovery, natural inactivating mutations in the Mstn gene 
have been characterised in cattle (Grobet, Martin et al. 1997), dogs (Mosher, 
Quignon et al. 2007), sheep (Clop, Marcq et al. 2006) and humans (Schuelke, 
Wagner et al. 2004). The hypermuscular phenotype is observed for all these 
natural mutations, with different inter- and intra-species mutations that act in 
different ways to inactivate Mstn. For example, in Belgian Blue cattle there is an 
11bp deletion in the mature region of Mstn which generates a shift in the open 
reading frame and introduces a premature stop codon (Grobet, Martin et al. 1997; 
Kambadur, Sharma et al. 1997). Alternatively in Piedmontese cattle, a missense 
mutation that results in the substitution of a tyrosine for a critical cysteine, 
disrupts the folding, and the activity of the mature protein (Kambadur, Sharma et 
al. 1997; McPherron and Lee 1997). In Texel sheep, a mutation in the 3’ UTR of 
the Mstn transcript generates a microRNA (miRNA) site, which results in the 
reduced translation of Mstn protein (Clop, Marcq et al. 2006). However, other 
mechanisms exist for regulating the extent of the hyper-muscular growth in 
addition to the absence of functional Mstn. In support, Lee et al 2004 have 
elegantly demonstrated that Mstn is not the only regulator of skeletal muscle 
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mass. They observed further increases in muscle mass of mice following the 
introduction of a follistatin transgene into a Mstn null background (Lee 2007). 
Similarly, studies in our laboratory have shown further increases in the muscle 
mass of Mstn null mice following introduction of an IGF-1 transgene 
(unpublished data). 
1.1.7.2 Expression of Mstn  
Mstn is expressed in embryonic, foetal and postnatal muscle cells, which 
supports a role for this protein in regulating many facets of myogenesis 
(McPherron, Lawler et al. 1997). The expression of Mstn has also been reported 
in heart muscle, adipose, liver, spleen, lung, kidney, and fibroblasts (Jiao, Yuan et 
al. 2011). Transcriptional regulation of Mstn has been reported to occur via a 
number of pathways. The Mstn promoter is rich in E-box motifs in a number of 
vertebrate species. MyoD and Myf5 have been shown to bind to E-box motifs and 
both have been shown to play a role in transactivation of the Mstn promoter (Ma, 
Mallidis et al. 2001; Spiller, Kambadur et al. 2002; Senna Salerno, Thomas et al. 
2004). Other regulators include MAPK (ERK and p38) signalling, activated 
glucocorticoid receptor, tumour necrosis alpha, FoxO1 and the Smad transcription 
factors (Ma, Mallidis et al. 2001; Allen and Unterman 2007; Lenk, Schur et al. 
2009; Bish, Morine et al. 2010). In addition, Mstn has also been shown to auto-
regulate its own expression through a mechanism dependant on Smad7 (Forbes, 
Jackman et al. 2006).  
1.1.7.3 Structure  
Mstn shares features common to other members of the TGF-β 
superfamily, including a putative N-terminal secretion signal, a conserved C-
terminal RXRR proteolytic processing site and nine conserved cystine residues in 
the C-terminal region, six of which are essential for forming a cystine knot 
structure and the dimerization of the mature protein (McPherron and Lee 1996; 
McPherron, Lawler et al. 1997). Processing of the precursor produces an N-
terminal latency associated peptide (LAP) and the mature C-terminal dimer. 
Initially, it was thought that Mstn was predominantly secreted as an inactive latent 
complex consisting of dimeric LAP non-covalently linked to the C-terminal 
dimer. However, other studies have suggested that the predominant form of 
secreted Mstn is a full length dimer that is processed and cleaved in the 
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extracellular matrix (Anderson, Goldberg et al. 2008). Disassociation or cleavage 
leads to the release of the ‘mature’ C-terminal dimer as the ‘biologically active’ 
form of the protein (Lee and McPherron 2001; Thies, Chen et al. 2001; Hill, 
Davies et al. 2002; Zimmers, Davies et al. 2002; Hill, Qiu et al. 2003; Wolfman, 
McPherron et al. 2003; McFarlane, Langley et al. 2005; Miura, Kishioka et al. 
2006). The complex has also been reported to bind its own N-terminal LAP in 
addition to other molecules modulating Mstn activity in vitro. These include, 
decorin, LTBP3, follistatin, follistatin-related gene (FLRG, follistatin like 3 or 
follistatin related peptide) and GDF-associated serum protein-1 (Thies, Chen et al. 
2001; Haidet, Rizo et al. 2008; Kishioka, Thomas et al. 2008; Elkina, von 
Haehling et al. 2011).  
1.1.7.4 Canonical signalling of Mstn 
The magnitude of the hyper-muscular phenotype observed in Mstn null 
animals has led to numerous studies aimed at delineating the mechanism 
underlying this phenomenon. Canonical TGF-β signalling involves binding of the 
mature dimer to the type II receptor, then recruitment of a type one receptor to 
form the active receptor complex. Similarly, the mature Mstn dimer binds activin 
receptor type IIB (ACTRIIB), then recruits either Alk4 or 5 (the type I TGF-β 
receptors), both of which are serine/threonine kinases. The active receptor 
complex then phosphorylates Smad2 or 3 proteins which bind to a common Smad 
or co-Smad (Smad4), which shuttles the complex into the nucleus. In the nucleus, 
Smad2/3 interact with binding partners to regulate Smad-dependant gene 
transcription, while Smad4 is shuttled back to the cytoplasm to continue the cycle 
(Jayaraman and Massague 2000; Lee and McPherron 2001). In addition, the Smad 
proteins also bind to a growing list of other transcription factors. These include 
key regulators such as MyoD and MEF2 (Liu, Black et al. 2001; Quinn, Yang et 
al. 2001) (see 1.1.5.1). More recent studies have identified a role for the Smad 
proteins in regulating miRNA expression (Blahna and Hata 2012), which provides 
an additional mechanism for Smad-dependent gene regulation. A role for 
canonical Mstn signalling in the inhibition of myogenic differentiation has been 
described. Early reports identified the down regulation of the myogenic regulatory 
factors MyoD and Myf5 as having a major role. The proposed mechanism 
suggested that increased Smad3 phosphorylation and thus Smad3:MyoD, 
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complex, in the presence of Mstn was responsible (Langley, Thomas et al. 2002). 
In support, a later study reported Smad3 could associate with and repress the 
activity of MyoD (Liu, Black et al. 2001).  
In vivo studies have demonstrated that Mstn regulates protein synthesis. 
Specifically, mice treated with antibodies to antagonise Mstn have increased 
phosphorylation of p70S6K and rpS6, suggesting increased protein synthesis 
following blockade of Mstn (Welle, Burgess et al. 2009). In addition, Mstn has 
been shown to inhibit the differentiation of human myoblasts via inhibition of the 
PI3K/AKT pathway. These studies demonstrated that reduced phosphorylation of 
AKT and the inhibition of differentiation required the activity of Smad2/3. Of 
interest, the reduction in the phosphorylation of AKT was reversed following the 
addition of IGF-1 via stimulation of the PI3K/AKT signalling pathway, without a 
change in the Mstn induced phosphorylation of Smad2/3. The authors suggested 
that IGF-1 signalling predominates over that of Mstn (Trendelenburg, Meyer et al. 
2009). In support, Morissette et al reported that adenoviral over-expression of 
Mstn in C2C12 myoblasts attenuates the IGF-1 induced phosphorylation of AKT 
(Morissette, Cook et al. 2009). These data suggest that there is a delicate balance 
between the stimulatory and inhibitory signals, with the phenotype reflecting the 
dominant signal.  
1.1.7.5 Non-Smad signalling pathways  
In addition to canonical signalling through Smad-dependant pathways, 
other signal transduction cascades have also been shown to play a role in the 
function of Mstn. These pathways are referred to as non-canonical pathways, the 
majority of which have been shown to work in conjunction with canonical 
signalling (Philip, Lu et al. 2005; Yang, Chen et al. 2006). Mstn inhibits the 
proliferation of myoblasts through induction of p21 (McFarlane 2003). The 
induction of p21 is coupled with a decrease in the activity of CDK2, which results 
in the accumulation of hypophosphorylated Rb, which blocks the transition from 
G1 to S phase (Thomas, Langley et al. 2000). In support, Seoane et al observed 
that Foxo and Smad signalling induces the expression of p21 in HaCat (human 
keratinocyte) cells (Seoane, Le et al. 2004), while Phillip et al (2005) proposed a 
Smad-independent activation of the p38 MAPK signalling cascade through the 
TGF-β activated kinase (TAK1), in conjunction with canonical signalling is 
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responsible for the reduced rate of proliferation (Philip, Lu et al. 2005). In 
addition, TAK1 activation by Mstn  has  been reported to stimulate IL-6 
production in C2C12 myoblasts (Zhang, Rajan et al. 2011).  
Mstn induces the phosphorylation of ERK1 and 2, which, with p38 constitutes 
another branch of MAPK signalling (Yang, Chen et al. 2006). The events leading 
to the Mstn-induced phosphorylation of ERK require the activation of Ras (Yang, 
Chen et al. 2006). However, the subsequent steps are not yet known. It is likely 
that this cascade is similar to that observed for the FGF-induced activation of 
ERK through the Ras/Raf/MEK pathway (see 1.1.6.1). Interestingly, 
pharmacological inhibition of type 1 TGF-β receptors has been reported to 
prevent the activation of ERK1/2 by Mstn (Yang, Chen et al. 2006). Recent 
studies have highlighted a role for Mstn regulating the activity of the AMP-
activated protein kinase has been described. Zhang et al propose that Mstn plays a 
role in the regulation of insulin signalling, through the regulation of AMPK 
activity in adipose and muscle tissue (Zhang, McFarlane et al. 2011). Figure 1.3 
gives an overview of the signal transduction associated with the function of Mstn.  
 
Figure 1.5: Overview of Mstn signalling. This figure shows the canonical 
(ACTRIIB binding and Smad activation) and non-conical (MAPK and 
PI3K/AKT/mTOR) branches of Mstn signalling. Arrows indicate activation, bars 
indicate an inhibition and dashed lines represent missing or unknown intermediate 
steps, source (Elkina, von Haehling et al. 2011). 
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1.1.7.6 Mstn and metabolism 
Disruption of the Mstn gene causes phenotypic changes that support a role 
for Mstn in regulating metabolism. The shift in specific types of muscle fibres 
(increased glycolytic fibre content) and the reduction in the mass of fat observed 
in Mstn null animals (Shahin and Berg 1985; Lin, Arnold et al. 2002; McPherron 
and Lee 2002; Girgenrath, Song et al. 2005; Elashry, Otto et al. 2009; McPherron, 
Huynh et al. 2009; Wilkes, Lloyd et al. 2009; Matsakas, Mouisel et al. 2010), 
suggests that Mstn regulates metabolism in skeletal muscle. In support, treatment 
of WT myoblasts with Mstn maintains the expression of type I MHC (oxidative 
muscle), while down-regulating the expression of type II MHC (glycolytic 
muscle) (Wang, Yu et al. 2012). Interestingly, post-natal inhibition of Mstn 
regulates the hypertrophy of skeletal muscle fibres and not hyperplasia, 
suggesting that the hyperplasia that is associated with Mstn deficiency occurs 
before the neonatal period (Zhu, Hadhazy et al. 2000; Grobet, Pirottin et al. 2003; 
Whittemore, Song et al. 2003; Lee, Reed et al. 2005; Tang, Yan et al. 2007; 
Welle, Bhatt et al. 2007; Haidet, Rizo et al. 2008; Matsakas, Foster et al. 2009; 
Morine, Bish et al. 2010). Mstn is strongly implicated in the regulation of protein 
synthesis, Mstn null mice have an increased rate of synthesis of myofibrillar 
proteins (Welle, Bhatt et al. 2006), as do C2C12 cells treated with antibodies or 
follistatin to block Mstn (Suryawan, Frank et al. 2006; Welle, Burgess et al. 
2009).  
The reduced mass of fat in Mstn null mice is accompanied by lower 
concentrations of circulating cholesterol, leptin and triglycerides as well as the 
content of triglycerides in the liver. This endocrine profile is consistent with 
increased insulin sensitivity and a reduced risk of insulin resistance (McPherron 
and Lee 2002; Guo, Jou et al. 2009). Beneficial effects of Mstn inactivation have 
been observed in murine models of obesity. In these studies, Mstn null animals 
were crossed with Agouti lethal yellow (Ay/a) or ob/ob mice, which reduced the 
mass of the fat pads, improved glucose tolerance (Ay/a) and reduced 
hyperglycaemia (ob/ob) (McPherron and Lee 2002). Resistance to the 
consequences of a high fat diet is a well-established feature of Mstn null mice. 
They have improved glucose tolerance and insulin sensitivity and show reduced 
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serum insulin, cholesterol, leptin and triglycerides compared to wild-type mice on 
the same high fat diet (McPherron 2010).  
A number of studies have reported an increased sensitivity to insulin in 
Mstn null mice. Mstn null mice have increased glucose uptake in response to 
insulin and increased phosphorylation of AKT and IRS-1 in muscle and fat tissue 
in response to insulin (Shahin and Berg 1985; McPherron and Lee 2002; Guo, Jou 
et al. 2009; Wilkes, Lloyd et al. 2009). In addition, Mstn null mice fed a high fat 
diet from weaning have increased growth of skeletal muscle compared with null 
mice on a standard diet (Yang and Zhao 2006; Wilkes, Lloyd et al. 2009). These 
changes in the composition of both muscle and fat in Mstn null animals has made 
Mstn an attractive therapeutic target for a number of disorders, especially those 
involving muscle wasting and metabolic disorders such as obesity or diabetes.  
More recently a role for Mstn in regulating the activity of the AMP-
activated protein kinase has been described. AMPK responds to alterations in the 
ratio of AMP/ATP, which is considered a metabolic switch. Activated AMPK has 
been shown inhibit non-essential ATP-consuming processes such as, glycogen, 
fatty acid and protein synthesis, to conserve ATP, while promoting ATP 
production through the increased activation of catabolic processes. Thus, AMPK 
supports processes such as glucose transport, glycolysis and fatty acid oxidation 
(Hardie, Ross et al. 2012). Zhang et al propose that Mstn plays a role in the 
regulation of insulin signalling via regulating the activity of AMPK in muscle and 
fat (Zhang, McFarlane et al. 2011). However, the ability of Mstn to regulate 
AMPK activity is somewhat controversial as two independent studies have 
reported conflicting results on the activation status of AMPK and its downstream 
target ACC (Chen, Ye et al. 2010; Zhang, McFarlane et al. 2011). Specifically, 
both of these studies presented data on the phosphorylation AMPKα and its 
downstream target Acetyl-CoA carboxylase (ACC) in WT and Mstn null 
gastrocnemius muscle. Chen et al, show reduced AMPKαThr172 and ACCSer79 
phosphorylation in the gastrocnemius of 15 week old female Mstn null mice on a 
standard diet (Chen, Ye et al. 2010). In contrast, Zhang et al show increased 
AMPKα (phosphorylation epitope not specified) and ACCSer79 in 19 week old 
male Mstn null mice (Zhang, McFarlane et al. 2011). Thus, it seems that Mstn 
influences the activity of AMPK and its downstream target ACC, but, given what 
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looks to be differential regulation between male and female animals, the effect of 
Mstn on AMPK activity is not well understood.   
1.2 Intermediary metabolism  
This thesis will investigate the role of Mstn signalling in ovine myoblasts. 
Given the significant role that Mstn plays in metabolism, this section on ruminant 
and general intermediary metabolism has been included. The reactions 
constituting intermediary metabolism are similar in ruminants compared with 
monogastrics. However, they are partitioned quite differently between these two 
types of digestive physiologies. This is primarily due to the forage diet of 
ruminants and differences in the primary metabolites produced to fuel whole body 
metabolism. The major substrate for glucose production in ruminants is 
propionate, which provides up to 50% of glucose production through 
gluconeogenesis (Brockman RP 1986). Ruminants on a normal diet absorb very 
small amounts of carbohydrates, which is largely due to the fermentation of 
dietary carbohydrate in the rumen to short chain fatty acids, with the main 
fermentation products being acetate, propionate and butyrate (Brockman RP 
1986). In essence, the primary function of metabolic regulation is to provide a 
constant concentration of glucose in the blood. For example, the brain relies 
almost exclusively on glucose for metabolic energy (Pappenheimer and Setchell 
1973). Thus, gluconeogenesis is essential to maintain concentrations of glucose, a 
major consequence of this in ruminants being a net output of glucose from the 
liver. The major substrate of lipid metabolism differs in ruminant animals, with 
acetate, not glucose providing the major precursor for acetyl-CoA, which is 
required for the synthesis of fatty acids. In fact, the contribution of glucose to 
lipogenesis in ruminant mammary gland and liver is greatly reduced compared to 
that of the rat (Balmain, Folley et al. 1953; Hanson and Ballard 1967), with later 
studies showing this applies to all ruminant tissues (Ballard, Hanson et al. 1969). 
The reason for this difference is suggested to be a low activity of ATP-citrate 
lyase in ruminant tissues (Ballard, Hanson et al. 1969).  
The major processes contributing to the dynamics of skeletal muscle 
metabolism revolve around the provision of mobility and the maintenance of what 
constitutes the largest store of mobile protein in the animal, with the activity of 
specific reactions controlling these differing between species and in an individual 
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depending on physiological state. In sheep held in confined laboratory conditions, 
skeletal muscle is reported to consume 8-19% of whole body energy requirements 
as measured by O2 consumption (Lobley 1990). Broken down further, the major 
energy consuming processes in muscle are: posture and activity, protein turnover, 
ion transport, and substrate cycles.  The specific contribution of these components 
is regulated by a number of physiological processes with age, nutrition, activity 
and hormonal regulation all playing a significant role (Lobley 1990). An example 
of the how O2 consumption is partitioned in skeletal muscle is given in Figure 1.6, 
showing the contribution of specific processes to the energy expenditure in the 
muscle of the hind limb of lambs fed a maintenance diet.   
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In skeletal muscle, all energy required for cellular function is provided by the 
hydrolysis of ATP to ADP. When contractile activity is induced, the demand for 
energy in skeletal muscle is greatly increased. To counter the huge fluctuations in 
energy requirements, the fibres of skeletal muscle require fast and efficient 
methods of re-synthesising ATP. This is accomplished through three main 
mechanisms: creatine kinase activity, glycolysis and mitochondrial oxidative 
phosphorylation, with small amounts of ATP also generated by adenylate-kinase, 
which converts two ADP molecules to ATP and AMP (Schiaffino and Reggiani 
2011).  
1.2.1 Creatine kinase  
Creatine kinase regenerates ATP using creatine as a high energy 
phosphate reserve. At rest, skeletal muscle produces an excess of ATP. This 
excess ATP is transferred to creatine to generate creatine phosphate. Although this 
system is extremely efficient at regenerating ATP, during sustained contraction it 
is rapidly exhausted within 20 s (Martini 2001; Schiaffino and Reggiani 2011). 
Figure 1.6: Energy expenditure in the hind-limb of sheep. The figure 
shows the relative contribution of the specific metabolic processes to 
energy (oxygen) consumption in the hindlimb of 35kg lambs fed a 
maintenance diet. Figure from (Lobley 1990). 
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Therefore, skeletal muscle must rely on other means of generating energy 
following the depletion of creatine phosphate reserves 
1.2.2 Glycolysis 
Glycolysis defines the intermediary metabolism reactions involved in ATP 
generation from glycogen or glucose to form lactate or pyruvate. This system is 
not as powerful as the creatine kinase system, but has a higher capacity for the 
generation of ATP. Glucose for fuelling glycolysis in skeletal muscle can be 
derived from multiple sources, which include the breakdown of glycogen 
reserves, active transport of circulating glucose and glucogenic amino acids. The 
major steps in glycolysis are illustrated in Figure 1.7, with pyruvate being the 
major end product. The metabolism of glucose to pyruvate generates a net yield of 
2ATP per glucose molecule processed. The pyruvate derived from glycolysis has 
a number of intracellular fates; it can be reversibly converted to lactate (via lactate 
dehydrogenase), irreversibly converted to acetyl-CoA (pyruvate dehydrogenase) 
or used for gluconeogenesis to synthesise glucose for the repletion of glycogen 
reserves. Similarly, lactate shares a number of fates. Lactate can be converted 
back to pyruvate or secreted. Secretion of lactate from skeletal muscle is fibre-
type dependant, wherein fast glycolytic fibres secrete more lactate than slow 
oxidative fibres. Secreted lactate is utilised by slow muscle fibres (cell-to-cell 
lactate shuttle hypothesis) or circulated to be processed back to glucose by the 
liver (the Cori cycle) (Martini 2001; Schiaffino and Reggiani 2011). 
1.2.3 Mitochondrial metabolism.  
Mitochondria further process acetyl-CoA produced from either glycolysis 
or the β-oxidation of fatty acids through the citric acid (TCA) cycle. Intermediate 
metabolites that fuel the TCA cycle are derived from multiple sources (e.g 
pyruvate, fatty acids and ketone bodies and amino acids) and these can enter the 
TCA cycle at a multiple number of entry points. The reactions and intermediates 
of the TCA cycle provide the basis of cellular respiration. Although only one net 
ATP molecule is generated per turn of the TCA cycle, the reducing power (in the 
form of H+) generated by the reactions provides the major source of mitochondrial 
ATP production. The organic
 
substrates of the TCA cycle reduce the co-enzymes 
NAD+ and FAD to NADH and FADH2, which provide the driving force for 
oxidative phosphorylation. 
 
In the inner mitochondrial membrane, NADH and 
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FADH2 transfer their hydrogen atoms to other co-enzymes, such as flavin 
mononucleotide and co-enzyme Q. This results in the release of protons into the 
inter-membrane space of the mitochondria as the electrons are shuttled 
sequentially from coenzymes to the cytochromes of the electron transport chain. 
The sequential flow of electrons through the co-enzymes and cytochromes is 
stopped following terminal electron acception by oxygen and generation of H2O. 
The gradient of H+ generates or regenerates ATP as H+ re-enter through the 
hydrogen ion channels in the inner mitochondrial membrane. Each pair of 
electrons removed from the TCA cycle by NAD+ and FAD generate 3 and 2 
molecules of ATP, respectively.  Oxidative Phosphorylation is the least powerful 
method for the production of ATP, but has the highest generation capacity 
(Martini 2001; Schiaffino and Reggiani 2011).  
1.2.4 Regulation of intermediary metabolism in skeletal muscle  
The metabolic reactions that generate ATP in skeletal muscle are subject 
to control through physiological and endocrine mechanisms. Much of this control 
is imposed by regulating the abundance and/or the activity of key metabolic 
enzymes. The concentration of metabolites such as glucose, triglycerides, free 
fatty acids, as well as their metabolic intermediates also play a significant role in 
the control of metabolic activity in skeletal muscle. The flux of metabolities and 
their intermediates is altered in a fibre-type dependant manner, as illustrated in 
Figure 1.7, with type 1 fibres being more reliant on oxidative metabolism for the 
generation of energy. This is also reflected in the expression of both the metabolic 
enzymes and the different substrate transport proteins that provide a bias toward 
oxidative rather than glycolytic fuel. Situations that place skeletal muscle under 
stress, such as sustained contraction, infection, heat shock or starvation can 
profoundly alter metabolism (Bonaldo and Sandri 2013; Rhoads, Baumgard et al. 
2013). Prolonged stress can also have detrimental consequences, because once the 
reserves of muscle glycogen are depleted, catabolic processes are activated to 
support the increased demand for energy. In skeletal muscle, this can cause a 
prolonged use of cellular protein as an energy source, which ultimately results in 
the atrophy of skeletal muscle (Bonaldo and Sandri 2013). 
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Figure 1.7:  Intermediary Metabolism and fibre-type influences. Illustrating 
some of the key reactions and enzymes in the intermediary metabolism of skeletal 
muscle and how they are biased in different fibre types. The predominant pathways 
in slow or fast skeletal fibres are shown as green or red arrows, respectively. DHAP, 
dihydroxyacetone phosphate; GLUT4, glucose transporter 4; F-6-P, fructose-6-
phosphate; FAT/CD36, fatty acid translocase; FFA, free fatty acids; F-1,6-P, 
fructose-1,6-bisphosphate; F-2,6-P, fructose-2,6-bisphosphate; G-3-P, 
glyceraldehyde-3-phosphate; G-6-P, glucose-6-phosphate; GPD1, glycerolphosphate 
dehydrogenase 1 (cytoplasmic); GPD2, glycerolphosphate dehydrogenase 2 
(mitochondrial); HK, hexokinase; LDH, lactate dehydrogenase; MCT1, 
monocarboxilic acid transporter 1; MCT4, monocarboxylic acid transporter 4; PDH, 
pyruvate dehydrogenase; PFK, phosphofructokinase; PFKFB3, 
phosphofructokinasefructose bisphosphatase 3; TG, triglycerides. Figure from 
(Schiaffino and Reggiani 2011). 
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Hormonal changes and cytokine production can influence the metabolism 
of skeletal muscle. For example, insulin plays a major role in the uptake of 
glucose, glycogen synthesis and the regulation of protein synthesis (Jameson and 
DeGroot 2010). Skeletal muscle itself can function as an endocrine organ 
secreting ‘myokines’ that have the potential to influence whole body metabolism, 
with the post-exercise secretion of  IL-6 providing a good example (Pedersen, 
Akerstrom et al. 2007). A more recent study identified 48 ‘myokines’ whose 
secretion is regulated by contractile activity (Raschke, Eckardt et al. 2013). 
Interestingly this list included: Furin (the protease that cleaves full length Mstn 
(Anderson, Goldberg et al. 2008)), IGF binding protein 1 (modulator of IGF and 
insulin activity (Ruan and Lai 2010)), TGFβ1, FGFs (see 1.1.6.1) and interlukin 
family members, all of which have the potential to regulate skeletal muscle 
metabolism.  
1.2.5 Signal transduction and metabolism 
There are multiple signal transduction pathways involved in regulating the 
metabolism of skeletal muscle. The processes controlled by these pathways can 
regulate all aspects of glucose, lipid and protein metabolism. The signalling 
networks that are implicated in the regulation of skeletal muscle metabolism 
include PI3K/AKT/mTOR (protein synthesis and glucose metabolism), MAPK 
(glucose, protein and lipid metabolism) and the Ca2+ (muscle fibre-type specific) 
signalling pathways. The metabolic control that is imposed by these pathways is 
mediated through the activity of downstream signalling hubs, with AMPK and 
mTOR representing two major hubs that orchestrate the metabolic change in 
skeletal muscle. These two pathways act as ‘energy sensing’ mechanisms in 
skeletal muscle and other tissues, responding to physiological or endocrine signals 
to effect metabolic change. 
AMPK is a heterotrimeric complex of α, β and γ subunits. In skeletal 
muscle activation of AMPK by a decreased AMP:ATP ratio or secreted factors 
such as IL6 (Kelly, Gauthier et al. 2009; Hardie, Ross et al. 2012). Activation of 
AMPK is a two-step process, firstly, binding of AMP to the γ-subunit induces a 
conformational change in the AMPK complex, and this allows upstream kinases 
to phosphorylate the α-subunit at threonine 172 to activate the complex. AMPK 
inhibits non-essential energy consuming processes such as protein and lipid 
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synthesis, to support the generation of ATP through increased catabolic processes 
(Hardie, Ross et al. 2012). For example, AMPK phosphorylates and inactivates 
acetyl-CoA carboxylase (ACC), an enzyme responsible for the conversion of 
acetyl-CoA to malonyl-CoA. Malonyl-CoA inhibits carnatine pamitoyltransferase, 
which transports fatty acids to the mitochondria, thus, providing a mechanism for 
increased fatty acid oxidation following the activation of AMPK (Ouchi, Shibata 
et al. 2005).  
The mTOR hub revolves around the serine/threonine kinase activity of 
two distinct mTOR complexes TORC1 and TORC2 (Cornu, Albert et al. 2013). 
Like AMPK, mTOR signalling plays a major role in metabolism, this pathway can 
regulate cell growth and metabolism in response to cellular nutrient, oxygen and 
energy levels. The activity of mTOR is stimulated by a number of growth factors, 
including insulin and IGF-1 (Harris, Chi et al. 2006; Vary 2006). In addition, 
activation of AMPK has been shown to inhibit mTOR activity (Ning and 
Clemmons 2010). The regulation of mTOR activity plays a critical role in a 
number of the metabolic processes in skeletal muscle, with a good example being 
the ability of mTOR to directly influence the translational control of protein 
synthesis. This is achieved, in part, through modulation of the activity of 4EBP1 
(Magnuson, Ekim et al. 2012). Thus the AMPK and mTOR complexes represent 
two critical control points in the signal transduction mediated changes of 
metabolism in skeletal muscle.    
1.3 Mstn splice variant (MSV) 
Mstn (see section 1.2) plays a significant role in regulating the mass of 
skeletal muscle mass. The expression of Mstn has been reported to be present in 
invertebrate species such as scallops, sea urchins and amphioxus, suggesting that 
Mstn in mammals arose from a common ancestral gene ~900 million years ago. 
The alternate splicing of the Mstn gene has been reported in bony fishes, and 
unpublished data from our laboratory has identified a cryptic intron in the third 
exon, which results in the generation of MSV in the Cetartiodactyl clade of 
mammals (Figure 1.6), including cattle, sheep, dolphins, pigs and alpaca. To date, 
the presence of MSV mRNA has been confirmed in cattle and sheep of different 
gestational and postnatal ages. The deduced polypeptide sequence of MSV 
contains an N-terminal domain of 256 amino acids, identical to that of Mstn and a 
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unique 65 amino acid C-terminal domain. This sequence is present in all 
organisms in the Cetartiodactyl clade, with the exception of alpacas, wherein the 
deletion of a single nucleotide in the C-terminal coding sequence codes for a 
premature stop codon (Jeanplong, Falconer et al. 2013).  
 
 
Figure 1.8: The Evolution of MSV. A phylogenetic topology plot showing the 
bootstrap consensus tree for a 1500 bp length of Mstn sequence from the start of 
exon 3 for a number of mammalian species (obtained from ensemble,
www.ensembl.org). Numbers above each branch indicate the percent confidence for 
each division. Incomplete splicing motifs (dogs, shrews, rat), or indels (horses, 
megabats, mice) either change the ORF (megabats), or introduce premature stop 
codons (horses, mice). The gradient of shading reflects the postulate that MSV 
splicing became progressively fixed in the Cetartiodactyl clade (A), but may be 
present in primates (B), although efforts have failed to detect MSV in human tissue 
and it is not present in other species. Taken from (Jeanplong, Falconer et al. 2013). 
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Included in the C-terminal region of MSV is a consensus cleavage site for 
precursor convertases, suggesting that as with other TGF-β family members, MSV 
is cleaved to liberate a 47 amino acid c-terminal region. An in-silico analysis of 
the secondary structure of the C-terminal region of MSV suggests that this region 
forms two putative alpha-helices in sheep, cattle, dolphin and pig, but not in 
primates where a single alpha-helix is predicted. The function of MSV has been 
investigated, using a recombinant protein for the 47 amino acid c-terminal region 
produced in E. coli. This preparation induces the proliferation of C2C12, Belgian 
Blue (double-muscled cattle) and ovine myoblasts in vitro. In support, ovine 
myoblasts treated with MSV were shown to have an increased number of cells in 
S-phase, with an increased nuclear abundance of CDK2 and cyclin E, critical 
regulators of the G1-S transition of the cell cycle (see 1.1.5.2). Treatment of ovine 
myoblasts with MSV has also been shown to increase the expression of Myf5 
transcript, which is consistent with the increased rate of proliferation. 
Furthermore, the expression of myogenin transcript is decreased, which indicates 
an inhibition of or delayed differentiation. Biacore analysis performed using 
MSV, demonstrated that MSV binds to both mature Mstn and its canonical 
receptor ACTRIIB with apparent high affinity with Kd values of 9.79 x 10-11 and 
3.18 x 10-9, respectively (Jeanplong, Falconer et al. 2013). Expression of MSV 
mRNA in foetal muscles from Belgian blue (double-muscled) and Friesian (wild-
type) cattle at different gestational ages showed increased concentrations in the 
developing Belgian Blue foetus. Interestingly, the Mstn mutation in Belgian Blue 
cattle (an 11 base pair deletion in exon 3) is contained in the cryptic intron 3 
sequence of the cattle Mstn gene, thus the alternate splicing of the sequence of 
MSV would not be affected. Despite the binding of MSV to both Mstn and its 
canonical receptor ACTRIIB, this binding does not appear to be able to directly 
antagonise Mstn function, because MSV could not repress the Smad dependant 
luciferase reporter activity induced by Mstn, suggesting that Mstn can still 
activate ACTRIIB in the presence of MSV. However, this does not rule out 
antagonism of Mstn in vivo by the N-terminal region of MSV, which contains 
almost the entire canonical LAP sequence of Mstn, which as mentioned earlier, 
has been previously shown to antagonise the function of mature Mstn (Thies, 
Chen et al. 2001). The inability of MSV to antagonise Mstn, coupled with its 
ability to increase the proliferation of myoblasts, strongly suggests that MSV may 
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signal through an alternate, as yet unidentified signalling cascade. Thus MSV 
appears to be a splice variant of Mstn, specific to the Cetartiodactyl clade of 
mammals.  MSV can interact with Mstn and its receptor and in so doing may 
modulate activity of Mstn, via acting as an intra-genic regulator of the Mstn gene. 
1.4 Scope and Aims 
The scope of this thesis is to build on the previous work investigating the 
function of MSV. Previous studies suggested that MSV could play a role in the 
growth of skeletal muscle, especially in livestock species given that they are in the 
Cetartiodactyl clade (Jeanplong, Falconer et al. 2013). Thus, understanding the 
mechanisms associated with MSV function and how they compare to those 
associated with Mstn, could prove useful in identifying elite animals for the meat 
industry. In addition, one aspect of the biology of Mstn that had not been 
addressed in the context of MSV is a potential role in skeletal muscle metabolism.  
Given the in vitro nature of these studies, the use of appropriate culture models 
was major consideration. Firstly, established protocols for isolating myoblasts 
(satellite cells) from sheep muscle, a tissue that contains endogenous MSV 
(Jeanplong, Falconer et al. 2013), provided an ideal model for investigating the 
signalling, gene expression and metabolic changes induced following the 
treatment of cultures with MSV. In addition, these could be compared to in 
parallel, with cultures treated with Mstn. Secondly, multiple studies have used 
C2C12 myoblasts that stably over-express proteins to investigate the function of 
target genes. Although they do not express endogenous MSV like ovine 
myoblasts, C2C12 myoblasts have been shown to respond to MSV treatment. 
Unlike primary cultures, C2C12 myoblasts have the added advantage that they can 
be maintained in proliferation for multiple passages and differentiated for more 
than two weeks, allowing investigations that cannot be performed using the more 
transient primary cultures. Thus, stable cell lines were generated to provide an 
additional model for investigating the function of MSV. This was done with the 
aim of further validating the changes observed in the ovine myoblast studies. 
These investigations were carried out to test the hypothesis that: MSV signals 
independently of Mstn to regulate myogenesis, and the intermediary metabolism 
of myoblasts. Furthermore, the studies performed on C2C12 myoblasts expressing 
MSV allowed initial testing of the hypothesis that, forced expression of MSV 
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influences myogenesis, intermediary metabolism and the abundance and/or 
phosphorylation of key molecules involved in the control of these processes.       
The aims of this thesis were to: 
1. Identify the early signal transduction (1 hr post treatment) and 
transcriptional expression changes (6 hr post treatment) associated 
with recombinant Mstn and MSV treatment in ovine myoblasts. 
2. Determine if MSV has a role in the intermediary metabolism of 
myoblasts.  
3. Identify the signal transduction cascades involved in MSV function 
and how these diverge from those regulated by Mstn. 
.     
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Chapter Two 
2 Materials and Methods 
2.1 Materials 
Common laboratory chemicals and reagents were procured from BDH 
(Radnor, PA, United States of America), Roche (Basel, Switzerland), Sigma-
Aldrich (St. Louis, MO, United States of America), BioRad (Hercules, CA, 
United States of America), Thermo Fisher Scientific (Waltham, MA, United 
States of America) and Life Technologies (Carlsbad, CA, United States of 
America). For specialised equipment and commercially available kits, the details 
are provided in the relevant Methods sections. 
2.1.1 Enzymes 
Enzymes were obtained from Roche, Life Technologies and Promega 
(Madison, WI, United States of America) as out lined in the relevant Methods 
sections.  
2.1.2 DNA Plasmids and glycerol stocks 
DNA plasmids used for these studies were the pET101D/-TOPO (Life 
Technologies), pcDNA3 (Life Technologies) and pGEM-T-easy (Promega) 
vectors. Glycerol stocks of transformed DH5α E. coli (Life Technologies) cells, 
were produced by diluting cultures in LB broth (Lennox Broth; Life 
Technologies) with 1:1 glycerol (BDH) before storage at -80°C. Plasmid DNA 
was isolated from stable transformants using either Quiagen mini- or maxi-prep 
plasmid isolation kits (Quiagen, Venlo, Limburg, Netherlands), according to 
manufacturer’s  instructions. Plasmid DNA isolated from bacterial transformants 
was re-suspended in H2O and stored at -20°C. 
2.1.3 Oligonucleotides (primers) 
Oligonucleotides used in these studies were obtained from Life 
Technologies and Custom Science Ltd (New Zealand). Sequences of primers and 
the experiments they were utilised for, are listed in Table 2.1. All oligonucleotides 
were resuspended in 100 µL MQ H20, with 1 µM and 10 µM primer stock 
solutions prepared from these parent solutions, all primer stocks were stored at     
-20°C. The design of specific primers for gene amplicons was performed using 
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Vector NTI (Life Technologies) software, to align RNA sequences from sheep 
and mouse, with primer design performed using Primer 3 software (Rozen and 
Skaletsky 2000). 
 
 
2.1.4 Antibodies 
Antibodies used for western blot analysis were purchased from multiple 
sources, the antibody catalogue number and the dilution used for western blot are 
outlined in brackets, with antibodies detecting phosphorylated protein denoted  
S CAACTTTGGGTCACTTGGAA
AS TGTCTGGAAACCTGAGCAGA
S ACATGAAGTTCTCCGCTGCT
AS AGCTTCTTTGGGACACTTGC
S TGTCAGTGCTCTTGCTCCAC
AS GCTTGCTTCACCCACTTCTT
S GGCAACGACTTTGACTACCC
AS CTGCTTCGCTTCGTCCTC
S AAACCACCTCTGCCATCCTT
AS CCATCTTGTGATTGCCAGTG
S CTGGGTTCCCTGGTCTGTAA
AS GGGTGGATGCTCTGTAGTGG
S AGAGCAGCAGGAAGGAGATG
AS CCACAGCATAACCGCACA
S CCTGGATACCTCGGAAACCT
AS GCTGATCTGGGCTTGATGAT
S TGGTGATGACTTCTGCTTTCC
AS GCCAGTGTCTCCTTGCTGTT
S GCGTGGAATCAATGACCTTT
AS AGGACTCAGAAGCGGATGG
S AACGTCGTCTCTCCAGCAAT
AS CAGCATGGTGAAGAGCTTGT
S CTGGAACTCGGAGAAGAAGG 
AS GCCACTCGGTCCTGATATGT
S GCAACTACGGTTTCCGTCTC
AS TCATGTGCTCCAGCTTCTTG
S ATGTGCCCTCACACCTCTTT
AS GCTAGGTCTCGGAGCAGTTG
ATP1B1
p53 195
PDK3 232
Ccl20
CEBPα
CTNND2
LDLRAD4
FGFR4
IL1A
IL6
OSR2
PTX3
Gene Sense/Antisence Sequence Amplicon size (bp)
188
188
211
190
202
190
183
189
165
207
171
208
BHLH40
Ccl2
Table 2.1: Oligonucleotides used for qPCR analysis. Sequences 
for sense (S) and anti-sense (AS) oligonucleotides used for qPCR 
analysis. Sequences are shown in 5’ to 3’ orientation. Sequences were 
designed to amplify ovine target sequence, with the exception of ATP1B1 
where a region that was conserved between mouse and ovine models was 
utilised for primer design.    
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(P-) and the phosphorylation epitope outlined in superscript where applicable. 
Antibodies were purchased from:  
1. Developmental Studies Hybridoma Bank (DSHB, Iowa, United States 
of America): Pax7 monoclonal antibody. 
2. Cell Signalling Technology (Danvers, MA, United States of America): 
Acetyl CoA Carboxylase (cs-3676, 1:2000),  P-Acetyl CoA CarboxylaseSer79 (cs-
3661, 1:3000), 4EBP-PThr37/46 (1:1000), rpS6 (cs-2217, 1:100000), P-rpS6Ser 235/236 
(cs-2211, 1:5000), p38 MAPK (cs-9212, 1:2000), P-p38 MAPKThr180/Tyr182 (cs-
9211, 1:1000), CyclinE (cs-4132, 1:2000), PDK1 (cs-9211, 1:10000), P-
PDK1Ser241 (cs-3061, 1:10000), P-AktSer473 (cs-4058, 1:1000), AMPK (cs-2532, 
1:30000), P-AMPKThr172 (cs-2535, 1:20000), p70s6K (cs-9027, 1:2000), P-
p70s6KThr389 (cs-9234s, 1:1000), with all antibodies derived from rabbit hosts. 
3. Santa Cruz Biotechnology, Inc (Dallas, TX, United States of America): 
Myf-5 (sc-302, 1:3000), CDK2 (sc-163, 1:20000), Myogenin (sc-576, 1:10000), 
4EBP1 (sc-6936, 1:2000), MRF4 (sc-784, 1:3000), P-AKTThr308 (sc-16646, 
1:30000), Smad2/3 (sc-6032, 1:3000), P-Smad2/3Ser 423/425 (sc-11769, 1:10000), 
Mef2 (sc-313, 1:20000), ERK1/2 (sc-94, 1:50000), P-ERK1/2Thr 202/204 (sc-16982, 
1:10000), MyoD (sc-304, 1:3000), AKT (sc-8312, 1:10000), with the antibodies 
derived from  rabbit hosts with the exception of Smad2/3 (Goat). 
4. Dako (Glostrup, Denmark): Goat anti mouse-HRP (P0447, 1:5000), 
Goat anti-rabbit-HRP (P0448, 1:5000) and Rabbit anti-goat (P0160, 1:5000).  
Antibodies utilised for other applications are outlined in the relevant 
method sections. 
2.1.5 Mammalian cell lines 
Mammalian cell lines used for this thesis include mouse C2C12 myoblasts, 
Chinese hamster ovary (CHO) cells and Human embryonic kidney (HEK) 293 
cells, with all of these cell lines sourced from ATCC (Manassas, VA, United 
States of America). Primary myoblasts were isolated in-house as described in the 
relevant method sections. 
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2.1.6 Cell Culture 
Cell culture medium components were from Life Technologies 
(Dulbecco’s Modified Eagle Medium (DMEM), chemical media, horse serum 
(H/S) and foetal bovine serum (FBS)) and Sigma-Aldrich (Phenol red, penicillin, 
streptomycin, ampicillin and geneticin). DMEM media with serum was 
supplemented with 7.22 nM phenol red, 1 x 105 U/L penicillin, and 100 mg/L 
streptomycin. Geneticin (500 µg/mL) was added to media used for the selection 
and maintenance of stably transfected cells. Chemical media was supplemented 
with 1 x 105 U/L penicillin, and 100 mg/L streptomycin. Cell lines were cultured 
at 37°C with an atmosphere of 5% CO2 in a ThermoForma Series II, water 
jacketed CO2 incubator (Thermo Fisher Scientific). Culture dishes were purchased 
from Thermo Fisher Scientific. Details for specialised cell culture components are 
outlined in the relevant methods sections.  
2.2 Methods 
2.2.1 Isolation of ovine myoblasts from late gestation foetal lambs 
Primary myoblasts were cultured from the semitendinosus muscle of late 
gestation foetal lambs, based on previously described techniques (Allen, Temm-
Grove et al. 1997; Partridge 1997; McCroskery, Thomas et al. 2003). Briefly, 5 g 
of muscle was excised, and then finely minced in sterile PBS (Thermo Fisher 
Scientific). The resulting slurry was centrifuged (1500 rpm for 1 min) to remove 
PBS. The muscle pellet was then resuspended in DMEM (no serum) that 
contained 0.2% collagenase type 1A (Sigma-Aldrich). The resulting slurry was 
incubated for 90 min with agitation at 37°C. Following centrifugation at 2500 rpm 
for 10 min, the collagenase solution was removed, fresh PBS was added and the 
digested muscle triturated to release attached myoblasts from muscle fibres. The 
resulting solution was then passed through a 100 µm cell strainer (Becton 
Dickinson (BD); Franklin Lakes, NJ, United States of America) to remove bulky 
muscle debris. The filtrate was then centrifuged at 2500 rpm for 10 min, and the 
supernatant removed. The resulting pellet was resuspended in growth media 
(DMEM with 20% FBS, 10% H/S). Cultures were then enriched for myoblasts by 
pre-plating on uncoated 10 cm cell culture plates (Thermo Fisher) for 3 h. 
Cultures were then transferred to 10 cm culture plates that were coated with 10% 
Matrigel (BD) in DMEM (no serum) and incubated in an atmosphere of 5% CO2 
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at 37°C for a period of 48 h to allow for the attachment and proliferation of 
myoblasts. Once sufficient numbers of myoblasts were present, cultures were 
trypsinised and the myoblasts cryogenically frozen in freeze media (DMEM with 
10% and 5% dimethyl sulfoxide (DMSO) (BDH)), and stored in liquid nitrogen 
for later use. A previous unpublished study in our laboratory demonstrated that 
ovine myoblasts isolated using this method yields cultures of high myogenic 
purity, with Pax 7 immunofluorescence demonstrating that approximately 90% of 
the cells isolated express this important myogenic marker.     
2.2.2 Trypsinisation of myoblasts 
The trypsinisation of all cell types was performed as follows: The culture 
medium was removed and the cells rinsed with sterile PBS (Thermo Fisher). 
Trypsin (Life technologies) was then added (0.25% solution in PBS)  and the cells 
were incubated for 5-10 min at 37°C. Once the cells had detached, fresh media 
was added to inactivate the trypsin and resuspend the cultured cells. Cell density 
was established using a haemocytometer before re-plating for further culture. 
2.2.3 Generation of a consistent ovine myoblast pool. 
In order to generate a pool of myoblasts that would be consistent 
throughout the course of these studies, myoblasts from seven individual male 
animals were removed from cryostasis and allowed to proliferate for one passage 
(~72 h). The proliferating cells were then trypsinised, pooled and cryopreserved in 
freeze media (DMEM with 5% FBS and 5% DMSO (BDH)) in 1 mL aliquots that 
contained ~2 x 106 cells. Cells were then stored in liquid nitrogen and resurrected 
as experimentally required. 
2.2.4 Culturing and treatment for microarray 
Primary ovine myoblasts were resurrected and plated at a density of 15000 
cells/cm2 in DMEM with 10% FBS on 10 cm diameter culture plates. Following 
overnight attachment, myoblasts were given a media change and allowed to 
proliferate for a further 24 h. Cells were then subjected to a 6 h treatment (in 
triplicate) with either 660 ng/mL Mstn (R&D Systems, MN, United States of 
America), 3 µg/mL in house recombinant MSV or vehicle alone (control) before 
RNA was harvested using 2 mL TRIZOL® reagent (Life Technologies) per plate 
as per manufacturers instructions.  
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2.2.5 RNA isolation and reverse transcription.  
RNA extraction from TRIZOL® (Life Technologies) samples was 
performed according to manufacturer’s instructions. The concentration of isolated 
RNA samples was determined in duplicate using a Nandrop 1000 
spectrophotometer. RNA samples were then diluted to a concentration 500 ng/mL 
and 2 µg (4 µL), of total RNA was used to synthesize cDNA with the superscript 
III (Life Technologies) reverse transcription kit as per manufactures instructions. 
2.2.6 Agarose gel electrophoresis of RNA  
RNA integrity was confirmed by running 1 µg of isolated RNA, on an 
agarose gel containing 1.2% agarose, 20 mM MOPS, and 0.66M formaldehyde. 
Prior to loading the RNA sample (made up to 5 µL total volume with DEPC 
water) was mixed with an equal volume of RNA loading dye (20 mM MOPS, 
20% formaldehyde, 50% formamide, 5 mM EDTA, 0.04% bromophenol blue, 50 
µg/mL ethidium bromide and 10% glycerol) and incubated at 65°C for 5 min, 
before loading. RNA was visualised under UV light using a Geldoc system 
(BioRad).  
2.2.7 Microarray Analysis 
Once the integrity of the purified RNA was confirmed, samples were sent 
to Auckland University for microarray analysis. Microarray analysis using 500 ng 
of total RNA was performed by the Microarray Facility (Centre for Genomics and 
Proteomics, University of Auckland).  Analysis was performed by labelling 
isolated RNA with the Ambion Message Amp Premier 3' labelling kit  using the 
GeneChip® Bovine Genome Array platform containing over 23000 bovine 
transcripts.  Microarray data was supplied as data files, containing the intensity 
values for all array analysis performed. Two standard methods were employed to 
normalise the microarray data before analysis (AgR Bioinformatics/Math and 
Statistics Department). Affymetrix MicroArray Suite 5 (MAS.5) and Robust 
Multi-array Average (RMA) analysis were used to independently normalise the 
microarray data. RMA analysis was favoured due to the reduced data variation 
observed using this normalisation method. Following RMA analysis, the resulting 
normalised data had fold expression changes calculated for the following 
comparisons: 
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i. Control vs Mstn 
ii. Control vs MSV 
Following normalisation, P-values were calculated using an empirical 
Bayesian technique to shrink the standard errors towards a common value. A data 
set containing gene identifiers and corresponding expression values was uploaded 
into Ingenuity Pathway Analysis platform (www.ingenuity.com). Each identifier 
was mapped to its corresponding object in the Ingenuity® Knowledge Base. Cut-
off values of a fold change of +/- 1.5 with a P-value of < 0.05 were imposed to 
identify molecules whose expression was significantly different between datasets. 
These molecules, called Network Eligible Molecules, were overlaid onto a global 
molecular network developed from information contained in the Ingenuity® 
Knowledge Base. Networks of Network Eligible Molecules were then 
algorithmically generated based on their connectivity. The results of each 
comparison were analysed using Ingenuity® Pathway Analysis (IPA: 
www.ingenuity.com) to provide extra information on the biological ‘themes’ of 
the data.  
2.2.8 Polymerase chain reaction (PCR) 
2.2.8.1 Standard PCR 
Two different DNA polymerases were used during the course of these 
studies. Expand long polymerase (Roche) was used for the initial amplification of 
the MSV expression cassettes, where proof reading activity was required. For 
standard PCR where visualisation of PCR products was required Taq polymerase 
(Roche) was used. PCR reactions were performed in a PTC-0200 DNA Engine 
Peltier Thermal Cycler (BioRad). For PCR reactions 2 µL of template DNA was 
amplified in a 50 µL reaction mix containing: 5 µL of 10 x PCR buffer (as 
supplied for individual enzymes), 1 µL of dNTPs (Life Technologies), 1 µL of 10 
µM sense and anti-sense primer, 1 µL of enzyme and 40 µL of PCR grade H20. 
PCR cycling was performed as follows: 94°C for 1 min (denaturation), then 35 
cycles of 94°C for 15 s, 55°C for 45 s (annealing) and 72°C for 2 min, then a final 
extension at 72°C for 5 min was performed. PCR products were visualised using 
agarose gel electrophoresis.  
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2.2.8.2 Quantitative real-time PCR (qPCR) 
PCR was carried out with 2.5 µL of a 1:20 dilution (in PCR grade H2O) of 
the reverse transcriptase reactions and 7.5 µL of master mix for each reaction (4.5 
µL water, 0.5 µL of a 1 µM solution of forward and reverse primers and 2.0 µL 
FastStart DNA Master plus SYBR Green I reagent (Roche). A dilution series of 
pooled cDNA generated from the treated ovine myoblasts was used to establish a 
standard curve. PCR cycling was performed as follows: denaturation (95°C for 5 
min), amplification (95°C for 5 s, 62°C for 10 s, 72°C for 20 s, with a single 
fluorescence measurement every cycle for 45 cycles), melt curve analysis (60-
95°C with a heating rate of 0.1ºC/s with continuous fluorescence measurement) 
using a LightCycler 2.0 PCR machine (Roche Diagnostics). Arbitrary 
concentrations were calculated by the LightCycler software using the standard 
curve (Roche Diagnostics). Data for each sample were normalized to cDNA 
concentration in each parent RT reaction as determined using the Quant-it 
OliGreen ssDNA kit (Life Technologies) as per manufacturer’s instructions. The 
PCR products were visualised using agarose gel electrophoresis to confirm the 
size and the specificity of the amplified products.  
2.2.9 Agarose Gel Electrophoresis of DNA  
Agarose gels contained 0.8-3% agarose or LMP agarose and were made in 
1 X Tris-acetate-EDTA (TAE) buffer (0.4M Tris (base), 1.14% Glacial acetic acid 
and 1mM EDTA (pH 8)), with 100 ng/mL ethidium bromide. Electrophoresis was 
performed using an Owl electrophoresis system (Owl Separation Systems) 
containing 1 X TAE buffer. DNA samples were mixed with DNA loading dye and 
then loaded. Electrophoresis was performed at 30-100 V until the desired 
separation was achieved. DNA samples were visualised under UV light and 
photographed using the Gel Doc system (BioRad). 
2.2.10 Methylene blue proliferation assay 
For proliferation assays, a previously published photometric endpoint 
assay was used (Oliver, Harrison et al. 1989). Briefly, for each cell-type or 
treatment 1000 cells/well were seeded in 96 well cell culture plates using one 
plate per time-point. Following the specified proliferation period, the cells were 
fixed in 100µl of 10% formaldehyde in 0.9% saline per well and stored at room 
temperature prior to assay. For methylene blue assay, fixative was removed and, 
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100 µl of methylene blue stain was added to each well for 20 min at room 
temperature. After the removal of the staining solution, the cells were washed four 
times with 200 µl of 0.01M Borate buffer (pH, 8.5), followed by the addition of 
200 µl of a 1:1 mixture of 0.1 M HCl and 70% ethanol to solubilise the cells and 
liberate the retained methylene blue stain. The absorbance of the wells was 
measured using a VersaMax tuneable microplate reader (Molecular Devices) at 
655 nm, with the absorbance directly proportional to cell number. 
2.2.11 Primary culture of mouse myoblasts 
Primary myoblasts were cultured from the hind limb muscle of four week 
old wild-type and Mstn null mice. Muscle was excised then minced finely in 
sterile PBS (Thermo Fisher).  The resulting slurry was then centrifuged (1500 rpm 
for 1 min) and PBS removed. The muscle pellet was then resuspended (5mL per 
mouse of DMEM (no serum) containing 0.2% collagenase type 1A (Sigma-
Aldrich) and digested for 90 min with agitation at 37°C. Following centrifugation 
(2500 rpm for 10 min), the collagenase solution was removed, with fresh PBS ~12 
mL per mouse added and the digested muscle triturated to release attached 
myoblasts from muscle fibres. The resulting solution was then passed through a 
100 µm cell strainer (BD) to remove bulky muscle debris. The filtrate was then 
centrifuged (2500 rpm for 10 min, the supernatant removed and the resulting 
muscle pellet resuspended in growth media (DMEM/ 20% foetal bovine serum 
(FBS), 10% Horse serum (H/S).  Cultures were then enriched for myoblasts by 
pre-plating on uncoated cell culture plates for 3 h. Cultures were then transferred 
to plates coated with matrigel (Beckton Dickenson) at a 1:10 dilution DMEM (no 
serum) and incubated in an atmosphere of 5% CO2 at 37°C for 48 h to allow the 
attachment and proliferation of myoblasts. Once sufficient numbers of myoblasts 
were present, cultures were trypsinised, counted using a haemocytometer and re-
plated for proliferation or differentiation studies.  
2.2.12 Assessment of Na+ K+ ATPase β1 subunit transcript abundance in wild-
type and Mstn null primary myoblasts.  
For proliferation wild-type and Mstn null primary myoblasts were plated 
at a density of 15000 cells/cm2 and left to attach overnight, following 24 h 
proliferation cells were harvested with TRIZOL® reagent for subsequent RNA 
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isolation. For differentiation studies myoblasts were seeded at a density of 25000 
cells/cm2 and allowed to attach overnight. Following overnight incubation at 37°C 
with 5% CO2 cultures were switched to differentiation media (DMEM + 2% H/S) 
and incubated for a further 48 h, before TRIZOL® reagent (Life Technologies) 
was used to harvest cultures for RNA extraction.  
2.2.13 Na+ K+ ATPase ATP hydrolysis assay 
The method for measuring NKA dependant ATP hydrolysis was based on 
the technique described by Hatou et al (Hatou, Yamada et al. 2010). For these 
studies, ovine myoblasts were seeded at a density of 15000 cells/cm2 in 24 well 
plates in DMEM with 10% FBS. Following overnight attachment cells were given 
a media change (DMEM + 5% FBS) and incubated for a further 24 h. The sub 
confluent cultures were then treated with R & D Mstn (100 ng/mL), MSV (3 
µg/mL), insulin (100 nM) or vehicle alone (control) and harvested after 1, 6, 12 
and 24 h intervals. Culture medium was then removed from cell monolayers, and 
ultrapure distilled water (150 µL) was added to each well. The culture plate was 
then placed in liquid nitrogen for 10 s (to freeze cultures), and 150 µL of lysis 
buffer (80 mM histidine, 20 mM KCl, 6 mM MgCl2, 2 mM EGTA, 2 µg/mL 
alamethicin (Sigma-Aldrich), 30 µM digitonin (Sigma-Aldrich), and 200 mM 
NaCl at pH 7.4) was added to each well. Half of the wells from each treatment 
(N=6), were then incubated with 20 µL of 15 mM ouabain (final concentration, 1 
mM) or vehicle alone (H2O) for 30 min at 37°C. Finally, 10 µL of 300 mM ATP 
(final concentration, 10 mM) was added and the reaction mixtures were incubated 
for an additional 30 min at 37°C. The ATP hydrolysis reaction was terminated by 
the addition of 75 µL of 50% trichloroacetic acid to each well. The contents of 
each well were then centrifuged at 3000rpm for 10 minutes at room temperature. 
The resultant supernatants were diluted 50-fold with ultrapure distilled water, and 
25 µL of the diluted samples were added to tubes containing 100 µL ammonium 
molybdate reagent (BiomolGreen; ENZO Life Sciences, Farmingdale, NY, United 
States of America), with phosphate content determined by measurement of 
absorbance at 640nm. Phosphate solutions of 0 to 40 µM diluted in Lysis buffer 
were used to generate a standard curve. Hydrolysed ATP values were normalised 
to protein concentration of the reaction mixtures as determined using the 
bicinchoninic acid assay (2.2.17). The Na+, K+-ATPase activity was calculated as 
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the difference in hydrolysed phosphate between cells exposed to ouabain and 
those not and was expressed as millimoles of ATP hydrolysed per mg of protein 
(per hour). 
2.2.14 Production of recombinant MSV  
The production of MSV was performed as follows, Origami B E. coli (Merck 
Millipore, Darmstadt, Germany) cells that were transformed with the pET100/D 
TOPO vector containing the putative mature sheep MSV sequence (aa 275-321) 
were used for the expression of MSV. Recombinant protein was purified with the 
use of the MSV N-terminal histidine tag and Ni-NTA resin (Life Technologies), 
according to the Life Technologies native purification protocol. Purified 
recombinant protein was dialysed against two changes of dialysis buffer (20 mM 
TRIS-HCl pH 7.0, 150 mM NaCl) at 4°C overnight. Protein concentration was 
determined using the bicinchoninic acid protein assay (2.2.17).    
2.2.15 Recombinant protein purification using Polymyxin or Triton X-114  
Purification of MSV with Affi-Prep® Polymyxin Matrix (BioRad) was 
performed as per manufacturer’s instructions by incubating 500 µL of 1 mg/mL 
MSV per mL Polymyxin (binding capacity 5 mg/mL endotoxin) with constant 
stirring at 4°C in a 1.5 mL tube. Mixtures were incubated overnight at 4°C with 
constant stirring, samples were the centrifuged (14000 x g for 10 min) and the 
supernatant recovered as purified recombinant protein.  Triton X-114 purification 
was performed by adding Triton X-114 to the protein preparation at a final 
concentration of 1%. The mixture was then incubated at 4°C for 30 min with 
constant stirring to ensure a homogenous solution. The sample was then 
transferred to a 37°C water bath, incubated for 10 min, and centrifuged at 14000 x 
g for 10 min at 25°C. The upper aqueous phase containing the protein was 
carefully removed and subjected to Triton X-114 phase separation for at least 
three further cycles. Protein concentration was then assessed with the 
bicinchoninic acid assay (2.2.19). All samples had endotoxin concentration 
assessed using the Lonza LAL Kinetic QCL kit (Lonza, Basel Switzerland).  
2.2.16 Isolation of cellular protein 
Protein was isolated from cultured myoblasts as follows. Following 
treatment, 300-500µL of low salt lysis buffer (10 mM Hepes-NaOH (pH 7.9), 10 
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mM MgCl, 5 mM KCl, 0.1 mM EDTA, 0.5 % IGEPAL (Sigma-Aldrich), 2mM 
vanadate, 2mM NaF, MQ H20 to 25 mL, with half a Complete protease inhibitor 
tablet (Roche)) was added to each plate or well. Cells were then scraped off the 
culture surface and the resulting lysates were transferred to individual 1.5 ml 
tubes before freezing at -80°C. Cell lysates were later thawed and repeatedly 
passed through a 29-gauge needle before centrifuging at 14000 x g for 5 min at 
4°C to pellet cell debris and the supernatant was taken as a total cell lysate.  
Alternatively, if enrichment of cytoplasmic and nuclear components was required, 
cells were initially triturated after thawing with a 100 µL pipette tip and incubated 
on ice for 15 min, lysates were then centrifuged at 14000 x g for 3 min at 4°C to 
pellet cell nuclei. The resulting supernatant was removed and stored separately as 
the cytoplasmic fraction. The pellet was then resuspended in 250 µL high salt 
lysis buffer (20 mM Hepes-NaOH (pH 7.9), 1.5 mM M MgCl, 500 mM NaCl, 0.2 
mM EDTA, 25% Glycerol, 2 mM vanadate, 2 mM NaF, MQ H20 to 25 mL, with 
half a Complete protease inhibitor tablet (Roche)) and repeatedly passed through a 
29-gauge needle (BD) before incubating on ice for 30 min with intermittent 
flicking. The lysate was then centrifuged at 14000 x g for 3 min at 4°C and the 
supernatant retained. The supernatant was then loaded into an Amicon® Ultra 3K 
centrifugal filter (Merck Millipore) and spun at 4500 x g for 30 min to reduce the 
salt concentration per unit protein. The portion remaining in the upper chamber 
(typically 170-200 µL) was retained as nuclear enriched lysate. Aliquots (30 µL) 
of each type of lysate were diluted 1:1 in MQ H2O to determine the concentration 
of the protein (see 2.2.19) and the remaining lysates were diluted 2:1 with 3x 
Laemmli buffer (final con 10% glycerol, 5% β-mercaptoethanol, 2% SDS, 60 mM 
Tris (pH 6.8)). Lysates were boiled for 5 min then stored at -20°C in 100 µL 
aliquots for subsequent western blot analysis. 
2.2.17 Determination of protein concentration 
The concentration of protein samples was determined using the 
bicinchoninic acid protein assay (Sigma-Aldrich). Protein lysates were diluted 1:1 
with MQ H20 and 25 µL was added to 200 µL of a 50:1 mix of bicinchoninic acid 
solution and Copper (II) Sulphate Pentahydrate 4% solution (Sigma-Aldrich). 
BSA standards (25 µL of 0 to 2 mg/mL solutions) were used to generate a 
standard curve. Assay mixtures were incubated in duplicate at 37°C on 96 well 
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plates (Thermo Scientific) for 30 min before OD562 for each sample was 
determined using a VERSAmaxTM tunable microplate reader (Molecular Devices, 
Sunnyvale, CA, United States of America) to estimate protein concentration.  
2.2.18 SDS Polyacrylamide Gel Electrophoresis and Membrane Transfer 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was performed using 
10-15% polyacrylamide gels. Typically 5 to 15 µg of protein pre-mixed and 
boiled in Laemmli buffer (3 x solution; 30% glycerol, 15% β-mercaptoethanol, 
6% SDS, 180 mM Tris (pH6.8) and a few grains of bromophenol blue) was 
thawed and loaded into the gels. Electrophoresis of the proteins was performed 
using 1 x running buffer (25 mM Tris base, 200 mM glycine, 0.1% SDS) at ~45 
mA per gel until the bromophenol blue band reached the bottom of the gel. 
Following electrophoresis, proteins were transferred from the gel to nitrocellulose 
or PVDF membrane (Bio-Rad) by electro-blotting at 30 V overnight at 4°C. 
Following transfer, the membranes were stained with Ponceau Stain (0.05g 
Ponceau powder, 2.5 mL acetic acid, then up to 50 mL with H20) and then rinsed 
in H2O until bands were clearly defined, to confirm proteins had been uniformly 
transferred to the membrane.  
2.2.19 Western blot analysis 
Membranes were blocked in BSA blocking solution (Tris Buffered Saline-
Tween (TBST) buffer (50 mM Tris (pH 7.6), 150 mM NaCl, 0.1% Tween 20), 
plus 1% PEG-4000, 1% PVP-10, 0.3% BSA and 0.01% Thimerosal) for at least 1 
hr at room temperature and then incubated with primary antibody diluted in BSA 
blocking solution overnight at 4°C (see 2.1.4 for antibody dilutions). Membranes 
were then washed in TBST for 5 min (x5), then incubated with species specific 
horseradish peroxidise conjugated antibodies (Dako) (1:5000 in BSA blocking 
solution) for 1 h at room temperature. The TBST washes were then repeated 
before subjecting the membrane to Western Lightning™ Chemiluminescence 
Reagent Plus (Perkin-Elmer, Waltham, MA, United States of America), 
chemiluminescence was then visualised by exposure to XAR film (Kodak, 
Rochester, NY, United States of America), or using the ImageQuant LAS 4000 
system (GE Healthcare; Little Chalfont, Buckinghamshire, United Kingdom). 
Developed films were scanned on a calibrated densitometer (GS-800, BioRad) 
and Quantity One software (Bio-Rad) used for the densitometry analysis of both 
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visualisation methods. Ponceau staining and visualisation was used to confirm 
equal loading and transfer of protein samples. The use of housekeeping genes 
such as tubulin, GAPDH and actin was not employed. The reasoning here was 
that these housekeeping genes are involved in pathways that have been shown to 
be influenced by treatment with Mstn, for example GAPDH in glycolysis and 
actin and tubulin in cell growth and differentiation. Thus comparing the 
abundance of western targets based on total protein loading was preferred. In 
addition, data obtained using this method for quantifying protein abundance has 
being published in numerous peer reviewed publications, with (Alway, Degens et 
al. 2002; Quadrilatero, Bombardier et al. 2010; Baseler, Dabkowski et al. 2013; 
Ilori, Blount et al. 2013) providing examples. 
2.2.20 MSV over-expression  
2.2.20.1 Restriction endonuclease digestion  
For restriction endonuclease digests, up to 10 µg of plasmid DNA was 
digested with 0.5-2 µL (3-20 U) of the appropriate enzyme. Digests were 
performed in 1 x restriction endonuclease buffer, with digest volumes between 30 
and 50 µL. Reactions were carried out at 37°C for at least 2 hours. DNA 
electrophoresis (2.2.9) was then used to characterise the digest and isolate DNA if 
required for subsequent manipulation. 
2.2.20.2 DNA Ligations   
Two types of ligation were used for the generation of the MSV expression 
constructs. Firstly the p-GEM-T easy system (Promega) was used to clone PCR 
products according to manufacturers protocol. Briefly, a 4-6 fold molar excess of 
insert DNA was used for cloning into the pGEM-T easy vector. The 10 µL 
ligation mix consisted of 1 x rapid ligation buffer, 50 ng pGEM-T easy vector, the 
appropriate volume of DNA insert and 0.3 Weiss units/µL of T4 DNA ligase. 
Ligations were incubated overnight at 4°C. Secondly, for the generation of MSV 
expression plasmids (Life Technologies), EcoRI digested insert (MSV) and vector 
(pcDNA3 (Invitrogen)) at a ratio of ~4:1, respectively, were combined for the 
ligation reaction, that was composed of 1 x ligation buffer (Roche, Basel, 
Switzerland) and 1U T4 DNA polymerase (Roche).  Reactions were incubated 
overnight at 4°C. 
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2.2.20.3 Transformation of competent cells 
Transformation of DH5α competent E. coli (Life Technologies) cells was 
performed by the addition of 2-5 µL of ligation mixture to 50 µL of competent 
cells. This mix was incubated on ice for 30 min and then heat shocked at 42°C for 
30-45 s. Cells were then cooled on ice for 2 min, after which, 450 µL of LB media 
was added. Transformed cells were then incubated with agitation for 1 h before 
plating 100-500 µL on to LB agar plates containing 50 µg/mL ampicillin (Life 
Technologies).  
2.2.20.4 Cloning of Full-length MSV 
Initially, MSV expression cassettes were PCR amplified using the 
previously generated pET101/D-MSV vector as the PCR template (Frank 
Jeanplong, Developmental Biology Group, AgResearch Ruakura, New Zealand). 
This vector contained full-length MSV with a mutated stop codon upstream of the 
sequence coding for V5 and histidine epitopes. PCR amplification of the MSV 
cassettes for cloning into the pcDNA3 vector was performed using the Expand 
Long Template high fidelity PCR System (Roche). Custom synthesis of two 
reverse primers allowed the generation of both C-terminal tagged                         
(C-MSV 5’- GGAATTCCTTTGTTAGCAGCCGGATCAAACTCA-3’) and non-
tagged (MSV 5’-GGAATTCCTTCGAATTGAGCTCGCCCTATTTCAT-3’) 
MSV cassettes. Reverse primers also contained sequence coding a 5’ EcoRI 
restriction enzyme sequence, to allow the subsequent cloning of the MSV 
expression cassettes into the pcDNA3 vector. The primer sequence for MSV R 
(non-tagged) contained a single nucleotide mutation (A in the MSV reverse 
primer sequence) to generate a correctly placed stop codon in the amplified MSV 
ORF. The C-MSV primer sequence was designed to include the V5 and histidine 
sequences thus, maintaining the mutated stop codon in the original template 
sequence. The T7 forward priming site, located in the pET101/D vector, upstream 
of the MSV ORF sequence used as the forward primer in the amplification of both 
MSV cassettes, which was upstream of an EcoRI restriction site. Following PCR 
amplification, reactions had standard Taq polymerase added for 5 min at 72°C to 
allow A tailing of the PCR products for their subsequent cloning into pGEM-T 
easy. PCR products were then purified by running on a low melting point agarose 
gel, with the MSV expression cassettes then excised and purified using the 
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Wizard DNA purification system (Life Technologies) as per manufacturers 
instructions. MSV cassettes were then TA cloned into the p-GEM T-easy vector 
(Promega) and the resulting ligation transformed into DH5α competent cells. 
EcoRI (Life Technologies) restriction digests were then used to identify positive 
transformants and to purify the MSV and C-MSV cassettes. Purified MSV 
cassettes were then ligated into EcoRI digested pcDNA3 vector using T4 DNA 
ligase (Roche), to generate the pcDNA3-MSV and pcDNA3-C-MSV expression 
constructs. Confirmation of the orientation of the MSV constructs were confirmed 
using restriction enzyme digestion in the first instance (data not shown). 
Secondly, clones displaying the expected restriction fragment sizes were DNA 
sequenced to confirm the integrity of MSV sequence (Allan Wilson Centre 
Genome Service; Massey University, Palmerston North, New Zealand). The DNA 
Sequence alignment of the pcDNA3/MSV and C-MSV constructs was performed 
using freely available online software (www.justbio.com), with the MSV 
construct sequences aligned to the predicted DNA and translated protein sequence 
of ovine MSV (GenBank accession number: DL465814.1).  
2.2.20.5 Transfection and generation of MSV over-expressing cell lines 
To generate stable (C2C12, HEK293 and CHO) MSV expressing cell lines, 
cells were transfected with the plasmids carrying the MSV expression cassettes or 
empty pcDNA3 vector using Lipofectamine 2000 reagent (LF2000, Life 
Technologies) according to the manufacturer’s protocol. Briefly for each 
individual transfection 12 µg of plasmid DNA in 1.5 mL DMEM (no serum) was 
mixed with 40 µL of LF2000 in 1.5 mL DMEM (no serum), the resulting mixture 
was added drop-wise to 7 mL of culture media (DMEM with 10% FBS) in a 10 
cm culture dish that contained sub-confluent cultures of the cell type to be 
transfected. Following a   24 h incubation period, the culture media was changed 
and cell lines were developed by selection in DMEM with 10% FBS containing 
500 µg/mL geneticin. Cells were the passaged as required until full neomycin 
resistance was acquired (~3 weeks of culture). Cells were the cryogenically stored 
for later use, with passage number kept consistent for all experiments and cells 
continually maintained in the presence of 500 µg/mL geneticin. Geneticin 
concentration was chosen based on similar studies performed previously 
(McFarlane, Hennebry et al. 2008). Clonal C2C12 cell lines were developed from 
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the initially transfected C2C12 cell pool. Clonal selection was achieved by seeding 
neomycin resistant C2C12 cells from MSV, C-MSV and pcDNA3 pools at 1000 
cells per plate in 10 cm culture dishes. Cells were allowed to proliferate under 
continued geneticin selection until individual clonal colonies were of sufficient 
size to remove cells. Cells scraped from individual colonies were seeded in 
individual culture dishes. Clonal cultures were then expanded until sufficient cells 
were available for cryogenic storage of individual clonal cell lines.   
2.2.21 Mitochondrial activity (EZ4U) assay  
Cultured C2C12 myoblasts expressing MSV were seeded in 96 well plates 
(Thermo Fisher) at 1000 cells per well. Cells were cultured in growth media 
(DMEM with 10% FBS) and allowed to attach overnight at 37°C with 5% CO2. 
Mitochondrial activity (EZ4U assay; Biomedica, Wein, Divischgasse, Austria) 
was determined following overnight attachment (T0) and after 24, 48 and 72 h of 
proliferation. The EZ4U assay was performed as per manufacturer’s instructions, 
with EZ4U reagent added (20 µL per well) and cells incubated for 2 h hour, 
before measuring OD450 (EZ4U) and OD620 (reference/background).  
2.2.22 C2C12 (MF20 fluorescence) differentiation assay  
The expression of Myosin heavy chain is a well-established marker of 
myoblast differentiation. Traditional methods for investigating myoblast 
differentiation involve manual counting of cell nuclei within and excluded from 
differentiated myotubes. To assess the extent of differentiation in C2C12 
myoblasts, a fluorescence assay was developed to determine the relative 
abundance of myosin heavy chain and cell nuclei during differentiation. Initially, 
standardisation was performed to ensure that fluorescent data correlated well with 
the expression of myosin heavy chain and the abundance of cell nuclei. To 
determine if the myosin:DAPI fluorescence ratio could give an indication of  the 
extent of myoblast fusion, an initial study was conducted using a previous model 
in which the inhibition of myoblast differentiation has been observed following 
Mstn treatment (see Appendix 1).  For differentiation assay studies cells were 
seeded at a density of 25000 cells/cm2 in multiple 96 well Optilux™ plates (BD) 
and allowed to attach overnight before the addition of differentiation media 
(DMEM + 2% H/S), which was designated time zero. Plates were then fixed 
periodically during differentiation (typically every 24 h) with ethanol, glacial 
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acetic acid and formaldehyde in a 20:2:1 ratio, respectively for 30 s, before 
rinsing with PBS. Wells then had 150µL PBS added and cells were then stored at 
4°C until the differentiation assay was performed.  
Fluorescent staining was the used to assess the abundance of myosin 
heavy chain and nuclei in fixed samples. Initially cells were permeabilised with 
150 µL 0.1% Triton X (Sigma-Aldrich) in PBS per well for 10 min at room 
temperature, before rinsing with PBS. Next, 200 µL of blocking solution (PBS 
containing 0.35% Carrageenan λ (Sigma-Aldrich) and 10% Normal Sheep Serum 
(NSS, isolated in house) was added to each well and cells incubated at room temp 
for 2 h. Blocking solution was removed and 200 µL of MF20 myosin heavy chain 
(MF20 (DSHB)) or negative control (mouse IgG) antibody, diluted at 1:200 (in 
PBS with 0.35% Carrageenan λ and 5% NSS)  was added to each well, plates 
were then incubated overnight at 4°C. Antibody solution was then removed and 
cells were rinsed 5 times for 5 min with PBS and gentle agitation at room 
temperature. Secondary antibody, anti-mouse Alexa Fluor® 488 conjugate (Life 
Technologies) was then added at a 1:500 dilution in PBS with 0.35% Carrageenan 
λ and 5% NSS) and plates incubated at room temperature in the dark for 1 h. Cells 
were then rinsed 5 times for 5 min with PBS, before addition of 4',6-diamidino-2-
phenylindole (DAPI (Life Technologies)) at 1 µg/mL in PBS for 10 min. After 
three final 5 min PBS washes, 100 µL of PBS was then added to each well before 
the fluorescence was measured for (MF20 (Alexa Fluor 488®, (excitation 485nm, 
emission 528nm) and DAPI (excitation 360nm, emission 460nm) using a 
Synergy™ 2 multi-detection microplate reader and Gen5 software (BioTek 
Instruments Inc; Winooski, VT, United States of America). The average 
background fluorescence for MF20 (negative control) and DAPI (empty wells) 
were subtracted from the individual well values before analysis.             
2.2.23 Statistical analysis 
All data, with the exception of the microarray dataset were analysed by 
ANOVA, using GenStat v13 software (VSN International Ltd, Hemel Hempstead, 
United Kingdom). Post-hoc student’s t-tests were used to generate P-values for in 
vitro comparisons. Data presented are mean +/- the standard error of the mean 
(S.E.M). 
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Chapter Three 
3 Microarray 
3.1 Introduction 
Following the discovery of MSV, a number of studies in our laboratory 
have focused on a functional interaction between Mstn and MSV. Initial 
investigations lead to the postulate that MSV was an antagonist of Mstn. This was 
supported by in vitro studies, which showed that recombinant MSV could induce 
the proliferation of myoblasts, bind Mstn and its receptor and inhibit the Mstn 
induced phosphorylation of Smad 2/3. However, the signal transduction events, 
and the gene expression changes associated with MSV treatment were not well 
understood. In particular, and as stated in section 1.4, investigating how MSV 
signalling differed from that of Mstn was a major aim of this thesis. To address 
this aim, the first experiment in this thesis employed microarray analysis to 
directly compare the genes regulated by recombinant MSV and Mstn in ovine 
myoblasts.          
In the past 10 years, significant advances have been made in the use of 
microarray analyses to investigate and compare changes in gene expression. 
Furthermore, the advent of analysis packages like Ingenuity Pathways Analysis 
(IPA) allows a much more in-depth look at the ‘biological themes’ of data sets, 
based on the observed gene expression changes. The only disadvantage is that the 
IPA analysis is based on findings in human, mouse and rat models. Thus, 
molecules in a microarray data set from another species (e.g. sheep as used for 
these studies) are included for analysis if they can be linked to orthologous genes 
in the IPA database (Ingenuity® Systems, www.ingenuity.com). In support for its 
use in this context, a number of sheep studies have cited the use of IPA for the 
analysis of micro array data (Bonnet, Bevilacqua et al. 2011; Burgess, Greer et al. 
2012).  
The Ingenuity® knowledge database is continually updated with new tools 
and scientific findings to assist with the analysis of data. Over the course of these 
studies, IPA analysis of the microarray data obtained for this chapter was repeated 
several times. This ensured that firstly, data obtained was kept up to date, and 
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secondly, that any new additions to the IPA analysis software that would assist in 
the interpretation of this data set, were included. The addition of the upstream 
activator analysis module provides a good example of how this approach was of 
benefit (3.2.3). This software enables a prediction of the upstream events 
regulating the expression changes in a microarray data set. This is based on which 
gene(s) are regulated, and the direction of change as referenced against findings in 
the Ingenuity database.    
3.2 Results 
Microarray analysis was performed on RNA isolated from primary ovine 
myoblasts treated for 6 h with recombinant Mstn, MSV or vehicle alone (control) 
prior to extraction of RNA. Each treatment was performed in triplicate, resulting 
in 9 RNA samples to be sent to Auckland University for microarray analysis 
(2.2.8). The raw microarray data was subjected to RMA (Robust Multichip 
Average) analysis by Paul Maclean (AgResearch, Bioinformatics Maths and 
Stats). The resulting normalised data was used to determine relative transcript 
levels for the following comparisons: 
1. Mstn vs. Control 
2. MSV vs. Control 
The results of each comparison were analysed using IPA to provide extra 
information on the ‘biological themes’ of the data.   
3.2.1 Top biological functions associated with Mstn and MSV gene expression 
predicted with IPA core analysis. 
The data presented in this section summarises the biological functions 
associated with Mstn or MSV treatment in primary ovine myoblasts, as assessed 
using IPA.  
A summary of the top biological functions predicted using IPA included 
three classes: diseases and disorders, molecular and cellular functions and 
physiological system development and function. Table 3.1 and 3.2 give a 
summary of the top biological functions associated with Mstn and MSV 
treatment, respectively. Consistent themes between Mstn and MSV datasets were, 
the regulation of genes involved in the inflammatory response, cellular movement, 
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cell growth and regulation, cell to cell signalling, cell to cell interaction and cell 
death and survival.   
3.2.2 Top molecules 
As an example of the changes in gene expression observed following 
analysis of the microarray data, Table 3.3 and 3.4 lists top ten up, and down-
regulated genes following treatment with Mstn and MSV, respectively. 
3.2.3 IPA Upstream Regulator analysis  
The upstream regulator analysis was not available when the microarray 
data was assessed in the first instance. Following the release of this analysis 
module, the microarray data set was periodically re-analysed. This allowed the 
capture of any new information that IPA could provide on the upstream pathways 
regulating the changes in gene expression. The upstream regulator analysis 
assigns two statistical measures for each potential regulator in the IPA database, 
the overlap P-value and the activation z-score. The overlap P-value calls potential 
upstream regulators based on a significant overlap between data set genes and 
their known transcriptional targets. The activation z-score is used to infer the 
activation status of the upstream regulator based on the significant pattern match 
of up or down-regulation of the target genes in the dataset (Ingenuity® Systems, 
www.ingenuity.com).  The data presented here were obtained following the most 
recent analysis of the microarray data set (May 2013).  
IPA analysis identified a number of potential upstream regulators. The top 
20 for each treatment are shown in Table 3.5 and 3.6 for Mstn and MSV, 
respectively. Presented in the table is the upstream regulator, its fold change (if 
contained in the array) and its predicted activation state based on the activation z-
score (a z-score higher than 2 predicts activation (positive values) or inhibition 
(negative values)). The notes column contains the bias term, a biased dataset is 
one in which there are more up- than down-regulated genes or vice versa. In these 
cases the P-value for the overlap is the main determinant for significance of an 
upstream regulator (Ingenuity® Systems, www.ingenuity.com). 
3.2.4 Selection and Validation of metabolic targets 
As outlined in section 1.4, one of the aims of this thesis was to determine 
if MSV plays a role in intermediary metabolism. To confirm the integrity of the 
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microarray data, three potential metabolic targets of recombinant Mstn and(or) 
MSV that were differentially expressed were selected for further analysis. These 
were p53 (increased 1.56 fold by MSV), Pyruvate dehydrogenase kinase 3 
(PDK3) (increased 1.55 fold by MSV) and the β1 subunit of the Na+-K+-ATPase 
(increased 2.13 fold by Mstn and  decreased 1.84 fold by MSV). To validate the 
changes observed following microarray analysis, qPCR was performed on cDNA 
reverse transcribed from the same RNA pool. All targets investigated reflected the 
above expression values that were obtained following the microarray analysis 
(Figure 3.1). 
3.2.5 Confirmation and removal of endotoxin present in recombinant MSV  
When first analysing the microarray data using IPA, a number of genes 
were differentially expressed that suggested caution in interpreting the data. In 
particular, a number of gene expression changes associated with recombinant 
MSV treatment, were also linked to the presence of endotoxin (Ingenuity® 
Systems, www.ingenuity.com). This was concerning, as some of the experimental 
studies presented later, which investigated the signal transduction events regulated 
by Mstn and MSV had already been performed (Chapter 4), before the extent of 
the problem was realised and addressed. The Mstn preparation used for this 
analysis (R&D Systems) has certified as having low concentrations of endotoxin 
(<0.1 EU/µg). However the concentration of endotoxin in the recombinant MSV 
preparation used for these studies (produced in E. coli) was an unknown. 
Therefore steps were taken to ensure this preparation was endotoxin free. This 
was primarily due to the confounding biological effect endotoxin would have on 
my myoblast cultures. The following section details the experimental steps take to 
address the concerns regarding the presence of endotoxin in the MSV preparation 
used for my studies. 
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Table 3.1.  Mstn vs. Control  top biological functions
Diseases and Disorders
Name P-value range # Molecules
Connective Tissue Disorders 3.16E-06 - 5.41E-03 9
Inflammatory Disease 3.16E-06 - 7.21E-03 11
Skeletal and Muscular Disorders 3.16E-06 - 5.41E-03 14
Inflammatory Response 9.46E-06 - 7.21E-03 9
Neurological Disease 1.89E-05 - 5.41E-03 11
Molecular and Cellular Functions
Name P-value range # Molecules
Cellular Movement 1.08E-07 - 7.21E-03 16
Cellular Growth and Proliferation 4.62E-07 - 7.21E-03 22
Cellular Development 5.01E-07 - 7.21E-03 19
Cell-To-Cell Signalling and Interaction 3.14E-05 - 7.21E-03 9
Cell Cycle 4.71E-05 - 7.21E-03 7
Physiological System Development and Function
Name P-value range # Molecules
Skeletal and Muscular System Development and Function 5.01E-07 - 7.21E-03 11
Endocrine System Development and Function 2.39E-06 - 5.41E-03 3
Nervous System Development and Function 2.39E-06 - 5.76E-03 5
Tumor Morphology 5.94E-06 - 7.21E-03 8
Cell-mediated Immune Response 9.46E-06 - 7.21E-03 7
Table 3.2. MSV vs. Control top biological functions
Diseases and Disorders
Name P-value range # Molecules
Inflammatory Response 1.53E-16 - 2.32E-05 45
Cancer 2.73E-15 - 2.19E-05 70
Cardiovascular Disease 4.51E-14 - 8.70E-06 36
Organismal Injury and Abnormalities 4.02E-13 - 1.76E-05 38
Immunological Disease 6.92E-13 - 7.21E-06 33
Molecular and Cellular Functions
Name P-value range # Molecules
Cellular Movement 1.04E-16 - 2.32E-05 51
Cell Death and Survival 1.89E-14 - 2.27E-05 56
Cellular Growth and Prolifera tion 1.49E-13 - 2.01E-05 60
Cell-To-Cell Signalling and Interaction 5.41E-12 - 2.18E-05 40
Cellular Function and Maintenance 8.60E-12 - 1.90E-05 48
Physiological System Development and Function
Name P-value range # Molecules
Cardiovascular System Development and Function 6.94E-22 - 2.19E-05 46
Organismal Development 6.94E-22 - 2.18E-05 46
Hematological System Development and Function 4.62E-15 - 2.32E-05 48
Immune Cell Trafficking 4.62E-15 - 2.32E-05 35
Organismal Survival 5.70E-15 - 2.31E-05 52
Table 3.1 and 3.2: Top biological functions influenced by Mstn or 
recombinant MSV treatment. IPA core analysis was used to identify the top biological 
functions associated with Mstn (Table 3.1) and MSV (Table 3.2) treatment of ovine 
myoblasts. Analysis covered three broad categories: Diseases and disorders, Molecular 
and cellular functions and Physiological system development and function. The P-value 
range and the number of differentially expressed molecules, associated with their 
respective function are also presented.       
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Column1 Table 3.4.  Top molecules regulated by MSV
Up Full gene name Fold change P-value
Saa3 Serum amyloid A1 32.85 8.69E-14
CCL20 Chemokine (C-C motif) ligand 20 17.55 7.68E-11
CCL2 Chemokine (C-C motif) ligand 2 7.30 4.43E-10
CXCL2 Chemokine (C-X-C motif) ligand 2 7.24 2.89E-08
CASP4 Caspase 4, apoptosis-related cysteine peptidase 4.96 7.86E-12
CHST9 Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9 4.47 1.21E-07
PTX3 Pentraxin 3, long 4.34 7.17E-09
RND1 Rho family GTPase 1 4.24 1.40E-07
ICAM1 Intercellular adhesion molecule 1 3.51 4.16E-08
IL6 Interleukin 6 3.46 5.70E-09
Down Full gene name Fold change P-value
TGFB2 Transforming growth factor, beta 2 -2.38 2.88E-05
GYKL1 Glycerol kinase-like 1 -2.07 5.86E-08
MAP1B Microtubule-associated protein 1B -1.84 5.56E-04
ATP1B1 β1 subunit of  the Na+-K+-ATPase -1.84 1.93E-07
JUN Jun oncogene -1.75 9.92E-04
Chn2 Chimerin (chimaerin) 2 -1.71 3.65E-06
LRRC17 Leucine rich repeat containing 17 -1.69 1.30E-05
ATF3 Activating transcription factor 3 -1.66 6.67E-07
DAB2 Disabled homolog 2, mitogen-responsive phosphoprotein -1.65 2.38E-05
FOXP2 Forkhead box P2 -1.61 7.95E-05
Column1Top Table 3.3. Top molecules regulated by Mstn Column3
Up Full gene name Fold change P-value
BHLHE40 Basic helix-loop-helix family member e40 2.20 9.95E-04
CCL2 Chemokine (C-C motif) ligand 2 2.15 4.23E-06
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 2.13 2.31E-08
LDLRAD4 Low density lipoprotein receptor class A domain containing 4 1.89 1.49E-06
CCL20 Chemokine (C-C motif) ligand 20 1.87 1.20E-04
IL6 Interleukin 6 1.87 3.91E-06
IL1A Interleukin 1, alpha 1.77 3.11E-06
TCF7 Transcription factor 7 1.72 2.16E-06
FAM101B Family with sequence similarity 101, member B 1.72 3.10E-05
TGFB3 Transforming growth factor, beta 3 1.72 3.15E-05
Down Full gene name Fold change P-value
FGFR4 Fibroblast growth factor receptor 4 -1.66 3.87E-06
KLF2 Kruppel-like factor 2 -1.61 5.59E-05
OSR2 Odd-skipped related 2 -1.60 1.36E-06
CTNND2 Catenin (cadherin- associated protein), delta 2 -1.56 4.66E-05
ATP2B1 ATPase, Ca2+  transporting, plasma membrane 1 -1.54 1.38E-03
PTX3 Pentraxin 3, long -1.46 1.08E-03
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha -1.42 6.81E-03
USP7 Ubiquitin-specific-processing protease 7 -1.39 2.05E-02
CPEB1 Cytoplasmic polyadenylation element binding protein 1 -1.38 1.25E-04
EPAS1 Endothelial PAS domain protein 1 -1.37 3.66E-03
Table 3.3 and 3.4: Top Molecules differentially expressed following 
recombinant Mstn or MSV treatment. Shown here, are the top 10 up or down-
regulated genes identified following treatment with Mstn (Table 3.3) or MSV (Table 3.4). 
The respective fold change (compared to control) and P-values are also presented.      
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Figure 3.1: Confirmation of microarray differential expression. 
Concentrations of Na+-K+-ATPase (A), PDK3 (B) and p53 (C) mRNA, 
quantified using qPCR, were determined in microarray samples following 
treatment with recombinant Mstn, MSV or vehicle alone (control). Data 
presented are mean +/- SEM, asterisks denote significant differences from 
controls (vehicle), (**P<0.01, *** P<0.001), n=3 for each treatment. 
Concentrations were normalised to vehicle alone (control) values following 
adjustment to oligreen (total cDNA) values. 
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3.2.5.1 Concentration of endotoxin in the recombinant MSV preparation 
Given the potential confounding influence that endotoxin may have in my 
myoblast cultures, the concentrations of endotoxin in the MSV preparation was 
assessed. Endotoxin was measured using the Lonza Limulus Amebocyte Lysate 
(LAL) Kinetic QCL kit (Cat# 50-650U). The assay data demonstrated that the 
MSV preparation contained a significant amount of endotoxin ~36470 EU 
(endotoxin units) /mL, which equated to ~300ng/mL of endotoxin in a 3 µg/mL 
MSV treatment. 
3.2.5.2 Low concentrations of LPS stimulate ovine but not C2C12 myoblast 
proliferation. 
Once the presence of endotoxin was confirmed, my major concern was 
that the bioactivity associated with MSV, could in fact be due to contamination 
with endotoxin. Thus, it was prudent to assess the effect of endotoxin on both 
ovine and C2C12 myoblasts using the methylene blue proliferation assay. Purified 
endotoxin (LPS) had a biphasic effect on the proliferation of ovine myoblasts. In 
these cells, concentrations of LPS between 1 ng and 10 µg/mL significantly 
increased myoblast proliferation, while higher concentrations inhibited myoblast 
proliferation (Figure 3.2). The C2C12 cells exhibited a different response profile to 
the ovine myoblasts, with no response to lower LPS concentrations (<100 ng/mL), 
but high concentrations (1-300 µg/mL) significantly inhibited proliferation 
(Figure 3.2).                 
3.2.5.3 Purification of MSV 
Once the presence of endotoxin had been confirmed in the MSV 
preparation, its removal became a primary focus. Two well described methods for 
the removal of endotoxin were used to address this problem. They were the use of 
a Polymyxin affinity resin (BioRad) and a detergent based phase separation using 
Triton X-114 (Sigma-Aldrich) as previously described (Liu, Tobias et al. 1997). 
The latter, was shown to be the most effective method for endotoxin removal. 
Purification of MSV was performed using these two methods (2.2.15), with the 
efficacy of each method validated using the Lonza LAL QCL kit. As shown in 
Figure 3.3, Polymyxin reduced the amount of endotoxin in the MSV preparation 
by approximately 75%. In contrast, Triton X-114 removed all traces of endotoxin 
from the MSV preparation. Both methods reduced the amount of protein in the 
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MSV preparation, with recoveries as assessed by BCA assay (2.2.19) of ~94% 
and 76% for polymyxin and Triton X-114 respectively (data not shown).  
3.2.6 Proliferation of ovine and C2C12 myoblasts with LPS free MSV 
To determine the effect of MSV on the proliferation of myoblasts 
following Polymyxin or Triton X-114 purification, ovine and C2C12 myoblasts 
were subjected to treatment with both treated and non-treated MSV. Proliferation 
was assessed using the methylene blue proliferation assay. For the ovine 
myoblasts, treated and non-treated LPS was included as an internal control for the 
purification process. As shown in Figure 3.3, ovine myoblasts had a significant 
increase in proliferation following exposure to untreated LPS (~20 %), and MSV 
(~25 %), at 100ng/mL and 10µg/mL, respectively (P<0.001). Treatment of ovine 
myoblasts with Polymyxin treated LPS and MSV also increased proliferation by 
~18 % (P<0.001) and 25 % (P<0.01), respectively. In contrast, Triton X-114 
treatment removed the proliferative response associated with both LPS and MSV 
in ovine myoblasts. For C2C12 myoblasts, only MSV was tested, as previous data 
(Figure 3.1) had shown that proliferation is not increased in response to LPS. 
Untreated MSV increased the proliferation of C2C12 cells by ~27 % (P<0.001), 
using 10 µg/mL of MSV. Similarly, polymyxin treated MSV induced an ~ 27% 
increase in proliferation (P<0.001). Triton X-114 treated MSV also stimulated the 
proliferation of C2C12 myoblasts, with the largest increase of ~27% (P<0.01) 
observed at 3 µg/mL MSV.  
3.2.7 MSV regulation of microarray targets differentially regulated by Mstn 
The data obtained from the microarray analysis for ovine myoblasts 
treated with MSV was compromised by the presence of LPS in the MSV 
preparation. Thus, the Mstn component of this study provided the only reliable 
dataset following microarray analysis. In an effort to determine if genes that were 
differentially expressed following treatment with Mstn, were also altered by 
Triton X-114 treated MSV, five of the top up or down-regulated transcripts 
influenced by Mstn (as identified from the microarray analysis (Table 3.3)) were 
assessed using qPCR. Of the 10 targets selected, qPCR data was obtained for 7, 
with 3 primer sets yielding multiple unspecific PCR products following qPCR 
(data not shown) as thus, unreliable analysis.  For the remaining targets qPCR 
analysis (Figure 4.13) showed that none of the targets initially thought to 
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regulated by MSV were altered following exposure to an endotoxin free 
preparation. 
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Figure 3.2: Effect of LPS on the proliferation ovine and C2C12 myoblasts. 
Myoblasts were cultured in the presence of increasing concentrations of LPS. 
Proliferation was determined using the methylene blue proliferation assay at an 
OD of 650nM for C2C12 (A) and ovine (B) cultures after 48h of proliferation. 
Data presented are mean +/- SEM, asterisks denote significant differences 
from vehicle controls at each LPS concentration (*P<0.05, **P<0.01, *** 
P<0.001). N=6 replicates per LPS concentration.     
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Figure 3.3: The concentrations of Endotoxin following purification of 
recombinant MSV or LPS solutions.  Endotoxin concentration of untreated 
and polymyxin or Triton X-114 treated LPS (A) or MSV (B) solutions, was 
determined using the LAL assay. Samples were assayed in duplicate, with 
the untreated LPS solution at a concentration of 1 mg/mL. Data presented are 
mean +/- SEM. 
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Figure 3.4: Proliferation of Ovine myoblasts exposed to MSV and LPS that was 
treated with Polymyxin or Triton X-114. Myoblasts were cultured in the presence of 
increasing concentrations of untreated or treated LPS or MSV. Proliferation was 
determined after 48 h of culture using the methylene blue proliferation assay at an OD of 
650nM. This was done for MSV and LPS treated with Polymyxin, (A) and (B) 
respectively and MSV and LPS treated with Triton X-114, (C) and (D) respectively. Data 
presented are mean +/- SEM, asterisks denote significant differences from vehicle 
controls at each concentration of LPS or MSV (†P<0.1, *P<0.05, **P<0.01, *** 
P<0.001). N=8 replicates per concentration of LPS or MSV.     
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Figure 3.5: Proliferation of C2C12 myoblast exposed to MSV that was treated 
with Polymyxin or Triton X-114. Myoblasts were cultured in the presence of 
increasing concentrations of treated or non-treated MSV. Proliferation was 
determined after 48 h of culture using the methylene blue proliferation assay at an 
OD of 650nM. This was done for MSV treated with Polymyxin, (A), and  MSV
treated with Triton X-114 (B). Data presented are mean +/- SEM, asterisks denote 
significant differences from vehicle controls (0) at each LPS or MSV 
concentration (†P<0.1, *P<0.05, **P<0.01, *** P<0.001). N=8 replicates per LPS 
or MSV concentration.     
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Figure 3.6: Effect of Triton-X 114 treated MSV on a selection of the top 
Mstn regulated transcripts (microarray) in ovine myoblasts. Using qPCR 7 of the 
top transcripts regulated by Mstn (from microarray analysis) were assessed in ovine 
myoblasts following treatment with 3 µg/mL MSV for 6 h. Shown in (A), transcripts 
that were increased following treatment with Mstn and in (B) decreased following 
treatment with Mstn (as evidenced by microarray data). Relative abundance was 
calculated by normalising values for MSV treatment to those of controls, with n=3 for 
each treatment. 
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3.3 Discussion  
Using microarray and IPA analyses, the changes in gene expression 
associated with Mstn and MSV treatment in ovine myoblasts was investigated. 
Both proteins induced significant gene expression changes after a 6 h treatment, 
and the integrity of the microarray data was confirmed by the validation of the 
metabolic targets using qPCR. With the use of IPA, the top biological functions 
associated with Mstn treatment appeared consistent with Mstn function. These 
included the regulation of genes involved in skeletal muscle disorders, cellular 
growth and proliferation, cellular development, the cell cycle and skeletal and 
muscular system development and function. The response to MSV on the other 
hand did not display any top biological functions associated with skeletal muscle. 
Rather, MSV induced changes in gene expression that had a greater connectivity 
with inflammatory responses, with three functions similar to those identified for 
Mstn (cellular movement, cellular growth and proliferation and the inflammatory 
response). Identification of the inflammatory response as a top biological function 
was a concern with 45 genes up-regulated by MSV vs. 9 for Mstn. Therefore, the 
purity of the MSV preparation was questioned. This was due primarily to the fact 
that it had been produced in E. coli, and no prior steps were taken to ensure it was 
LPS free. This was not a concern with the commercial Mstn preparation, which is 
produced in a eukaryotic system and has certified low concentrations of endotoxin 
(<0.1 EU/µg protein). Upon investigating the top 10 genes up-regulated by MSV 
treatment, 8 have been previously shown to be regulated by LPS as opposed to 4 
in the Mstn top 10 (Ingenuity® Systems, www.ingenuity.com). Interestingly, IPA 
upstream regulator analysis predicted LPS as an upstream regulator for both 
datasets, with MSV regulating 34 out of 45 and Mstn 10 out 12 identified LPS 
target genes from their respective data sets, in a manner consistent with LPS as an 
upstream activator. However, there were key differences in this analysis 
indicating that the regulation of Mstn targets occurred via different mechanisms. 
Importantly, the MSV data set also identified Toll like receptor 4 (TLR4), the LPS 
receptor, as an upstream regulator. In addition, TGFβ1, a close relative of Mstn, 
was identified as an upstream regulator in the Mstn but not the MSV data set. This 
is of particular importance, as activation of this pathway can regulate 7 of the 10 
LPS target genes (referred to above) identified in the Mstn analysis, with the 
remaining three not influenced by MSV treatment in this analysis (data not 
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shown), illustrating that the changes induced following exposure to Mstn are 
consistent with TGF-β treatment.  
Following my discovery that recombinant MSV preparations were likely 
to be contaminated with endotoxin, the extent of this problem had to be 
investigated. This required firstly determining if endotoxin could regulate the 
proliferation of myoblasts and, secondly, the removal of endotoxin from the MSV 
preparation. LPS significantly increased the proliferation of ovine myoblasts at 
concentrations consistent with those observed in the MSV preparation using the 
LAL assay. This had significant consequences on my interpretation of the 
microarray data. With no clear way to discriminate between an LPS and/or an 
MSV dependent target, the Mstn data was the only reliable portion of this 
analysis. As the differential regulation of the β1 subunit of the Na+-K+-ATPase by 
both Mstn and MSV containing LPS (Figure 3.1) had been confirmed, this target 
was selected for further investigation from the Mstn perspective (Chapter 5). This 
and other Mstn targets would be investigated following treatment with MSV, once 
an endotoxin free preparation was available. To determine if the purified MSV 
preparation influenced the transcription of Mstn targets identified from the 
microarray analysis, primers for qPCR were designed to amplify top molecules 
regulated by Mstn. Purified MSV did not alter the transcription of any of the top 
molecules influenced by Mstn that were investigated in this study.    
Following the determination of the endotoxin concentration present in the 
MSV preparation, its removal became a strong focus. The use of Polymyxin resin 
and Triton X-114 phase separation were used as established methods for the 
removal endotoxin from bacterially produced recombinant proteins. Polymyxin 
reduced the concentration of endotoxin present in the MSV preparation by ~75%, 
but not enough to warrant its use as a purification method. Purification with Triton 
X-114 reduced endotoxin content to undetectable levels. However, this method 
introduced a caveat for ongoing studies using this preparation. This is due to 
residual Triton X-114 remaining in the preparation, which could potentially alter 
protein folding, have bioactivity of its own or interfere with the MSV contained in 
this preparation. This was addressed by including dialysis buffer and LPS 
solutions that had also been subjected to Triton X-114 as controls where 
appropriate. Given that concentration of endotoxin in the Triton X-114 purified 
75 
MSV was zero, this method was chosen to purify MSV for further investigations. 
It is noteworthy here that purification with Polymyxin was performed with a 
single incubation with MSV, while Triton X-114 involved 4 phase separations 
(see 2.2.16). Thus, it is possible that a refined Polymyxin protocol could yield 
similar results to that of Triton X-114. However, concerns regarding the use of 
Triton X-114 were lessened from other studies reporting that proteins treated with 
Triton X-114 maintain bioactivity in binding as well as physiological studies (Liu, 
Tobias et al. 1997; Magalhaes, Lopes et al. 2007). Furthermore, residual Triton X-
114 is reported to be less than 0.018% (Aida and Pabst 1990). 
The proliferative response was the first bioassay used to determine if the 
LPS free MSV had retained its bioactivity. Interestingly, proliferation assays 
showed that the MSV preparation could still stimulate C2C12, but not ovine 
myoblast proliferation as previously shown (unpublished data). This was done in 
parallel with a purified LPS preparation to ensure the Triton X-114 procedure 
yielded endotoxin free and biologically inactive medium. The species specific 
response to the MSV, suggests that there may be differing mechanisms that 
convey the function of MSV in myoblasts. Alternatively, primary ovine myoblasts 
may be more sensitive to residual Triton X-114 as compared to the immortalised 
C2C12 cells. Importantly, this resulted in a purified MSV preparation that could be 
used for signal transduction and metabolic studies in ovine myoblasts.  
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Chapter Four 
4 The effect of Mstn and MSV on signal transduction in ovine 
myoblasts.  
4.1 Introduction 
The signal transduction mechanisms that Mstn induces, give this molecule 
the ability to regulate gene transcription in myoblasts and to ultimately play a 
major functional role in the growth and development of skeletal muscle (see 
1.1.7.4-6). The binding of mature Mstn to activin type IIB receptors activates a 
number of signal transduction cascades, in conjunction with non-canonical 
signalling, these events culminate in the inhibition of myoblast proliferation, 
reduced synthesis of protein and ultimately reduced myogenesis. Given that 
recombinant MSV can interact directly with Mstn and with the type IIB activin 
receptor (Jeanplong, Falconer et al. 2013), It was anticipated that MSV would 
influence or block signal transduction pathways activated by Mstn. Therefore the 
aim of the studies in this chapter was to determine the pathways through which 
MSV signals in ovine myoblasts in comparison to those known for Mstn.  
One of the major setbacks faced while conducting the experiments in this 
chapter, was the presence of endotoxin in the MSV preparation. As detailed in the 
previous chapter we had success in removing this contaminant from the MSV 
preparation. Unfortunately, this was not before ovine myoblasts had been treated 
for the first signalling experiment presented in this chapter. Therefore, data are 
presented for the signalling pathways activated by Mstn in the first experiment. 
Then, data are presented for MSV, following the treatment of myoblasts with a 
preparation that was free of endotoxin. This allowed comparison of the signal 
transduction pathways as influenced following treatment with Mstn or MSV.  In 
addition, the generation of stable C2C12 myoblasts expressing MSV provided a 
eukaryotic model for investigating MSV function and signalling, while 
circumventing the issues associated with the use of recombinant protein, and is 
presented in Chapter 6.  
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4.2 Results 
4.2.1 Mstn signalling in ovine myoblasts 
To identify the early signalling events associated with the presence of 
Mstn on, cytoplasmic and nuclear enriched protein lysates were isolated following 
a 1 h treatment of ovine myoblasts. Western blot analysis was used to determine 
the relative abundance of multiple intracellular targets. These included the major 
transcription factors that control myogenesis, signalling molecules in the TGF-β, 
MAPK and PI3K signalling cascades and targets involved in regulation of the cell 
cycle and cellular metabolism.  
4.2.1.1 Myogenic transcription factors 
Previous studies have identified a role for Mstn in the regulation of 
transcription factors with well-established roles in myogenesis  
(1.1.7). To determine if Mstn altered the abundance of major myogenic 
transcription factors, the relative abundance of MyoD, Myf5, MRF4, myogenin, 
Pax7 and Mef2 was determined using western blot analysis. As shown in Figure 
4.1, cytoplasmic lysates isolated from myoblasts treated with Mstn had an 
increased abundance of MyoD (~1.3 fold, P<0.05) and MRF4 (~1.6 fold, P<0.01), 
with a decrease in the abundance of Myf5 (~0.65 fold, P<0.05). No change was 
observed in the abundance of Myogenin, Mef2 or Pax7. Mstn also increased the 
abundance of MyoD (~1.7 fold, P<0.01), Mef2 (~3 fold, P<0.01) and Pax7 (~5.2 
fold, P<0.05) in nuclear enriched lysates, with no changes observed in the 
abundance of MRF4, Myogenin or Myf5 (Figure 4.2).   
4.2.1.2 Canonical Mstn signalling 
To confirm that canonical Mstn signalling was induced in ovine myoblasts 
treated with Mstn, the relative abundance of total and phosphorylated Smad 2/3 
was determined. There was no change in the abundance or phosphorylation of 
Smad 2 or 3 in cytoplasmic lysates (Figure 4.3). Consistent with the data from 
cytoplasmic lysates, there was no change in the abundance of total Smad 2 or 3 in 
nuclear enriched lysates. However, as shown in Figure 4.3 (B, F), treatment with 
Mstn increased the abundance of phosphorylated Smad 2 (~1.8 fold, P<0.05) in 
nuclear enriched lysates, while phosphorylated Smad 3 was not detected in this 
study. 
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4.2.1.3 PI3K/AKT Signalling  
Mstn has a well-established role in regulating the activity of the 
PI3K/AKT signalling cascade (1.1.7.5). To establish if the Mstn treatment of 
ovine myoblasts altered the abundance or the phosphorylation of molecules in the 
PI3K/AKT signalling cascade, the abundance and phosphorylation of AKT and its 
major upstream kinase PDK1 were assessed. As shown in Figure 4.4, treatment 
with Mstn decreased total cytoplasmic AKT (~0.9 fold, P<0.05), had no effect on 
the phosphorylation of AKT at threonine (T) 308, but increased the 
phosphorylation of AKT at serine (S) 473 (~1.7 fold, P<0.001).  Total PDK1 was 
increased by Mstn treatment (~1.2 fold, P<0.05) with no change in the 
phosphorylation of PDK1. In nuclear enriched lysates (Figure 4.5), Mstn 
treatment increased both total AKT and phosphorylated of AKTS473 (~2 fold, 
P<0.05 and ~1.6 fold, P<0.05, respectively), with no change observed in the 
phosphorylation of AKTT308. Finally, treatment with Mstn did not alter the 
abundance or the phosphorylation of PDK1 in nuclear enriched lysates. 
4.2.1.4 MAPK signalling 
Mstn has been previously shown to signal through MAPK signalling 
pathways, targeting both ERK and p38 MAPK signalling intermediates (see 
section 1.1.7.5). To determine if Mstn signals through these MAPK pathways in 
ovine myoblasts, the abundance and phosphorylation of these molecules was 
determined in cytoplasmic and nuclear enriched lysates. In cytoplasmic lysates, 
Mstn treatment did not alter the abundance of total ERK1, ERK2 or p38. In 
contrast, as shown in Figure 4.6, Mstn treatment altered the phosphorylation of 
these molecules, with increases observed in the phosphorylation of ERK1 (~1.4 
fold, P<0.001), ERK 2 (~1.7 fold, P<0.001, respectively), and p38 (~2 fold, 
P<0.01). Data from nuclear enriched lysates (Figure 4.7) were more variable, with 
an increase in the abundance of total ERK1 (~2 fold, P<0.05), and a tendency 
towards increased ERK2 and p38 (~1.5 fold, P<0.1 and ~4.4 fold, P<0.1, 
respectively). In terms of the phosphorylation of MAPK intermediates, only the 
phosphorylation of ERK2 was increased in nuclear enriched lysates (~1.6 fold, 
P<0.05), with no change in the abundance of phosphorylated ERK1, and no 
detection of phosphorylated p38.  
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4.2.1.5 Metabolic targets  
Although it is clear that Mstn plays a functional role in metabolism of 
skeletal muscle (see 1.1.7.6), the early signal transduction events through which 
Mstn initiates metabolic change, especially in ruminant myoblasts, is not well 
understood. Thus, the ability of Mstn to regulate the abundance and 
phosphorylation of major effectors of metabolic change in skeletal muscle was 
investigated. Included for analysis were AMPK and its downstream effector ACC. 
This system has been shown to be influenced by Mstn and play a major role in the 
control of cellular metabolism (Chen, Ye et al. 2010; Zhang, McFarlane et al. 
2011). Also included in this section are 4EBP1, rpS6 and p70S6K (an upstream 
kinase that plays a role in the phosphorylation of rpS6 and 4EBP1). These 
molecules play a role in the regulation of protein synthesis, a major point of 
control for cellular metabolism. In addition, the phosphorylation of these 
molecules can be influenced through both the PI3K and/or MAPK signalling 
pathways (Roux, Shahbazian et al. 2007). Mstn treatment did not alter the 
abundance or the phosphorylation of AMPK or its downstream target ACC in 
cytoplasmic lysates (Figure 4.8). Mstn treatment did not alter the abundance, but 
increased the phosphorylation of rpS6 (~1.3 fold, P<0.05), Mstn also increased 
4EBP1 (~1.6 fold, P<0.01), with no change in the phosphorylation of 4EBP1 in 
cytoplasmic lysates (Figure 4.8). Finally, Mstn treatment did not alter the 
abundance p70S6K, but increased the phosphorylation of p70S6K at threonine (T) 
389 (~1.8, P<0.01) in cytoplasmic lysates (Figure 4.8). Mstn treatment had a 
tendency to increase the abundance of rpS6 (~1.9 fold, P<0.1) and increased the 
phosphorylation of rpS6 (~1.5 fold, P<0.05) in nuclear enriched lysates (Figure 
4.9). Mstn did not alter the abundance, but increased the phosphorylation of 
4EBP1 (~1.9 fold, P<0.01). Mstn tended to increase the abundance of p70S6K (~2 
fold, P<0.1), and increased phosphorylation of p70S6K at T389 (~2 fold, P<0.05) 
in nuclear enriched lysates. The abundance of AMPK and ACC were not 
determined in nuclear enriched lysates. 
4.2.1.6 Cell cycle 
Mstn has been shown to regulate the expression of the cell cycle regulators 
Cyclin E and Cdk2  in muscle precursor cells (Langley, Thomas et al. 2004). 
Thus, the relative abundance of Cyclin E and Cdk2 was assessed to establish if 
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treatment with Mstn altered the abundance of these cell cycle regulators in ovine 
myoblasts. As shown in Figure 4.10, Mstn did not alter the abundance of cyclin E 
or Cdk2 in cytoplasmic lysates. In nuclear enriched lysates Cyclin E was 
unchanged, while Cdk2 was increased (~1.6 fold, P<0.05) following Mstn 
treatment (Figure 4.10). 
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Figure 4.1: Abundance of myogenic transcription factors in the cytoplasmic 
lysates of ovine myoblasts treated with Mstn. For western blot analysis, cytoplasmic 
lysates were isolated from ovine myoblasts treated with vehicle (controls) or 100 ng/mL 
of Mstn for 1 h. Isolated protein (10 µg per sample) was run on a SDS/PAGE gel and 
blotted onto nitrocellulose. Immunoblots were performed for the depicted proteins (A), 
with representatives (n=3) shown. Blots were then exposed to autoradiographic film to 
capture the chemiluminescent signal. Equal loading of protein samples was assessed 
using Ponceau stain, with a representative blot shown in (B). The optical density of 
individual bands was obtained using a GS800 scanning densitometer and Quantity One 
software (BioRad). Relative abundance (C) was calculated by normalising the density 
values obtained from the cells treated with Mstn to those of their control counterparts. 
Normalised data presented are mean +/- SEM, asterisks denote significant differences 
between ovine myoblasts treated with Mstn and controls, with: *P<0.05, **P<0.01, n=6 
replicates per treatment. 
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Figure 4.2: Abundance of myogenic transcription factors in the nuclear 
enriched lysates of ovine myoblasts treated with Mstn. For western blot analysis, nuclear 
enriched lysates were isolated from ovine myoblasts treated with vehicle (controls) or 100 
ng/mL of Mstn for 1 h. Isolated protein (5 µg per sample) was run on a SDS/PAGE gel and 
blotted onto nitrocellulose. Immunoblots were performed for the depicted proteins (A), with 
representatives (n=3) shown. Blots were then exposed to autoradiographic film to capture 
the chemiluminescent signal. Equal loading of protein samples was assessed using Ponceau 
stain, with a representative blot shown in (B). The optical density of individual bands was 
obtained using a GS800 scanning densitometer and Quantity One software (BioRad). 
Relative abundance (C) was calculated by normalising the density values obtained from the 
cells treated with Mstn to those of their control counterparts. Normalised data presented are
mean +/- SEM, asterisks denote significant differences between ovine myoblasts treated with 
Mstn and controls, with: *P<0.05, **P<0.01, n=6 replicates per treatment. 
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Figure 4.3: Abundance of Smad2/3 transcription factors in the cytoplasmic and nuclear enriched 
lysates of ovine myoblasts treated with Mstn. For western blot analysis, 10 µg of cytoplasmic, or 5 µg of 
nuclear enriched lysate that was isolated from ovine myoblasts treated with vehicle (control) or 100 ng/mL of
Mstn for 1 h, was run on  SDS/PAGE gels and blotted onto nitrocellulose. Immunoblots were performed for the 
depicted proteins, with representatives (n=3) shown for cytoplasmic (A) and nuclear enriched lysates (B). Blots 
were then exposed to autoradiographic film to capture the chemiluminescent signal. Equal loading of protein 
samples was assessed using Ponceau stain, with a representative blot shown for cytoplasmic (C), and nuclear 
enriched (D) lysates. The optical density of individual bands was obtained using a GS800 scanning densitometer 
and Quantity One software (BioRad). Relative abundance was calculated by normalising the density values 
obtained from the cells treated with Mstn to those of their control counterparts for cytoplasmic (E) and nuclear 
enriched (F) lysates. Normalised data presented are mean +/- SEM, asterisks denote significant differences 
between ovine myoblasts treated with Mstn and controls, with:  *P<0.05, n=6 replicates per treatment. 
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Figure 4.4: Abundance of PI3K/AKT targets in the cytoplasmic lysates of ovine 
myoblasts treated with Mstn. For western blot analysis, cytoplasmic lysates were isolated 
from ovine myoblasts treated with vehicle (controls) or 100 ng/mL of Mstn for 1 h. Isolated 
protein (10 µg per sample) was run on a SDS/PAGE gel and blotted onto nitrocellulose. 
Immunoblots were performed for the depicted proteins (A), with representatives (n=3) shown. 
Blots were then exposed to autoradiographic film to capture the chemiluminescent signal. 
Equal loading of protein samples was assessed using Ponceau stain, with a representative blot 
shown in (B). The optical density of individual bands was obtained using a GS800 scanning 
densitometer and Quantity One software (BioRad). Relative abundance (C) was calculated by 
normalising the density values obtained from the cells treated with Mstn to those of their 
control counterparts. Normalised data presented are mean +/- SEM, asterisks denote 
significant differences between ovine myoblasts treated with Mstn and controls, with:  
*P<0.05, ***P<0.001, n=6 replicates per treatment. 
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Figure 4.5: Abundance of PI3K/AKT targets in the nuclear enriched lysates of 
ovine myoblasts treated with Mstn. For western blot analysis  nuclear enriched lysates 
were isolated from ovine myoblasts treated with vehicle (controls) or 100 ng/mL of Mstn for 
1 h. Isolated protein (5 µg per sample) was run on a SDS/PAGE gel and blotted onto 
nitrocellulose. Immunoblots were performed for the depicted proteins (A), with 
representatives (n=3) shown. Blots were then exposed to autoradiographic film to capture the 
chemiluminescent signal. Equal loading of protein samples was assessed using Ponceau 
stain, with a representative blot shown in (B). The optical density of individual bands was 
obtained using a GS800 scanning densitometer and Quantity One software (BioRad). 
Relative abundance (C) was calculated by normalising the density values obtained from the 
cells treated with Mstn to those of their control counterparts. Normalised data presented are 
mean +/- SEM, asterisks denote significant differences between ovine myoblasts treated with 
Mstn and controls, with:  *P<0.05, n=6 replicates per treatment. 
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Figure 4.6: Abundance of MAPK targets in the cytoplasmic lysates of ovine 
myoblasts treated with Mstn. For western blot analysis, cytoplasmic lystates were 
isolated from ovine myoblasts treated with vehicle (controls) or 100 ng/mL of Mstn for 1 
h. Isolated protein (10 µg per sample) was run on a SDS/PAGE gel and blotted onto 
nitrocellulose. Immunoblots were performed for the depicted proteins (A), with 
representatives (n=3) shown. Blots were then exposed to autoradiographic film to capture 
the chemiluminescent signal. Equal loading of protein samples was assessed using 
Ponceau stain, with a representative blot shown in (B). The optical density of individual 
bands was obtained using a GS800 scanning densitometer and Quantity One software 
(BioRad). Relative abundance (C) was calculated by normalising the density values 
obtained from the cells treated with Mstn to those of their control counterparts. 
Normalised data presented are mean +/- SEM, asterisks denote significant differences 
between ovine myoblasts treated with Mstn and controls, with: **P<0.01, ***P<0.001, 
n=6 replicates per treatment. 
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Figure 4.7: Abundance of MAPK targets in the nuclear enriched lysates of ovine 
myoblasts treated with Mstn. For western blot analysis nuclear enriched lysates were 
isolated from ovine myoblasts treated with vehicle (controls) or 100 ng/mL of Mstn for 1 h. 
Isolated protein (5 µg per sample) was run on a SDS/PAGE gel and blotted onto 
nitrocellulose. Immunoblots were performed for the depicted proteins (A), with 
representatives (n=3) shown. Blots were then exposed to autoradiographic film to capture 
the chemiluminescent signal. Equal loading of protein samples was assessed using Ponceau 
stain, with a representative blot shown in (B). The optical density of individual bands was 
obtained using a GS800 scanning densitometer and Quantity One software (BioRad). 
Relative abundance (C) was calculated by normalising the density values obtained from the 
cells treated with Mstn to those of their control counterparts. Normalised data presented are 
mean +/- SEM, asterisks denote significant differences between ovine myoblasts treated 
with Mstn and controls, with: †P<0.1, *P<0.05, n=6 replicates per treatment. 
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Figure 4.8: Abundance of metabolic targets in the cytoplasmic lysates of ovine 
myoblasts treated with Mstn. For western blot analysis, cytoplasmic lysates were isolated from 
ovine myoblasts treated with vehicle (controls) or 100 ng/mL of Mstn for 1 h. Isolated protein (10 
µg per sample) was run on a SDS/PAGE gel and blotted onto nitrocellulose. Immunoblots were 
performed for the depicted proteins (A), with representatives (n=3) shown. Blots were then exposed 
to autoradiographic film to capture the chemiluminescent signal. Equal loading of protein samples 
was assessed using Ponceau stain, with a representative blot shown in (B). The optical density of 
individual bands was obtained using a GS800 scanning densitometer and Quantity One software 
(BioRad). Relative abundance (C) was calculated by normalising the density values obtained from 
the cells treated with Mstn to those of their control counterparts. Normalised data presented are mean 
+/- SEM, asterisks denote significant differences between ovine myoblasts treated with Mstn 
and controls, with:  *P<0.05, **P<0.01, n=6 replicates per treatment. 
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Figure 4.9: Abundance of metabolic targets in the nuclear enriched lysates 
of ovine myoblasts treated with Mstn. For western blot analysis nuclear enriched 
lysates were isolated from ovine myoblasts treated with vehicle (controls) or 100 ng/mL 
of Mstn for 1 h. Isolated protein (5 µg per sample) was run on a SDS/PAGE gel and 
blotted onto nitrocellulose. Immunoblots were performed for the depicted proteins (A), 
with representatives (n=3) shown. Blots were then exposed to autoradiographic film to 
capture the chemiluminescent signal. Equal loading of protein samples was assessed 
using Ponceau stain, with a representative blot shown in (B). The optical density of 
individual bands was obtained using a GS800 scanning densitometer and Quantity One 
software (BioRad). Relative abundance (C) was calculated by normalising the density 
values obtained from the cells treated with Mstn to those of their control counterparts. 
Normalised data presented are mean +/- SEM, asterisks denote significant differences 
between ovine myoblasts treated with Mstn and controls, with: †P<0.1, *P<0.05, 
**P<0.01, n=6 replicates per treatment. 
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Figure 4.10: Abundance of the cell cycle regulators cyclin E and CDK2 in the cytoplasmic and 
nuclear enriched lysates of ovine myoblasts treated with Mstn. For western blot analysis, 10 µg of 
cytoplasmic, or 5 µg of nuclear enriched lysate that was isolated from ovine myoblasts treated with vehicle 
(control) or 100 ng/mL of Mstn for 1 h, was run on  SDS/PAGE gels and blotted onto nitrocellulose. 
Immunoblots were performed for the depicted proteins, with representatives (n=3) shown for cytoplasmic (A) 
and nuclear enriched lysates (B). Blots were then exposed to autoradiographic film to capture the 
chemiluminescent signal. Equal loading of protein samples was assessed using Ponceau stain, with a 
representative blot shown for cytoplasmic (C), and nuclear enriched (D) lysates. The optical density of 
individual bands was obtained using a GS800 scanning densitometer and Quantity One software (BioRad). 
Relative abundance was calculated by normalising the density values obtained from the cells treated with Mstn 
to those of their control counterparts for cytoplasmic (E) and nuclear enriched (F) lysates. Normalised data 
presented are mean +/- SEM, asterisks denote significant differences between ovine myoblasts treated with 
Mstn and controls, with: *P<0.05, n=6 replicates per treatment. 
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4.2.2 MSV signalling in ovine myoblasts 
Once the use of Triton X-114 was validated as a suitable method for the 
removal of LPS, the signalling of the purified MSV protein was investigated. One 
caveat, introduced through the use of Triton X-114 was the presence of residual 
detergent in the preparation, which is reported to be less than 0.018% (Aida and 
Pabst 1990). Thus, in control treatments, dialysis buffer that was also subjected to 
Triton X-114 treatment, was added to control ovine myoblast media at equivalent 
volumes to those used for the addition of MSV. The abundance of a targeted 
subset of the genes was investigated in whole cell lysates using western blot 
analysis. The targeted molecules representing a subset of those investigated 
following the treatment of ovine myoblasts with Mstn as described above.  
4.2.2.1 Myogenic transcription factors 
As shown above (4.2.1.1) the myogenic transcription factors MRF4 and 
Myf5 were altered in ovine myoblasts in response to treatment with Mstn. In, 
addition Mstn treatment also induced the phosphorylation of Smad2. Thus, the 
ability of MSV to regulate the abundance of these transcription factors and the 
phosphorylation of Smad2/3 was investigated. As shown in Figure 4.11, treatment 
with MSV increased the abundance of Myf5 (~2.4 fold, P<0.01), while the 
abundance of MRF4 was not altered. Treatment with MSV also increased the 
abundance of total Smad2 and Smad3 proteins (~1.4 fold, P<0.05 and ~1.3 fold 
P<0.05, respectively), with no change observed in the phosphorylation of Smad2 
and no detection of phosphorylated Smad3. 
4.2.2.2 PI3K, MAPK and metabolic targets 
As shown above, Mstn treatment of ovine myoblasts influences signalling 
components involved the PI3K and MAPK signalling cascades, in addition to 
metabolic targets that are controlled by the activation of these pathways.  Thus, 
the ability of MSV to regulate the phosphorylation of AKT (S473) and ERK1/2 
was investigated, with the abundance and the phosphorylation of 4EBP1 and the 
phosphorylation of rpS6 also assessed in this study. As shown in Figure 4.12 (A) 
treatment with MSV had a tendency to increase the phosphorylation of AKT (~1.5 
fold, P<0.1), while no change was observed in the phosphorylation of ERK1 or 2. 
Treatment with MSV also increased the abundance and phosphorylation of 4EBP1 
92 
(~3.5 fold, P<0.05, ~1.8 fold, P<0.01, respectively), while the phosphorylation of 
rpS6 was not altered. 
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Figure 4.11: Abundance of myogenic transcription factors in ovine myoblasts 
treated with MSV. For western blot analysis whole cell lysates were isolated from ovine 
myoblasts treated with vehicle (controls) or 3 µg/mL of recombinant MSV for 1 h. Isolated 
protein (10 µg per sample) was run on a SDS/PAGE gel and blotted onto nitrocellulose. 
Immunoblots were performed for the depicted proteins (A), and the blots were then exposed to 
autoradiographic film to capture the chemiluminescent signal. Equal loading of protein samples 
was assessed using Ponceau stain, with a representative blot shown in (B). The optical density 
of individual bands was obtained using a GS800 scanning densitometer and Quantity One 
software (BioRad). Relative abundance (C) was calculated by normalising the density values 
obtained from the cells treated with MSV to those of their control counterparts. Normalised 
data presented are mean +/- SEM, asterisks denote significant differences between ovine 
myoblasts treated with MSV and controls, with:   *P<0.05, **P<0.01, n=3 replicates per 
treatment. 
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Figure 4.12: Abundance of PI3K/AKT, MAPK and metabolic targets in ovine 
myoblasts treated with MSV. For western blot analysis whole cell lysates were isolated from 
ovine myoblasts treated with vehicle (controls) or 3 µg/mL of recombinant MSV for 1 h. Isolated 
protein (10 µg per sample) was run on a SDS/PAGE gel and blotted onto nitrocellulose. 
Immunoblots were performed for the depicted proteins (A), and the blots were then exposed to 
autoradiographic film to capture the chemiluminescent signal. Equal loading of protein samples 
was assessed using Ponceau stain, with a representative blot shown in (B). The optical density of 
individual bands was obtained using a GS800 scanning densitometer and Quantity One software 
(BioRad). Relative abundance (C) was calculated by normalising the density values obtained from 
the cells treated with MSV to those of their control counterparts. Normalised data presented are 
mean +/- SEM, asterisks denote significant differences between ovine myoblasts treated with MSV
and controls, with: †P<0.1,*P<0.05, **P<0.01, n=3 replicates per treatment. 
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       Control          MSV  
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4.3 Discussion 
The studies undertaken in this chapter investigated the early signalling 
events regulated by Mstn and MSV in ovine myoblasts. The majority of previous 
studies describing the signalling events that are regulated by Mstn, have focused 
primarily on human or mouse cells and tissues (Trendelenburg, Meyer et al. 2009; 
Elkina, von Haehling et al. 2011). Those studies elucidated a number of the 
critical signalling events that are regulated by Mstn and play a role in the growth 
and development of skeletal muscle. These include ability of Mstn to influence 
signalling events involved in the synthesis and degradation of protein, the control 
of cell proliferation and differentiation, and in the control of energy metabolism. 
Therefore, previous work investigating the signalling of Mstn provided a list of 
candidate targets for investigation in the current studies. In an effort to maximise 
the information gained from this study, the cell lysates from the ovine myoblasts 
treated with Mstn were fractionated. This allowed the analysis of cytoplasmic and 
nuclear enriched lysates, with the aim of providing further insight into the 
localisation of target molecules following Mstn treatment. There is a caveat here, 
in that the nuclear enriched lysates are also likely to contain membrane bound 
proteins, which are solubilised during the isolation procedure. This point is 
particularly important in the signalling context, given that a number of signal 
transduction molecules can interact either directly or in complex with the cell 
membrane. Thus, the data presented here needs to be interpreted with that in 
mind.   
Transcription factors that have defined roles in myogenesis were the first 
candidate genes that were investigated in this study. These transcription factors 
represent key molecules involved in the regulation of myoblast growth and 
indeed, myogenesis (see 1.1.4).  Treatment with Mstn induced changes in the 
abundance of five out of the six myogenic transcription factors investigated in this 
study. In cytoplasmic lysates, Mstn treatment increased the abundance of MyoD, 
MRF4 and decreased the abundance of Myf5, while nuclear enriched lysates 
showed increases in MyoD, Mef2 and Pax7. The down-regulation of Myf5, and 
increased Mef2 is consistent with earlier reports (Langley, Thomas et al. 2002; 
Hennebry, Berry et al. 2009). Here, Langley et al, showed that Mstn decreased the 
expression of Myf5 in proliferating C2C12 myoblasts following a 72 h of 
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treatment, an observation that the authors link to the decreased myogenesis 
observed following the treatment of differentiating myoblasts with Mstn for the 
same time period. However, the treatments with Mstn investigated in that study 
were much longer that those investigated here, with the current studies focusing 
on the early signalling events influenced by Mstn. With regard to Mef2, one of my 
earlier studies demonstrated that the expression of Mef2 is higher in the nuclear 
extracts of myoblasts, and the muscle isolated from WT vs Mstn-/- mice 
(Hennebry, Berry et al. 2009). In that study we proposed that increased nuclear 
Mef2, associated with the presence Mstn plays a role in the regulation of fibre-
type specific genes, through the regulation of muscle-specific gene transcription. 
This idea is consistent with later, independent studies investigating the 
differentiation of mouse myoblasts, where treatment with Mstn has been shown to 
promote the expression of structural muscle genes that are associated with the 
slow muscle phenotype (Wang, Yu et al. 2012).  
More difficult to explain here, is the increased abundance of MRF4 in 
cytoplasmic lysates and, of Pax7 and MyoD in nuclear enriched lysates. Previous 
studies investigating the role of Mstn in the regulation of these transcription 
factors have shown that Mstn decreases rather than increases their levels of 
expression. This is especially true for MyoD and Pax7, where other studies have 
clearly demonstrated that Mstn reduces the abundance of these factors (Langley, 
Thomas et al. 2002; McFarlane, Hennebry et al. 2008). In fact, in a recent study in 
ovine myoblasts, where siRNA targeting Mstn was used, decreases in the 
expression of MyoD transcript at 48, 72 and 96 h of differentiation were observed 
(Liu, Li et al. 2012). However, as with MEF 2 and Myf5, there is a lack of studies 
investigating the response of these major myogenic transcription factors following 
a short interval of treatment with Mstn. One aspect of the current study that may 
be of major importance, is the ability of Mstn to target these transcription factors 
in or, perhaps, to specific cellular compartments. This is particularly evident in the 
increased expression of MyoD, Mef2 and Pax7 found in nuclear enriched lysates 
and in the reduced abundance of cytoplasmic Myf5. In support, the microarray 
data shows a reduced abundance of MyoD transcript following 6 h of Mstn 
treatment (~1.3 fold, P<0.01, data not shown). Thus, these data extend our 
knowledge on the effect of Mstn on these key myogenic transcription factors, 
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detailing aspects of their early responses to Mstn treatment differ from those 
observed following prolonged exposure to Mstn.  
A potential explanation for these discrepancies may lie with the 
interactions of the myogenic transcription factors, with molecules whose activity 
is altered following Mstn treatment. For example, the role of the Smad and Mef2 
transcription factors in addition to p38 are likely to play pivotal role. Interactions 
between MyoD and Smad 3 have been described (Liu, Black et al. 2001; Langley, 
Thomas et al. 2002), and between Mef2 and Smad 2 proteins (Quinn, Yang et al. 
2001). Mef2 has also been shown to interact with the MRF family members to 
regulate the transcription of muscle specific genes, an interaction that is 
independent of DNA binding activity (Molkentin, Black et al. 1995). In addition, 
the MyoD:Pax7 ratio has been shown to be important for myogenic fate decisions, 
including the proliferation and differentiation of myoblasts in addition to the 
induction of cellular quiescence. Although studies suggest that there is no direct 
interaction between MyoD and Pax7, immunoprecipitation experiments suggest 
they complex with each other through common intermediates to regulate 
myogenesis (Olguin, Yang et al. 2007; Olguin and Pisconti 2012). Furthermore, 
the activity of p38, a well-established target of Mstn, has been shown to be 
important in the control of MyoD, MEF2 and Pax7 activity (Knight and Kothary 
2011).  Thus, these observations clearly demonstrate an altered distribution of key 
myogenic transcription factors following a short interval of Mstn treatment, that 
occurs in parallel with modulation of the activity of key signalling pathways that 
regulate the activity of key myogenic transcription factors. Indeed, further 
investigations will be required to elucidate the specific nature of these interactions 
and how they control the activity of the myogenic transcription factors. 
         To establish the early effects of exposure to Mstn on components of the 
PI3K/AKT signalling cascade (see 1.1.6.2), the abundance and phosphorylation of 
PDK1 and AKT in the protein lysates from ovine myoblasts was investigated.  
Consistent with no change in the phosphorylation status of PDK1, the 
phosphorylation of AKTT308 was not altered following Mstn treatment. 
Unexpectedly, Mstn treatment induced the phosphorylation of AKTS473, with 
increases observed in both cytoplasmic and nuclear enriched lysates. The increase 
in the phosphorylation of AKTS473, was accompanied by a decrease in the 
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abundance of cytoplasmic AKT, with a corresponding increase in the abundance 
of AKT observed in nuclear enriched lysates. These data conflict with previous 
literature regarding the effect of Mstn on AKT phosphorylation and also suggest 
that Mstn treatment alters the distribution of AKT within the cell. Previous studies 
have reported that Mstn inhibits the phosphorylation of AKT, specifically, 
reducing the phosphorylation of AKTS473 in human myoblasts (Trendelenburg, 
Meyer et al. 2009). Again, the timeframes of these observations in previous 
studies is the major point of difference with the data presented here. Alternatively, 
these data may highlight points of difference in Mstn signalling between 
myoblasts isolated from ruminant vs monogastric species.   
In the previous myoblast study that reported reduced phosphorylation of 
AKTS473, following treatment with the same Mstn preparation, AKT 
phosphorylation was assessed 24 h after the addition of Mstn (Trendelenburg, 
Meyer et al. 2009). Therefore, an initial increase in the phosphorylation of 
AKTS473 would have been missed. In addition, other observations from the current 
study support the increase in the phosphorylation of AKTS473. Firstly, the 
phosphorylation of p38 MAPK was induced following treatment with Mstn, 
presumably through TAK1 as reported in other myoblast models and in 
fibroblasts (Philip, Lu et al. 2005; Li, Kollias et al. 2008; Zhang, Rajan et al. 
2011). AKT and p38 have being shown to associate with each other in human 
neutrophils and vascular smooth muscle cells with the later study demonstrating 
that p38 recruits the MAPKAPK-2 kinase to phosphorylate AKT specifically at 
S473 (Rane, Coxon et al. 2001; Taniyama, Ushio-Fukai et al. 2004). Furthermore 
Li et al reported that Mstn induces the phosphorylation of AKTS473 in fibroblasts, 
an increase that is blocked by the pharmacological blockade of p38 (Li, Kollias et 
al. 2008). Interestingly, a recent study demonstrated that specific phosphorylation 
of AKT at S473, targets AKT for ubiquitination and subsequent proteasomal 
degradation (Wu, Ouyang et al. 2011). In this study the authors also show that this 
mechanism is independent of the phosphorylation of AKT at T308, which has also 
been show to target the degradation of AKT through independent mechanisms. 
This provides a plausible explanation for the increased phosphorylation of 
AKTS473 observed in this study. In addition, they support a mechanism involving 
MAPK signalling, through which AKT may be targeted for degradation following 
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exposure to Mstn. Thus, these early observations may represent the starting point 
of the reduced activity of AKT that is observed following longer periods of 
exposure to Mstn.   
The treatment of ovine myoblasts with Mstn also altered the abundance 
and the phosphorylation of additional components of the MAPK signalling 
cascade in conjunction with p38. Treatment with Mstn altered both the abundance 
and the phosphorylation of ERK1 and 2 in ovine myoblasts. The ERKs represent 
major intermediates for the MAPK signalling cascade, with their activity 
influenced by a an array of growth factors and mitogens (Knight and Kothary 
2011). ERK signalling has also being shown to play a crucial role in the control of 
the proliferation and differentiation of  myoblasts (Knight and Kothary 2011). 
Others have reported that Mstn activates ERK signalling to inhibit both the 
proliferation and the differentiation of C2C12 myoblasts (Yang, Chen et al. 2006). 
Unfortunately, the mechanistic details of cellular events downstream of ERK1/2 
in myoblasts, have remained elusive (Knight and Kothary 2011). Thus, the data 
presented here confirm that Mstn regulates the abundance and phosphorylation of 
ERK1/2 in ovine myoblasts. 
The metabolic role of Mstn in skeletal muscle has been the focus of a 
number of studies.  Genetic ablation of Mstn in mice has been shown to improve 
tolerance to diets high in fat (McPherron and Lee 2002), to increase protein 
synthesis (Welle, Burgess et al. 2009) and, reports have also proposed a role for 
Mstn in the regulation of glucose metabolism (Chen, Ye et al. 2010). Thus, the 
effect of Mstn treatment on some of the key signalling molecules involved in the 
regulation of these processes was investigated. Firstly, the ability of Mstn to alter 
the abundance and the phosphorylation of AMPK and its downstream target ACC 
were investigated. No changes in the abundance or the phosphorylation of AMPK 
or ACC were observed following treatment with Mstn. Previous studies have 
shown that Mstn increased the phosphorylation of AMPK and ACC in HeLa cells, 
and observed differences in the phosphorylation of these molecules between WT 
and Mstn null mice (Chen, Ye et al. 2010; Zhang, McFarlane et al. 2011).  In the 
HeLa cells these changes were observed following a 6 h treatment with E. coli 
derived Mstn, at concentrations (750-1500ng/mL) that are orders of magnitude 
higher than those that used for the current study (Chen, Ye et al. 2010). Thus, the 
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treatment time and the Mstn concentration, or the nature of the Mstn preparation 
are likely explanations for the lack of AMPK and ACC activation observed here.  
Also investigated was the abundance and phosphorylation of rpS6, 4EBP1 
and p70S6K, all of which are molecules with established roles in cellular growth 
and the regulation of protein synthesis (Magnuson, Ekim et al. 2012). Mstn 
treatment altered the abundance and phosphorylation of all three of these 
molecules. The increased abundance of 4EBP1 in cytoplasmic lysates is 
interesting. 4EBP1 has a well-defined role in the inhibition of cap-dependant 
translation, binding in complex to the translation initiation factor eIF4E, to inhibit 
translation. This inhibition of translation is reversed following the 
phosphorylation dependant dissociation of 4EBP1 (Magnuson, Ekim et al. 2012). 
Thus, increased cytosolic 4EBP1 should result in decreased cap-dependant 
translation (Choo, Yoon et al. 2008), consistent with a role for Mstn in the 
reduction of protein synthesis. The reason for increased phosphorylation of 
4EBP1 in nuclear enriched lysates is unclear. However, this does suggest that the 
distribution of 4EBP1 within the cell plays a role in the changes induced 
following Mstn treatment.  
Treatment with Mstn also induced changes in rpS6, primarily through 
increased phosphorylation. The consequences of rpS6 phosphorylation are not 
well understood, with conflicting data on a direct link between the 
phosphorylation of rpS6 and protein synthesis (Meyuhas 2008). However, Mouse 
embryonic fibroblasts with a knock-in, phosphorylation inactive form of RPS6 
show increased synthesis of protein and an accelerated rate of growth. Thus, in 
these cells rpS6 phosphorylation is refractory to protein synthesis, which would be 
consistent with the function of Mstn and the increased phosphorylation of rpS6 
observed in this study. The last metabolic target investigated was p70S6K, this 
kinase has been shown to regulate multiple downstream targets, including 4EBP1 
and rpS6 via preceding activation through both the PI3K/AKT and MAPK 
pathways. Treatment with Mstn stimulated the phosphorylation of p70S6K at 
T389, a phosphorylation site regulated through the mTOR complex. Interestingly, 
the phosphorylation of p70S6K through mTOR can occur following activation of 
the PI3K/AKT and MAPK pathways (Magnuson, Ekim et al. 2012). Importantly 
the mTOR/p70S6K pathway plays a role in the control of both the 
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phosphorylation of rpS6 and 4EBP1, with rpS6 being a direct substrate for 
p70S6K and, 4EBP1 a target of mTOR (Magnuson, Ekim et al. 2012). Given the 
absence of signalling through PDK1 that was observed in this study, it is likely 
that the increased phosphorylation of p70S6K at T389 is a result of mTOR 
activation, with the MAPK signalling observed following Mstn treatment a likely 
candidate for the activation of this pathway. Previous studies investigating the 
effect of Mstn on the phosphorylation of p70S6K, have shown that extended 
periods of exposure to Mstn reduced the phosphorylation of p70S6K 
(Trendelenburg, Meyer et al. 2009). Thus, as with AKT, the early effects of Mstn 
on this molecule may differ from those observed following extended periods of 
Mstn treatment.  
The ability of Mstn to alter the abundance of the cell cycle regulators 
cyclin E and CDK2 was also assessed. Previous studies have shown that treatment 
with Mstn reduces the abundance of this factor, with this linked to the reduced 
proliferation associated with Mstn treatment (Langley, Thomas et al. 2004). In the 
current study, an increase in the abundance of CDK2 in nuclear enriched lysates 
was the only difference observed in the abundance of these key cell cycle 
regulators. Interestingly, over-expression of Mstn has been shown to increase the 
abundance of CDK2 transcript in sheep fibroblasts (Lu, Ren et al. 2012). Thus, 
similar to the increases observed in the phosphorylation of AKT, other models 
support the data observed in these studies.  
In addition to investigating the signalling of Mstn, the signalling events 
induced by MSV were also investigated in this chapter. The range of targets 
investigated following MSV treatment was reduced, this was done for a number 
reasons. Firstly, to focus on molecules that had been altered following Mstn 
treatment. Secondly, although LPS had been removed, there were still concerns 
regarding the proper folding of MSV following LPS removal with Triton X-114. 
Finally, with the successful generation of C2C12 myoblasts stably expressing MSV 
(Chapter 6), a decision between further studies investigating MSV signalling or a 
more substantial investigation of C2C12 cells expressing MSV had to be made. As 
the C2C12 cells provided the most robust model for further investigating the 
function of MSV, a larger study in this model was preferred (see Chapter 6).     
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Initially, the abundance of members of the MRF family were investigated. 
In contrast to Mstn treatment, ovine myoblasts exposed to MSV showed an 
increased abundance of Myf5, showing that the regulation of Myf5 is 
differentially regulated by Mstn and MSV.  The consequence of this increase is 
uncertain, although Myf5 is thought to play an important role in the expansion of 
myogenic precursors, in addition to working in concert with other myogenic 
transcription factors to regulate myogenesis (Rudnicki, Schnegelsberg et al. 1993; 
Knight and Kothary 2011). The ability of MSV to regulate canonical signalling of 
Mstn was assessed, with the abundance and phosphorylation of Smad 2/3 
determined following MSV treatment. Interestingly MSV increased the 
abundance of both Smad 2 and 3, while no change was observed in Smad 
phosphorylation. The effect of the increased Smad 2 and 3 induced by MSV is 
unclear, but demonstrates that MSV influences the content of key molecules 
involved in canonical Mstn and thus TGF-β signalling. However, an increased 
abundance of total Smad2 and 3 may have implications for canonical Mstn 
signalling pathways. Studies have shown that the ratio of phosphorylated:total 
Smad may be important in determining Smad activity, thus increased abundance 
of total Smad2/3 may reduce Smad activity or, alternatively, this response may 
constitute a positive feedback mechanism to counter reduced Smad activity.    
Treatment with Mstn altered components of the PI3K and MAPK 
signalling pathways. Thus, the ability of MSV to alter components of these 
pathways was investigated. Treatment with MSV had a tendency to increase the 
phosphorylation of AKT at S473, thus, the phosphorylation of AKT represents a 
potential target for MSV signalling.  No change was observed in the 
phosphorylation of ERK1/2, thus the function of MSV does not appear to involve 
the regulation of this major intermediate of MAPK signalling. Metabolic targets 
were also investigated following MSV treatment. As with Mstn treatment MSV 
induced an increase in the abundance of 4EBP1, MSV also increased the 
phosphorylation of 4EBP1. Thus, both Mstn and MSV regulate the abundance and 
activity of 4EBP1, highlighting a target with an important role in protein synthesis 
that is targeted by both Mstn and MSV. 
In summary, the data presented in this chapter shows that treatment of 
ovine myoblasts with Mstn alters the abundance and the phosphorylation of 
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targets involved in signal transduction across multiple pathways. In addition, Mstn 
altered the abundance of myogenic transcription factors that play important roles 
in the regulation of myogenic gene expression, in addition to the abundance and 
the phosphorylation of metabolic targets involved in the control of protein 
synthesis. Consistent with previous studies, Mstn increased the phosphorylation of 
components in the MAPK, and Smad signalling pathways. In addition, the data 
obtained from this short interval of Mstn treatment also conflicted with earlier 
reports, especially with regard to the phosphorylation of AKT and 4EBP1, and the 
abundance of the major myogenic transcription factors Pax7 and MyoD. The 
current data extend the knowledge of these early events controlled by Mstn, 
demonstrating that the initial signalling events differ from those observed 
following longer periods of exposure to Msn. The early signalling events 
regulated by MSV were also investigated in this chapter. Common molecules 
targeted by both Mstn and MSV were the Smads, 4EBP1, phosphorylated AKT 
(S473) and the myogenic regulatory factor Myf5.  Thus, these targets provide 
potential convergence points for Mstn and MSV signalling in the regulation of 
myogenesis and protein synthesis and provide a starting point for the further 
investigations of MSV signalling, in a myoblast model expressing MSV (see 
Chapter 6).  
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Chapter Five 
5 Mstn regulates the expression of the β1 subunit of the Na+- K+ 
-ATPase through a Smad dependant mechanism. 
5.1 Introduction 
This chapter follows on from the identification that the β1 subunit of the 
Na+-K+-ATPase is a downstream target of Mstn (Chapter 3). The following 
section gives an overview of what is known about the Na+-K+-ATPase.  
The Na+-K+-ATPase complex was discovered in 1957 by Jens Christian 
Skou, a discovery that would some 40 years later see him awarded the Nobel 
Prize in chemistry. The Na+-K+-ATPase complex belongs to the P-type ATPase 
family and is expressed in the plasma membrane of all mammalian cells. The Na+-
K+-ATPase complex mediates coupled cellular export of 3Na+ and import of 2K+ 
ions against their electrochemical gradients in an ATP dependant process (Skou 
1957; Clausen 2003). The maintenance and control of ionic gradients by the Na+-
K+-ATPase complex is crucial for many biological processes including: early 
embryonic development, cell volume regulation, transport of metabolites (e.g. 
glucose and amino acids), stimulation of glycolysis, H+ and Ca2+ transport and 
maintaining the electrical activity of muscle and nerve (Devarajan, Gilmore-
Hebert et al. 1992; James, Wagner et al. 1999; Madan, Rose et al. 2007; Doi and 
Iwasaki 2008). In fact, the ion transport controlled by this complex is 
indispensable for maintaining the contractility of skeletal muscle (Clausen 2003).  
The Na+-K+-ATPase complex consists of three subunits, an essential 
hetero-dimer of an α and β-subunit, which constitutes the functional body of the 
complex, and a regulatory γ-subunit (FXYD) protein. The Na+-K+-ATPase α and 
β subunits are expressed in various isoforms and, to date four α isoforms (α1-α4), 
three β isoforms (β1-β3), and seven FXYD family members have been identified. 
The α1 and β1 isoforms are ubiquitously expressed, while other α, β and γ isoforms 
have a more tissue specific profile (Tokhtaeva, Clifford et al. 2012). The Na+-K+-
ATPase complex in skeletal muscle is comprised predominantly of α1-α2/β1-β2 
hetero-dimers with FXYD1 (phospholemma) the only γ-subunit identified in 
muscle (Kristensen and Juel 2010).  In skeletal muscle, there are three cellular 
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pools of the Na+-K+-ATPase, which reside within the sarcolemma, t-tubules and 
an intracellular component(s) that lacks a precisely defined location (Clausen 
2003). Interestingly, a recent study identified a functional Na+-K+-ATPase 
complex in the nuclear membrane of HEK 293 cells, a site not yet studied in 
skeletal muscle, which in conjunction with sub-sarcolemmal vesicles and triad 
junctions, provide potential locations for this unidentified intracellular pool 
(Clausen 2003; Galva, Artigas et al. 2012).  
In terms of specific subunit functionality, the α-subunit contains the major 
trans-membrane region of the Na+-K+-ATPase complex, harbouring ten trans-
membrane domains, which include the ion and the cardiotonic steroid binding 
sites. The alpha subunit contains three distinct cytoplasmic domains, the actuator, 
the nucleotide binding and the phosphorylation domains. These domains control 
specific aspects of ATPase function including, ion flow, ATP binding and 
interaction with a growing list binding partners, a list that includes insulin, the 
nicotinic acetylcholine receptor, CD36 (fatty acid transporter) and Src kinase 
(Heiny, Kravtsova et al. 2010; Oubaassine, Weckering et al. 2012; Kennedy, Chen 
et al. 2013; Reinhard, Tidow et al. 2013). The β-subunit is composed of a short 
cytoplasmic N-terminal tail, a single trans-membrane helix and a highly 
glycosylated extracellular domain. The β subunit has been shown to influence 
Na+-K+-ATPase K+ affinity and plays a crucial role in the trafficking of the α1/β1 
complex and subsequent insertion in the plasma membrane (Clifford and Kaplan 
2008). A role for the β1 subunit in mediating cell-cell interactions and a critical 
role in early embryonic development have also been described (Madan, Rose et al. 
2007). 
Na+-K+-ATPase ion transport is specifically inhibited by cardiotonic 
steroids (CTS), through their interaction with the α subunit. Members of the CTS 
family include the plant derived, digitalis drugs ouabain and digoxin as well as the 
vertebrate derived aglycones, bufalin and marinobufagenin. Both ouabain and 
marinobufagenin have been reported in humans as circulating endogenous 
hormones (Reinhard, Tidow et al. 2013). CTS have been used for decades as 
positive inotropic agents to treat congestive heart failure. Initially, this choice of 
treatment was attributed to the ability of CTS to increase intracellular Ca2+. 
However, it was later demonstrated that CTS treatment not only improves cardiac 
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contractility, but also induced hormone like effects, independent of changes in 
intracellular ion concentrations (Xie and Askari 2002). These effects include the 
initiation of signal transduction cascades, and the modulation of a number of 
cellular processes including: cardiomyocyte growth and hypertrophy, increased 
protein synthesis, altered gene expression and perturbation of cell to cell 
interactions (Xie and Askari 2002). These  investigations led to the postulate that 
the Na+-K+-ATPase complex has a role in signal transduction, in addition to its 
critical role in regulating Na+-K+ transport (Xie and Askari 2002). Importantly, 
the CTS ouabain influences both the signal transduction and ion flow functions of 
the Na+-K+-ATPase, and involves the direct interaction of ouabain with the α 
subunit of the Na+-K+-ATPase (Kometiani, Li et al. 1998; Laursen, Yatime et al. 
2013). The specificity of ouabain for the Na+-K+-ATPase was highlighted in a 
recent study that solved the structure of ouabain bound to the α1 subunit of the 
Na+-K+-ATPase (Laursen, Yatime et al. 2013).  In fact, after decades of research 
on the Na+-K+-ATPase, the use of ouabain as a selective inhibitor of the ‘ion flow’ 
function of the Na+-K+-ATPase complex remains the primary method for 
determining specific Na+-K+-ATPase activity. Indeed, subsequent studies have 
revealed a significant role for Na+-K+-ATPase induced signal transduction in 
major intracellular cellular signalling cascades that include MAPK, Phospholipase 
C and PI3K (Yuan, Cai et al. 2005; Kotova, Al-Khalili et al. 2006; Zhang, Zhang 
et al. 2008). Many of the mechanisms governing these effects are not fully 
elucidated. In addition, a significant role for the β subunit cannot be discounted 
with its role in the trafficking of the Na+-K+-ATPase complex and its interaction 
with an upstream regulator of MAPK signalling (Src), providing good examples 
(Bhullar, Clough et al. 2007; Clifford and Kaplan 2008).  
A number of factors have been shown to regulate the activity and 
abundance of the Na+-K+-ATPase complex in skeletal muscle, a list that includes: 
exercise, calcitonins, epinephrine, β2- agonists, insulin, IGF-1, amylin, AMPK, 
glucose concentration and PGC-1α (Benziane, Bjornholm et al. 2009; Ingwersen, 
Kristensen et al. 2011; Benziane, Bjornholm et al. 2012; Rivelli, Amaiden et al. 
2012). The primary stimulus for muscle Na+-K+-ATPase activity is the increase in 
the concentration of intracellular Na+ ([Na+]i) that is induced by electrical 
stimulation. Myofibre-type specific responses for Na+-K+-ATPase have been 
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described, with Na+-K+-ATPase activity in type I muscle fibres being more 
sensitive to increased [Na+]i than that of type II fibres (Juel 2009). Interestingly, 
the fibre-type specific differences are not accounted for by differences in the 
abundance of the Na+-K+-ATPase complex. However, fibre-type dependant 
differences in the abundance of the Na+-K+-ATPase β subunits have been 
observed in rat skeletal muscle with a greater abundance of Na+-K+-ATPase β1 
subunits in ‘slow’ oxidative than ‘fast’ glycolytic muscle, with the opposite being 
true for the β2 subunit (Fowles, Green et al. 2004).   These differences illustrate 
the importance of the other mechanisms that regulate the activity and 
concentration of the Na+-K+-ATPase complex in skeletal muscle. In addition, a 
role for TGF-β in the regulation of both the abundance of α and β subunits in 
addition to the activity of the Na+-K+-ATPase has been described (Tang, Wang et 
al. 1995; Rajasekaran, Huynh et al. 2010). However, reports have not yet 
demonstrated a role for TGF-β dependant regulation of specific Na+-K+-ATPase 
subunits in skeletal muscle. Given the critical role of the Na+-K+-ATPase complex 
in maintaining the contractile function of skeletal muscle and the signal 
transduction function of the Na+-K+-ATPase complex, its regulation by Mstn may 
constitute a critical aspect of Mstn function. Thus, the following chapter presents 
studies that further characterise the Mstn-dependant regulation of the Na+-K+-
ATPase β1 subunit.      
5.2 Results 
5.2.1 Regulation of the Na+- K+-ATPase β1 subunit by Mstn. 
To quantify the relative abundance of the Na+-K+ ATPase β1 subunit 
mRNA, and to confirm the differential expression that was observed in the 
microarray analysis, qPCR primers were designed that would amplify a 171bp 
amplicon spanning across exons 2, to 3 of the Na+-K+- ATPase β1 gene transcript. 
This region is conserved across human, murine, bovine and ovine species. 
Consistent with the microarray analysis, qPCR confirmed that, 6 h of Mstn 
treatment induced a ~3 fold (P<0.01) increase in the abundance of Na+-K+ 
ATPase β1 transcript (Figure 5.1) in the same pool of RNA from ovine myoblasts.  
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5.2.2  Regulation of the Na+-K+-ATPase β1 transcript in proliferating and 
differentiating ovine myoblasts is not a transient response. 
Regulation of the Na+-K+-ATPase β1 subunit by Mstn has not been 
previously reported. To establish that the regulation of the Na+-K+-ATPase β1 
subunit by Mstn was not a transient response, qPCR was used to assess the 
relative abundance of the Na+-K+-ATPase β1 subunit following prolonged Mstn 
treatment. This was performed on both proliferating and differentiating ovine 
myoblasts, cultured in the presence of Mstn. The Mstn dependant induction of 
Na+-K+-ATPase β1 transcript was sustained in proliferating myoblasts following 
48 h of Mstn treatment (2-fold, P<0.01). The increase in concentrations of β1 
subunit mRNA was also observed in myoblast cultures differentiated for 48 h in 
the presence of Mstn (1.4-fold, P<0.01), as shown in Figure 5.2.  
5.2.3 Na+- K+-ATPase activity plays a role in ovine myogenesis. 
5.2.3.1 Proliferation 
To establish if the Na+-K+-ATPase plays a role in the control of 
proliferation in ovine myoblasts, myoblast cultures were incubated in the presence 
ouabain throughout proliferation. Proliferation was assessed using the Methylene 
blue proliferation assay (see 2.2.5). In proliferating myoblasts, ouabain treatment 
at low concentrations (100 pM-10 nM) produced small, but, significant increases 
in the proliferation of ovine myoblasts after 24 h in culture, see Figure 5.3. 
Treatment with ouabain at 300pM induced the greatest increase in proliferation 
(~15%, P<0.001). This increase was not observed following 48 h of proliferation, 
with reduced methylene blue staining observed in the pico-molar range for this 
time-point. Treatment with Ouabain at concentrations higher than 30nM, reduced 
the proliferative capacity of primary ovine myoblasts (P<0.001), with 
concentrations of ouabain higher than 300nM for at 24 and 48 h yielding OD650 
values below their
 
12
 
and 24 h counterparts. 
5.2.3.2 Differentiation 
To establish if the Na+-K+-ATPase complex plays a role in regulating the 
differentiation of ovine myoblasts, differentiating myoblasts were incubated in the 
presence of ouabain. The extent of differentiation was assessed using the MF20 
antibody to identify when myosin heavy chains appear. Ouabain consistently 
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increased the differentiation of ovine myoblasts at a concentration of 10nM 
(Figure 5.4) at 12 h (~2.8 fold, P<0.001), 24 h (~2.1 fold, P<0.001) and 48 h (~1.4 
fold, P<0.001). In contrast, very low concentrations of ouabain (1-30pM) reduced 
differentiation, with a ouabain concentration of 30pM giving the greatest 
reduction in this range (~0.76 fold, P<0.001). The treatment of differentiating 
cultures with ouabain concentrations at 30nM and above severely compromised 
the expression of myosin heavy chain (P<0.001).  
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Figure 5.1: Concentrations of Na+-K+- ATPase β1 subunit mRNA in Mstn 
treated ovine myoblasts. Microarray RNA samples were used for qPCR 
analysis, with myoblasts treated with Mstn (600ng/ml) or vehicle alone 
(control) for 6 h. Data presented are mean +/- SEM, asterisks denote a 
significant difference from control, with: **P<.001), n=3 for each treatment. 
Concentrations were normalised control values following adjustment to 
oligreen (total cDNA) values. 
** 
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Figure 5.2: Na+-K+-ATPase β1 subunit expression in ovine myoblasts. The 
arbitrary concentrations (mean +/- SEM) of Na+-K+-ATPase β1 subunit 
mRNA, as determined by qPCR in proliferating (A) or differentiating (B) 
ovine myoblasts treated in the presence or absence of 100ng/mL Mstn or 
vehicle alone (control) for 48 h. Data presented are mean +/- SEM, asterisks 
denote a significant difference from control (** P<0.01), n=3 for each 
treatment. Concentrations were normalised to vehicle alone (control) values 
following adjustment to oligreen (total cDNA) values (2.2.1.4)  
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Figure 5.3: The effect of ouabain on ovine myoblast proliferation. Ovine 
myoblasts were cultured in the presence of increasing concentrations of ouabain, 
and proliferation was determined using the methylene blue assay and read at an 
optical density (OD) of 650nm. Data presented are mean +/- SEM, asterisks denote 
significant differences from vehicle controls at each concentration of ouabain: 
*P<0.05, **P<0.01, *** P<0.001, n=6 replicates per concentration. 
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Figure 5.4: The effect of ouabain on the induction of myosin heavy chain in 
differentiating ovine myoblasts using the MF20 antibody. The relative 
expression of MF20 in ovine myoblast cultures differentiated in the presence of 
increasing concentrations of ouabain for 12 h (A), 24 h (B) and 48 h (C), as 
determined by measuring the intensity of MF20 fluorescence (2.2.22). Data 
presented are mean +/- SEM, the dagger and asterisks denote significant 
differences from vehicle alone: †P<0.1, *P<0.05, **P<0.01, ***P<0.001, n=6 
replicates per concentration. 
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5.2.4 Mstn dependent regulation of the Na+- K+-ATPase β1 subunit occurs 
through a canonical Smad mechanism.  
To identify signal transduction cascades involved in the Mstn dependant 
regulation of the Na+-K+-ATPase β1 transcript, proliferating ovine myoblasts 
were treated with Mstn for 6 h in the presence or absence of inhibitors for the 
MAPK, PI3K/AKT and ALK/Smad signal transduction cascades (Figure 4.5). The 
inhibitors of the MAPK and PI3K/AKT cascades did not alter the concentration of 
Na+-K+-ATPase β1 transcripts. In contrast, inhibition of ALK/Smad signalling 
reduced the concentration of β1 transcript (~0.4 fold, P<0.01). Co-treatment of 
myoblasts with Mstn and inhibitors showed that Mstn retained the ability to 
increase Na+-K+-ATPase β1 transcript abundance following the pharmacological 
blockade of both MAPK and PI3K/AKT pathways, (~2.3 fold, P<0.01) and (~2.1 
fold, P<0.01) respectively, vs inhibitor alone. In contrast, Mstn could not induce 
the transcription of Na+-K+-ATPase β1 in the presence of the ALK/Smad 
inhibitor. 
5.2.5 The effect of Mstn on Na+- K+-ATPase activity in vitro. 
The hydrolysis of ATP inhibited by ouabain was assessed as a proxy for 
Na+-K+-ATPase activity at 1, 6, 12 and 24 h post Mstn or insulin treatment. 
Insulin was included as a positive control. Treatment of ovine myoblasts with 
Mstn had a tendency to reduce the hydrolysis of ATP inhibited by ouabain, with 
reductions at 1 h (28%, P<0.1), 6 h (62%, P<0.1) and 12 h (50%, P<0.1) post 
addition of Mstn. Unexpectedly, reduced ATP hydrolysis inhibited by ouabain at 
1 h (78%,  P <0.01), 6 h (76%, P <0.01) and 12 h (70%, P<0.01) was observed 
following insulin treatment. At 24 h post treatment there were with no significant 
changes in hydrolysis of ATP inhibited by ouabain in the presence of Mstn or 
insulin. 
5.2.6 Na+- K+-ATPase β1 transcript is differentially expressed in the skeletal 
muscles and myoblasts of WT and Mstn-null mice. 
To determine if the Na+-K+-ATPase β1 subunit was differentially 
expressed in muscles and myoblasts lacking functional Mstn, gastrocnemius 
muscles and primary myoblasts, isolated from wild-type (WT) and Mstn null 
mice, were used to assess the concentration of the β1 subunit transcript. 
Consistent with ovine myoblasts, gastrocnemius muscles of WT mice had 
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significantly higher concentrations of Na+-K+-ATPase β1 transcript (Figure 5.7) 
than their Mstn null counterparts (~1.8 fold, P<0.05). In contrast, primary WT 
myoblasts had reduced concentrations of Na+-K+-ATPase β1 subunit message 
(Figure 5.7) compared with their Mstn null counterparts in both proliferating and 
differentiating conditions (~2.2 fold, P<0.01, and ~4.2  fold, P<0.01), 
respectively.  
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Figure 5.5: Mstn regulates the Na+-K+-ATPase β1 subunit through a Smad 
dependant mechanism. The relative abundance of Na+-K+-ATPase β1 subunit 
transcript in proliferating ovine myoblasts was assessed using qPCR. This was 
done in the presence or absence of Mstn and (A), PI3K/AKT (LY294002 (LY), 
10µM), (B), MAPK (PD98059 (PD), 10µM) and (C), ALK/Smad (SB431542 
(SB), 1µM) pharmacological inhibitors. Data presented are mean +/- SEM, 
asterisks denote significant differences from controls (**P<0.01), n=6 replicates 
per treatment. Concentrations were normalised to vehicle alone (control) values 
following adjustment to oligreen (total cDNA) values (2.2.1.4). 
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Figure 5.6: The effect of Mstn on the hydrolysis of ATP inhibited by 
ouabain (an assay of Na+-K+-ATPase activity) in ovine myoblasts. Activity 
of the  Na+-K+-ATPase was determined in myoblast cultures treated with Mstn 
(100ng/mL), insulin (100nM) or vehicle alone (control). The reduction in ATP 
hydrolysis induced by ouabain for each treatment was used to calculate the 
ouabain inhibitable (OI) portion of ATP hydrolysis at 1 h (A), 6 h (B), 12 h (C) 
and 24 h (D) post Mstn or insulin treatment. Data presented are mean +/- SEM, 
asterisks denote significant differences from vehicle alone (control) values, 
†p<0.1, **p<0.01). n=6 replicates per treatment.  
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Figure 5.7: The Na+-K+-ATPase β1 subunit transcript is differentially 
expressed in skeletal muscles and myoblasts derived from WT and Mstn null 
mice. An arbitrary concentration of Na+-K+-ATPase β1 transcript was determined 
using qPCR in WT and Mstn-/- gastrocnemius muscle (A), proliferating myoblasts 
(B), and differentiating myoblasts (C). Data presented are mean +/- SEM, 
asterisks denote significant differences from WT (*p<0.05, **p<0.01). n=6 
replicates per genotype for muscle and n=3 for myoblast cultures. Concentrations 
were normalised to vehicle alone (control) values following adjustment to 
oligreen (total cDNA) values. 
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5.3 Discussion 
Mstn plays a major role in the regulation of skeletal muscle mass and a 
number of signalling pathways and downstream targets have now been identified 
(for review see (Elkina, von Haehling et al. 2011)). In the current study the Na+-
K+-ATPase β1 subunit was identified as a transcriptional target of Mstn.  
Furthermore this regulation is dependent on canonical ALK/Smad signalling. 
Microarray analysis provided the first indication that the Na+-K+-ATPase β1 
transcript was regulated by Mstn. This was subsequently confirmed using qPCR 
in both proliferating and differentiating ovine myoblasts treated with Mstn for 48 
h. These data further demonstrated that Na+-K+-ATPase β1 transcript is not 
transiently regulated, but is sustained during extended periods of myoblast 
proliferation and differentiation.  
To determine if Na+-K+-ATPase plays a functional role in myoblast 
proliferation or differentiation, the effect of ouabain was assessed in myoblasts 
during proliferation and differentiation. These studies demonstrated that the Na+-
K+-ATPase complex plays a role in both the proliferation and differentiation of 
ovine myoblasts. An increased rate of cell proliferation following ouabain 
treatment has been previously described in a number of cell types, including: 
myocardial cells, smooth muscle cells, astrocytes, and renal proximal tubule cells 
(Nguyen, Wallace et al. 2007). The proliferative response seen here with low 
concentrations of ouabain (100pM-10nM) is consistent with other studies 
(Nguyen, Wallace et al. 2007) where proliferation is associated with the signal 
transduction rather than the ion flow function of the Na+-K+-ATPase (Xie and 
Askari 2002). However, the increases in proliferation observed at 24 h, were not 
seen following 48 h of proliferation.  The reason for this discrepancy is not clear, 
but could be an artefact due to the spontaneous fusion of the myoblast cultures as 
they reach confluence at the later time points. After differentiation, myotubes 
absorb less methylene blue stain than proliferating myoblasts (unpublished 
observations). Treatment of myoblast cultures with high concentrations of ouabain 
(>30nM) significantly impaired myoblast proliferation, which illustrates the 
importance of the ion flow controlled by Na+-K+-ATPase in the maintenance of 
the proliferative phenotype. The inhibitory and most likely toxic action of high 
concentrations of ouabain on myoblast differentiation observed here, have been 
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previously described in cultured rat and mouse myoblasts (Pauw and Hermann 
1994). Of particular interest here, were the changes observed in the expression of 
myosin heavy chain, following treatment with ouabain. Treatment with low 
concentrations of ouabain, suggested that the signal transduction function of the 
Na+-K+-ATPase can influence the early steps involved in the execution of the 
differentiation program. In support, previous studies have reported a stimulatory 
effect of ouabain on the hypertrophic gene expression in rat cardiomyocytes 
(Kometiani, Li et al. 1998), in addition to a role in facilitating the cardiac 
differentiation of mouse embryonic stem cells (Lee, Ng et al. 2011). As with 
proliferation, differentiating myoblasts were refractory to high concentrations of 
ouabain, which is most likely due the toxicity of ouabain at high concentrations 
and, illustrate the importance of the ion flow function of the Na+-K+-ATPase for 
myogenesis.             
After establishing that Mstn regulates the β1 subunit of the Na+-K+-
ATPase, identifying the signal transduction cascade responsible for this action 
became a strong focus. These studies revealed that Mstn signalled via the 
canonical Alk/Smad pathway, but not through PI3K or MAPK pathways to 
regulate the β1 subunit. This was evidenced by the inability of PI3K or MAPK 
blockade to influence the Mstn dependant regulation of the β1 subunit transcript. 
Interestingly, the pharmacological inhibition of ALK/Smad alone significantly 
reduced the concentration Na+-K+-ATPase β1 subunit, which implies this pathway 
is of major importance in the regulation of the Na+-K+-ATPase β1 subunit in 
myoblasts. Therefore, this mechanism may not be exclusive to Mstn and may be 
common to other members of the TGF-β super-family, conveying the ability to 
regulate β1 transcript in both muscle, and potentially, other tissues.  
 In an effort to determine if Mstn also regulates Na+-K+-ATPase activity, 
the hydrolysis of ATP inhibited by ouabain was assessed in proliferating ovine 
myoblasts treated with Mstn over a 24 h period. A trend to reduce the ouabain 
inhibitable hydrolysis of ATP was observed following Mstn treatment for 1, 6 and 
12 h. Therefore, Mstn may directly regulate the activity of the Na+-K+-ATPase. 
Interestingly, insulin treatment also reduced ouabain inhibitable ATP hydrolysis.  
This was an unexpected finding given that insulin was included as positive control 
and was expected to stimulate the activity of the Na+-K+-ATPase (Omatsu-Kanbe 
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and Kitasato 1990; Al-Khalili, Kotova et al. 2004; Hatou, Yamada et al. 2010). 
However, other studies in rat skeletal muscle have demonstrated that insulin 
treatment can increase the activity of the Na+-K+-ATPase, as assessed by 86Rb 
uptake, without altering the ouabain binding affinity of the Na+-K+-ATPase 
(McKenna, Gissel et al. 2003). Alternatively, it cannot be discounted that insulin 
may differentially affect the activity of the Na+-K+-ATPase in these cells 
compared with other cell types. the effect of insulin on Na+-K+-ATPase activity in 
ovine myoblasts has not being previously reported 
To support a role for Mstn in the regulation of the Na+-K+-ATPase β1 
subunit, the concentration of the β1 transcript was quantified in WT and Mstn null 
gastrocnemius muscles and myoblasts. Consistent with Mstn increasing the 
concentration of β1 transcript, WT gastrocnemius muscles contained higher 
concentrations of β1 transcript. In contrast, the concentration of β1 transcript was 
higher in proliferating and differentiating Mstn null myoblasts. The reason for this 
discrepancy is unclear. It should be noted that the culture medium is common to 
both WT and Mstn null myoblasts, and with the numerous growth factors present 
in the culture medium a differential effect on the two genetic backgrounds cannot 
be discounted.  
In conclusion, Mstn regulates the β1 subunit of the Na+-K+-ATPase 
transcript through a canonical signalling mechanism, and potentially, regulates the 
activity of the Na+-K+-ATPase in ovine myoblasts. However, it is likely that other 
TGF β family members also influence the expression of this subunit, with the 
ALK/Smad pathway common to this super-family. Given that the β1 subunit of 
the Na+-K+-ATPase is one of the most abundantly expressed isoforms in skeletal 
muscle (Murphy, Medved et al. 2008) and that it plays a significant role in the 
assembly and localisation of the functional Na+-K+-ATPase complex (Johar, Priya 
et al. 2012), its regulation by Mstn may play a significant role in myogenesis. 
Others have reported that TGF-β1, also a member of the TGF-β super-family, 
regulates the β1 subunit via a Smad dependant pathway in renal epithelial cells 
(Rajasekaran, Huynh et al. 2010).  In support a much earlier study identified an 
effect of TGF- β treatment on Na+-K+-ATPase α and β transcript (isoform was not 
specified), and the activity of the Na+-K+-ATPase in proximal tubule cells (Tang, 
Wang et al. 1995). The β1 subunit has also been shown to be a target of the 
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MicroRNA-192 (Mladinov, Liu et al. 2013), a MicroRNA that has also been 
shown to be altered in response to TGF-β signalling (Hong, Li et al. 2013). Thus, 
the β1 subunit can be regulated by TGF-β signalling in at least two different 
tissues through Smad dependant pathways. These findings suggest that regulation 
of the Na+-K+-ATPase β1 subunit through TGF-β signalling constitutes a 
conserved mechanism that may prove to be important in the tissue specific 
regulation and activity of the Na+-K+-ATPase.  
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Chapter Six 
6 Over-expression of MSV in C2C12 myoblasts 
6.1 Introduction 
The production of eukaryotic proteins in prokaryotic systems such as E. 
coli has provided a valuable research tool, allowing the mass production of 
specific proteins to aid in the investigation of protein function. However, the use 
of prokaryotic systems for protein production has limitations that often depend on 
the nature of the expressed protein. This can include the incorrect folding of the 
expressed protein due to the absence of necessary chaperone proteins. In addition, 
bacterial contaminants such as LPS or bacterial proteins can be co-purified as 
contaminants in the recombinant preparation. The presence of incorrectly folded 
protein or bacterial contaminants can compromise protein function and 
potentially, introduce artefacts which confound bioactivity. Furthermore, methods 
for the removal of these contaminants can alter the yield and the function of the 
target protein. Therefore, the aim of the following chapter is to address the 
function of MSV in a murine myoblast line (C2C12) that expresses MSV. The use 
of this model allows the production of MSV in a eukaryotic cell line, with the 
advantage of avoiding the confounding issues associated with the production of 
this protein in E. coli. Thus, the hypothesis for these studies was that: The over-
expression of MSV in C2C12 myoblasts would alter the proliferation, 
differentiation and/or metabolic characteristics of these cells. In addition, that the 
over-expression of MSV would alter the abundance and/or the phosphorylation of 
signal transduction molecules involved in this processes.    
With the aim of investigating the function of over-expressed MSV in C2C12 
myoblast proliferation, differentiation, metabolism and signal transduction,  C2C12 
cell lines expressing full length ovine MSV (GenBank accession number: 
DL465814.1) were generated. One challenge faced in the generation of MSV 
expressing cell lines, was the detection of translated MSV protein. Thus, CHO 
and HEK293 cells expressing MSV were generated to provide additional models 
to confirm the translation of the expressed MSV protein. To provide an alternative 
means of detecting MSV, two over-expression constructs were generated, one 
containing the full length ovine MSV open reading frame (MSV) and one 
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containing full length MSV with in frame C-terminal V5 and histidine tags (C-
MSV). The tagged construct provided a means of demonstrating that the over-
expressed MSV transcript is translated into protein, with the caveat that the C-
terminal tag may perturb the functionality of over-expressed MSV protein. 
Control cell lines were also generated using the pcDNA3 vector lacking the MSV 
expression cassettes. 
6.2 Results  
6.2.1 Sequence integrity of full length MSV constructs  
The MSV expression cassettes were cloned into the pcDNA3 (Invitrogen) 
vector, containing an upstream CMV promoter and an independent neomycin 
resistance cassette. The integrity of the MSV sequence was confirmed using DNA 
sequencing (Massey University). Subsequent alignment of the DNA sequences 
(www.justbio.com) revealed two discrepancies at positions 435 and 600 of the 
predicted ovine MSV open reading frame. These corresponded to the third bases 
of codons 135 and 150 respectively. These mutations were subsequently identified 
as wobble bases, with the protein sequence coded for by the cloned MSV cassettes 
being identical to that of the predicted ovine MSV sequence. In addition, sequence 
data confirmed that the C-terminal V5 and histidine epitopes of the tagged MSV 
construct (C-MSV) were in-frame, with a correctly placed stop codon. Figure 6.1 
outlines the DNA, and Figure 6.2 the translated protein alignment of the two MSV 
constructs as compared to the predicted sequence of ovine MSV (GenBank 
accession number: DL465814.1).  
6.2.2 Confirmation of over-expression in transfected cell lines 
Following transfection and neomycin selection, two approaches were used 
to confirm that the MSV transgene was being expressed. Reverse transcriptase 
PCR was used to confirm the presence of the MSV transcript in neomycin 
resistant C2C12 cells from pooled and clonal cell lines. As seen in Figure 6.3 (A), 
the full-length MSV transcript was detected in pooled and clonal C2C12 cell lines. 
MSV transcript was also detected in C-MSV stable cell lines. Furthermore, 
primers specific for C-MSV only amplified MSV in C-MSV myoblasts (Figure 
6.3 (B)). To confirm that over-expressed MSV transcript was translated into 
protein, stable MSV, C-MSV expressing and control cell lines were cultured in 
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serum free chemically defined media (Invitrogen), and conditioned media was 
harvested following 72 hours of culture. In house antibodies raised against the C-
terminal portion of MSV failed to detect MSV in the conditioned media from 
C2C12, CHO or HEK 293 cells expressing MSV or C-MSV (data not shown). 
However, western blot analysis of conditioned media from cells expressing C-
MSV, showed the presence a V5 reactive band close to the expected molecular 
weight (~40kDa) of MSV, present in conditioned media from CHO and HEK293 
cells (Figure 6.3 (C)), but not in C2C12 cells.  Thus, a further investigation of 
conditioned media from clonal C2C12 cell lines that were derived from the original 
neomycin resistant C-MSV C2C12 cell pool was performed. As shown in Figure 
6.3 (D), conditioned media from some clonal C-MSV cell lines demonstrated a 
V5 reactive band of the same molecular weight as that observed in conditioned 
media from C-MSV HEK293 and CHO cells. This result gave me confidence that 
the presence of the MSV expression cassette resulted in the translation and 
secretion of MSV protein, albeit at low concentrations in the C2C12 myoblasts. To 
reduce the variation that is associated with the use of clonal C2C12 cell lines, the 
parent C2C12 cell pool was preferred over individual clonal MSV expressing cell 
lines to continue investigating MSV function. Thus, remaining studies in this 
chapter investigated the differences between MSV expressing and control C2C12 
cell lines.  
6.2.3 Proliferation of over-expressing cell lines 
Given the well-established role of Mstn as a regulator of myoblast 
proliferation, it was hypothesised that the expression of MSV would influence the 
proliferative capacity of C2C12 myoblasts.  To assess a potential role for MSV in 
myoblast proliferation, stable MSV and control C2C12 cultures were seeded on 96-
well plates at a density of 1,000 cells per well and proliferation was assessed with 
the methylene blue proliferation assay.  Cells were fixed at 24h intervals, over a 
96h time-course to assess proliferation. As shown in Figure 6.4, myoblasts 
expressing MSV showed, small, but significant increases in proliferation 
following 48 h (10%, P<0.001) and 72 h (2.5%, P<0.001) of proliferation, with no 
changes in proliferation observed at earlier time-points.   
126 
6.2.4 Differentiation of over-expressing cell lines 
Mstn has been shown to inhibit myoblast differentiation, thus it was 
hypothesised that the expression of MSV may enhance this process in myoblasts. 
To assess a potential role for MSV in myogenic differentiation, MSV and control 
C2C12 cell lines were seeded at 25000 cells per well in growth media and left 
overnight before the addition of differentiation media (T0). Cells were then fixed 
at 24h intervals over a 96h differentiation time course. The extent of 
differentiation assessed using a myosin heavy chain fluorescence assay (2.2.22 
and Appendix 1).  As shown in Figure 6.4 (B), C2C12 cells expressing MSV 
displayed significantly more MHC immunoreactivity at 48 h (1.9 fold, P<0.01), 
72 h (1.8 fold, P<0.001) and 96 h (1.4 fold, P<0.001) of differentiation, as 
compared to control C2C12 cells. In addition, the DAPI (Invitrogen) fluorescent 
DNA dye was used to detect nuclei in the same cells (Figure 6.4 (C)), with DAPI 
fluorescence increased at all time-points in cells expressing MSV (~1.5-1.8 fold, 
P<0.001). The MHC:DAPI ratio (i.e. MF20 expression per nuclei) was used to 
indicate the relative fusion of the differentiating cultures. As shown in Figure 6.4 
(D) no difference was observed in the MHC:DAPI ratio between MSV and 
pcDNA3 cultures.   
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Ovine MSV      ATGCAAAAACTGCAAATCTTTGTTTATATTTACCTATTTATGCTGCTTGTTGCTGGCCCA  
pcDNA3 MSV     ATGCAAAAACTGCAAATCTTTGTTTATATTTACCTATTTATGCTGCTTGTTGCTGGCCCA 
pcDNA3 C-MSV   ATGCAAAAACTGCAAATCTTTGTTTATATTTACCTATTTATGCTGCTTGTTGCTGGCCCA  
               ************************************************************  
Ovine MSV      GTGGATCTGAATGAGAACAGCGAGCAGAAGGAAAATGTGGAAAAAAAGGGGCTGTGTAAT  
pcDNA3 MSV     GTGGATCTGAATGAGAACAGCGAGCAGAAGGAAAATGTGGAAAAAAAGGGGCTGTGTAAT  
pcDNA3 C MSV   GTGGATCTGAATGAGAACAGCGAGCAGAAGGAAAATGTGGAAAAAAAGGGGCTGTGTAAT  
               ************************************************************  
Ovine MSV      GCATGCTTGTGGAGACAAAACAATAAATCCTCAAGACTAGAAGCCATAAAAATCCAAATC  
pcDNA3 MSV     GCATGCTTGTGGAGACAAAACAATAAATCCTCAAGACTAGAAGCCATAAAAATCCAAATC  
pcDNA3 C-MSV   GCATGCTTGTGGAGACAAAACAATAAATCCTCAAGACTAGAAGCCATAAAAATCCAAATC  
               ************************************************************  
Ovine MSV      CTCAGTAAGCTTCGCCTGGAAACAGCTCCTAACATCAGCAAAGATGCTATAAGACAACTT  
pcDNA3 MSV     CTCAGTAAGCTTCGCCTGGAAACAGCTCCTAACATCAGCAAAGATGCTATAAGACAACTT  
pcDNA3 C-MSV   CTCAGTAAGCTTCGCCTGGAAACAGCTCCTAACATCAGCAAAGATGCTATAAGACAACTT  
               ************************************************************  
Ovine MSV      TTGCCCAAGGCTCCTCCACTCCGGGAACTGATTGATCAGTACGATGTCCAGAGAGATGAC  
pcDNA3 MSV     TTGCCCAAGGCTCCTCCACTCCGGGAACTGATTGATCAGTACGATGTCCAGAGAGATGAC  
pcDNA3 C-MSV   TTGCCCAAGGCTCCTCCACTCCGGGAACTGATTGATCAGTACGATGTCCAGAGAGATGAC  
               ************************************************************ 
Ovine MSV      AGCAGCGACGGCTCCTTGGAAGACGATGACTACCACGTTACGACGGAAACGGTCATTACC   
pcDNA3 MSV     AGCAGCGACGGCTCCTTGGAAGACGATGACTACCACGTTACGACGGAAACGGTCATTACC  
pcDNA3 C-MSV   AGCAGCGACGGCTCCTTGGAAGACGATGACTACCACGTTACGACGGAAACGGTCATTACC  
               ************************************************************  
Ovine MSV      ATGCCCACGGAGTCTGATCTTCTAGCAGAAGTGCAAGAAAAACCCAAATGTTGCTTCTTT  
pcDNA3 MSV     ATGCCCACGGAGTCTGATCTTCTAGCAGAAGTGCAAGAAAAACCCAAATGTTGCTTCTTT  
pcDNA3 C-MSV   ATGCCCACGGAGTCTGATCTTCTAGCAGAAGTGCAAGAAAAACCCAAATGTTGCTTCTTT  
               ************************************************************  
Ovine MSV      AAATTTAGCTCTAAAATACAACACAATAAAGTAGTAAAGGCCCAACTGTGGATATATCTG 
pcDNA3 MSV     AAATTTAGCTCTAAGATACAACACAATAAAGTAGTAAAGGCCCAACTGTGGATATATCTG  
pcDNA3 C-MSV   AAATTTAGCTCTAAGATACAACACAATAAAGTAGTAAAGGCCCAACTGTGGATATATCTG   
               ************** *********************************************  
pcDNA3 MSV     AGACCTGTCAAGACTCCTACAACAGTGTTTGTGCAAATCCTGAGACTCATCAAACCCATG  
pcDNA3 C-MSV   AGACCTGTCAAGACTCCTACAACAGTGTTTGTGCAAATCCTGAGACTCATCAAACCCATG  
Ovine MSV      AGACCTGTCAAGACTCCTACAACAGTGTTTGTGCAAATCCTGAGACTCATCAAACCCATG  
               ************************************************************  
Ovine MSV      AAAGACGGTACAAGGTATACTGGAATCCGATCTCTGAAACTTGACATGAACCCAGGCACT  
pcDNA3 MSV     AAAGACGGTACAAGGTATACTGGAATCCGATCTCTGAAACTTGACATGAACCCAGGCACC  
pcDNA3 C-MSV   AAAGACGGTACAAGGTATACTGGAATCCGATCTCTGAAACTTGACATGAACCCAGGCACC  
               ***********************************************************   
Ovine MSV      GGTATTTGGCAGAGCATTGATGTGAAGACAGTGTTGCAAAACTGGCTCAAACAACCTGAA  
pcDNA3 MSV     GGTATTTGGCAGAGCATTGATGTGAAGACAGTGTTGCAAAACTGGCTCAAACAACCTGAA  
pcDNA3 C-MSV   GGTATTTGGCAGAGCATTGATGTGAAGACAGTGTTGCAAAACTGGCTCAAACAACCTGAA  
               ************************************************************  
Ovine MSV      TCCAACTTAGGCATTGAAATCAAAGCTTTAGATGAGAATGGTCATGATCTTGCTGTAACC  
pcDNA3 MSV     TCCAACTTAGGCATTGAAATCAAAGCTTTAGATGAGAATGGTCATGATCTTGCTGTAACC  
pcDNA3 C-MSV   TCCAACTTAGGCATTGAAATCAAAGCTTTAGATGAGAATGGTCATGATCTTGCTGTAACC  
               ************************************************************  
Ovine MSV      TTCCCAGAACCAGGAGAAGAAGGACTGAATCCTTTTTTAGAAGTCAAGGTGCATTTTTAC  
pcDNA3 MSV     TTCCCAGAACCAGGAGAAGAAGGACTGAATCCTTTTTTAGAAGTCAAGGTGCATTTTTAC  
pcDNA3 C-MSV   TTCCCAGAACCAGGAGAAGAAGGACTGAATCCTTTTTTAGAAGTCAAGGTGCATTTTTAC  
               ************************************************************  
Ovine MSV      ACTCCTCCCTATGGGCAATGGATTTTCCATAAAGAAAGAAAAATCATTTTTCTAGAGGTC  
pcDNA3 MSV     ACTCCTCCCTATGGGCAATGGATTTTCCATAAAGAAAGAAAAATCATTTTTCTAGAGGTC  
pcDNA3 C-MSV   ACTCCTCCCTATGGGCAATGGATTTTCCATAAAGAAAGAAAAATCATTTTTCTAGAGGTC  
               ************************************************************  
Ovine MSV      TACATTCAATTCTGTAGCATACTTGGAGAAGCTGTGTTTAAAAGGCAGTCAAAAAGTATT  
pcDNA3 MSV     TACATTCAATTCTGTAGCATACTTGGAGAAGCTGTGTTTAAAAGGCAGTCAAAAAGTATT  
pcDNA3 C-MSV   TACATTCAATTCTGTAGCATACTTGGAGAAGCTGTGTTTAAAAGGCAGTCAAAAAGTATT  
               ************************************************************  
Ovine MSV      CATTTTTGTCAAAATTTCAAAATTATAGCCTGCCTTTGCAATACTGCAGCTTTTAGGATG  
pcDNA3 MSV     CATTTTTGTCAAAATTTCAAAATTATAGCCTGCCTTTGCAATACTGCAGCTTTTAGGATG  
pcDNA3 C-MSV   CATTTTTGTCAAAATTTCAAAATTATAGCCTGCCTTTGCAATACTGCAGCTTTTAGGATG  
               ************************************************************  
Ovine MSV      AAATAA 
pcDNA3 MSV     AAATAG------------------------------------------------------  
pcDNA3 C-MSV   AAAAAGGGCGAGCTCAATTCGAAGCTTGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGT  
               *** **                                                       
Ovine MSV      ------------------------------------------  
pcDNA3 MSV     ------------------------------------------  
pcDNA3 C-MSV   CTCGATTCTACGCGTACCGGTCATCATCACCATCACCATTGA  
Figure 6.1: Sequence alignment of MSV expression cassettes. The MSV 
expression cassettes were sequenced and the predicted open reading frames of MSV 
(GenBank: DL465814.1), pcDNA3 MSV and pcDNA3 C-MSV were aligned. 
(www.justbio.com). Stars (*) indicate agreement between all three sequences for 
individual nucleotides. Highlighted are the mutations at nucleotides 435 and 600 
(yellow), stop codons (red), the mutated stop of the C-MSV cassette (green). Also 
shown are the V5 sequence (red letters) and histidine tag sequence (blue letters). 
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 Ovine MSV             MQKLQIFVYIYLFMLLVAGPVDLNENSEQKENVEKKGLCNACLWRQNNKSSRLEAIKIQI 
 MSV in pcDNA3         MQKLQIFVYIYLFMLLVAGPVDLNENSEQKENVEKKGLCNACLWRQNNKSSRLEAIKIQI 
 C-MSV in pcDNA3       MQKLQIFVYIYLFMLLVAGPVDLNENSEQKENVEKKGLCNACLWRQNNKSSRLEAIKIQI 
                       ************************************************************ 
  
 Ovine MSV             LSKLRLETAPNISKDAIRQLLPKAPPLRELIDQYDVQRDDSSDGSLEDDDYHVTTETVIT 
 MSV in pcDNA3         LSKLRLETAPNISKDAIRQLLPKAPPLRELIDQYDVQRDDSSDGSLEDDDYHVTTETVIT 
 C-MSV in pcDNA3       LSKLRLETAPNISKDAIRQLLPKAPPLRELIDQYDVQRDDSSDGSLEDDDYHVTTETVIT 
                       ************************************************************ 
  
 Ovine MSV             MPTESDLLAEVQEKPKCCFFKFSSKIQHNKVVKAQLWIYLRPVKTPTTVFVQILRLIKPM 
 MSV in pcDNA3         MPTESDLLAEVQEKPKCCFFKFSSKIQHNKVVKAQLWIYLRPVKTPTTVFVQILRLIKPM 
 C-MSV in pcDNA3       MPTESDLLAEVQEKPKCCFFKFSSKIQHNKVVKAQLWIYLRPVKTPTTVFVQILRLIKPM 
                       ************************************************************ 
  
 Ovine MSV             KDGTRYTGIRSLKLDMNPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVT 
 MSV in pcDNA3         KDGTRYTGIRSLKLDMNPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVT 
 C-MSV in pcDNA3       KDGTRYTGIRSLKLDMNPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVT 
                       ************************************************************ 
  
 Ovine MSV             FPEPGEEGLNPFLEVKVHFYTPPYGQWIFHKERKIIFLEVYIQFCSILGEAVFKRQSKSI 
 MSV in pcDNA3         FPEPGEEGLNPFLEVKVHFYTPPYGQWIFHKERKIIFLEVYIQFCSILGEAVFKRQSKSI 
 C-MSV in pcDNA3       FPEPGEEGLNPFLEVKVHFYTPPYGQWIFHKERKIIFLEVYIQFCSILGEAVFKRQSKSI 
                       ************************************************************ 
  
 Ovine MSV             HFCQNFKIIACLCNTAAFRMKX 
 MSV in pcDNA3         HFCQNFKIIACLCNTAAFRMKX 
 C-MSV in pcDNA3       HFCQNFKIIACLCNTAAFRMKKGELNSKLEGKPIPNPLLGLDSTRTGHHHHHHX 
                       ********************* 
 
Figure 6.2: Predicted protein sequence from MSV expression 
cassettes. Protein sequences for MSV, pcDNA3 MSV and pcDNA3 C-MSV, 
derived from the respective nucleotide sequence for each, were aligned 
(www.justbio.com). Stars (*) indicate agreement between all three sequences for 
individual amino acids. Highlighted are the stop codons (red), and the V5 (red 
letters) and histidine tag (blue letters) epitopes. 
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Figure 6.3: Confirmation of MSV over-expression. Firstly, the expression of 
MSV in C2C12 pooled and clonal myoblasts was confirmed using PCR. The full MSV 
sequence was amplified from reverse transcribed cDNA, isolated from distinct neomycin 
resistant C2C12 cell lines. (A) PCR amplification using primers specific for MSV (expected 
size, 1064bp), with: Lane 1, 1kb+ DNA ladder, 2, negative control, 3-7, MSV C2C12 clones 
a-e, 8, control (pcDNA3 only) C2C12 cell pool,  9, MSV C2C12 pool and 10, C-MSV cell 
pool. (B) PCR amplification using primers specific for C-MSV (expected size, 1160bp), 
with Lane 1, 1kb+DNA ladder, 2, control C2C12 cell pool, 3, C-MSV cell pool, 4, MSV 
C2C12 pool and 5, negative control. Secondly, neomycin resistant cells transfected with C-
MSV were cultured and used to condition chemical media for 72 h. Western blot analysis 
following SDS PAGE was performed on ~20 µL of conditioned media from each cell line 
tested. Anti V5 antibody was used to detect the C-terminal V5 tag of C-MSV, with the 
theoretical molecular weight of C-MSV ~40 kDa (www.justbio.com). (C), V5 immunoblot 
performed on C-MSV and control C2C12, HEK293 CHO cell pools. (D) Clonal analysis of 
C-MSV in C2C12 cells, with Lane 1, C-MSV HEK293 cells (positive control), 2-5 C-MSV 
C2C12 clones a-d, 6, control C2C12 clonal cell line.     
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Figure 6.4: Proliferation of C2C12 cells expressing MSV. Stable C2C12
myoblasts expressing MSV or pcDNA3 (control), were cultured over a 72 h
period in growth media to assess proliferation, with cells fixed at 24 h intervals. 
Proliferation was determined using the methylene blue assay and read at an 
optical density (OD) of 650nm. Data presented are mean +/- SEM, asterisks 
denote significant differences between MSV expressing and control cultures,
with: **P<0.01, *** P<0.001, n=8 replicates per cell type. 
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Figure 6.5: Differentiation of C2C12 cells expressing MSV. Stable C2C12
myoblasts expressing MSV or pcDNA3 (control), were cultured in differentiation 
media over a 96 h time-course. At 24 h intervals cells were fixed and assessed for 
relative DAPI (nuclei) and MF20 (myosin heavy chain) fluorescence. Shown in 
(A) are representative images of differentiating MSV and control cells at 0, 48 and 
96 h of differentiation. Relative fluorescence values are shown for (B), MF20 
(excitation 485nm, emission 528nm), (C), DAPI (excitation 360nm, emission 
460nm) and (D) the MF20:DAPI ratio.  Data presented are mean +/- SEM, 
asterisks denote significant differences between MSV and control cells at each 
time-point: *** P<0.001, n=12 replicates per cell-type per time-point. 
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6.2.5 Gene expression analysis in C2C12 cells over-expressing MSV. 
To establish if the expression of MSV in C2C12 myoblasts affected the 
same signalling targets as those investigated earlier for Mstn (4.2.1), western blot 
analysis of whole cell lysates derived from MSV and control C2C12 cultures was 
performed. Included in the analysis, were major transcription factors that control 
myogenesis, signal transduction molecules with crucial roles in the TGF-β, 
MAPK and PI3K cascades, and targets involved in metabolic regulation.   
6.2.5.1 Regulation of myogenic transcription factors in MSV over-expressing 
cell lines 
Mstn activates signalling pathways that regulate the expression of muscle 
specific transcription factors. To determine if the expression of MSV altered the 
abundance of key myogenic transcription factors, the relative abundance of Pax7, 
Mef2 and the MRF family of transcription factors (MyoD, Myf5, myogenin and 
MRF4) was assessed. Western analysis (Figure 6.5) showed that the expression of 
MSV increased the abundance of MyoD (1.3 fold, P<0.05), MRF4 (~1.3 fold, 
P<0.05) and myogenin (~1.3 fold, P<0.05).  With no difference in the abundance 
of Pax7, Mef2 and Myf5 transcription factors between the MSV and control cell 
lines.  
6.2.5.2 Canonical Mstn signalling in MSV over-expressing cell lines 
To determine if the expression of MSV influenced cellular targets 
involved in Mstn signalling, the abundance and phosphorylation status of Smad 2 
and 3 were investigated. As shown in Figure 6.6, C2C12 cells expressing MSV had 
an increased abundance of Smad 3 protein (~1.6 fold, P<0.05), with no change in 
the abundance of Smad 2. In addition, phosphorylation of Smad 2 or 3 was not 
detected by western blot in this study (data not shown). 
6.2.5.3 MAPK signalling in MSV over-expressing cell lines      
To establish if the expression of MSV influenced components of the 
MAPK signalling cascade, the abundance and phosphorylation status of ERK 1, 
ERK 2 and p38 MAPK was investigated (Figure 6.7). In C2C12 expressing MSV, 
no change was observed in the abundance of ERK 1 or 2. The expression of MSV 
tended to increase the phosphorylation of ERK1 (~1.3 fold, P<0.1), with no 
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change observed in the phosphorylation of ERK 2. Neither p38 MAPK, nor 
phosphorylated p38 were able to be detected in these lysates (data not shown). 
6.2.5.4 PI3K/AKT signalling in MSV over-expressing cell lines  
To determine if the expression of MSV altered components in the PI3K 
signalling cascade, the abundance and phosphorylation status of AKT and PDK1 
were investigated. As shown in Figure 6.8, the expression of MSV increased the 
abundance of total AKT and phosphorylated AKT at S473 (~1.2 fold, P<0.05 and 
~1.5 fold, P<0.05, respectively), but not the phosphorylation of AKT at T308. 
However, no changes in the abundance or phosphorylation of PDK1 were 
observed in C2C12 myoblasts expressing MSV. 
6.2.5.5 Metabolic Targets 
Given that Mstn plays a role in regulating metabolism in skeletal muscle 
(1.1.7.6), the expression of MSV may alter similar metabolic targets to those 
regulated by Mstn. Key metabolic targets previously reported to be influenced by 
Mstn include, AMPK, ACC, rpS6 and 4EBP1. Therefore, the abundance and 
phosphorylation of these targets was assessed in C2C12 cells expressing MSV 
(Figure 6.9). In comparison to control cells, C2C12 cells expressing MSV tended to 
have higher abundance of total AMPK (~1.2 fold, P<0.1), with no change in the 
abundance of phosphorylated AMPK.  The abundance and the phosphorylation of 
ACC (a downstream target of AMPK) was increased in cells expressing MSV 
(~1.3 fold, P<0.05 and, ~1.3 fold, P<0.01, respectively). The abundance of total 
rpS6 was increased in cells expressing MSV (~2.2 fold, P<0.01), with no change 
observed in the phosphorylation of rpS6 (data not shown). Finally, the abundance 
and the phosphorylation of 4EBP1 was increased in cells expressing MSV (~1.4 
fold, P<0.01 and ~1.3 fold, P<0.01, respectively).     
6.2.6 Metabolic capacity of over-expressing cell lines using the EZ4U assay  
To assess if the increases in proliferation observed in myoblasts 
expressing MSV could be due to an increase in metabolic capacity, the EZ4U 
assay (ALPCO) was used to measure the metabolic capacity of C2C12 cells 
expressing MSV. The EZ4U assay utilises the ability of functional mitochondria 
to metabolise tetrazolium salts, this yields coloured, soluble formazan derivatives. 
These can be quantified with the use of spectrophotometry, with the OD 
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proportional to the amount of formazan derivative formed and thus, the 
functionality of the cellular mitochondria. As shown in Figure 6.10, there was no 
difference in EZ4U activity at the start of the proliferation time-course (0 h) or 
following 24 h of proliferation. After 48 and 72 h of proliferation EZ4U activity 
was increased in myoblasts expressing MSV as compared with their control 
counterparts (~5.8%, P<0.01 and ~9.4%, P<0.001, respectively).   
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Figure 6.6: Abundance of myogenic transcription factors in C2C12 cells 
expressing MSV. For western blot analysis, 10µg of whole cell lystates isolated from actively 
growing C2C12 cells expressing MSV, and controls were run on a SDS/PAGE gel and blotted 
onto nitrocellulose. Immunoblots were performed for the depicted proteins (A), with the 
image capture performed using a LAS4000 imaging system (GE healthcare). Equal loading of 
protein samples was assessed using Ponceau stain, with a representative blot shown in (B). 
Density values were obtained using Quantity One software (BioRad), with the relative 
abundance calculated by normalising the density values obtained from MSV expressing cells 
to those of their control counterparts (C). Normalised data presented are mean +/- SEM, 
asterisks denote significant differences between MSV expressing and control C2C12 cells,
with:  *P<0.05, n=3 replicates per cell type. 
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Figure 6.7: Abundance of the Smad transcription factors in C2C12 cells 
expressing MSV. For western blot analysis, 10µg of whole cell lysates isolated from 
actively growing C2C12 cells expressing MSV, and controls were run on a SDS/PAGE 
gel and blotted onto nitrocellulose. Immunoblots were performed for the depicted 
proteins (A), with the image capture performed using a LAS4000 imaging system (GE 
healthcare). Equal loading of protein samples was assessed using Ponceau stain, with a 
representative blot shown in (B). Density values were obtained using Quantity One 
software (BioRad), with the relative abundance calculated by normalising the density 
values obtained from MSV expressing cells to those of their control counterparts (C). 
Normalised data presented are mean +/- SEM, the asterisk denotes a significant 
difference between MSV expressing and control C2C12 cells, with: *P<0.05, n=3 
replicates per cell type. 
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Figure 6.8: Abundance of MAPK targets in C2C12 cells expressing MSV.
For western blot analysis, 10µg of whole cell lysates isolated from actively growing 
C2C12 cells expressing MSV, and controls were run on a SDS/PAGE gel and blotted 
onto nitrocellulose. Immunoblots were performed for the depicted proteins (A), with 
the image capture performed using a LAS4000 imaging system (GE healthcare). 
Equal loading of protein samples was assessed using Ponceau stain, with a 
representative blot shown in (B). Density values were obtained using Quantity One 
software (BioRad), with the relative abundance calculated by normalising the density 
values obtained from MSV expressing cells to those of their control counterparts (C). 
Normalised data presented are mean +/- SEM, The dagger denotes a trend between 
MSV expressing and control C2C12 cells, with: †P<0.1, n=3 replicates per cell type. 
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Figure 6.9: Abundance and phosphorylation of PI3K and AKT targets in C2C12
cells expressing MSV. For western blot analysis, 10µg of whole cell lysates isolated from 
actively growing C2C12 cells expressing MSV, and controls were run on a SDS/PAGE gel and 
blotted onto nitrocellulose. Immunoblots were performed for the depicted proteins (A), with the 
image capture performed using a LAS4000 imaging system (GE healthcare). Equal loading of 
protein samples was assessed using Ponceau stain, with a representative blot shown in (B). 
Density values were obtained using Quantity One software (BioRad), with the relative 
abundance calculated by normalising the density values obtained from MSV expressing cells to 
those of their control counterparts (C).  Normalised data presented are mean +/- SEM, asterisks
denote a significant difference between MSV expressing and control C2C12 cells, with:
*P<0.05, n=3 replicates per cell type. 
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Figure 6.10: Abundance and phosphorylation of metabolic targets in 
C2C12 cells expressing MSV. For western blot analysis, 10µg of whole cell lysates 
isolated from actively growing C2C12 cells expressing MSV, and controls were run 
on a SDS/PAGE gel and blotted onto nitrocellulose. Immunoblots were performed 
for the depicted proteins (A), with the image capture performed using a LAS4000 
imaging system (GE healthcare). Equal loading of protein samples was assessed 
using Ponceau stain, with a representative blot shown in (B). Density values were 
obtained using Quantity One software (BioRad), with the relative abundance 
calculated by normalising the density values obtained from MSV expressing cells to 
those of their control counterparts (C). Normalised data presented are mean +/- SEM, 
asterisks denote significant differences between MSV expressing and control C2C12
cells, with: *P<0.05, *P<0.01, n=3 replicates per cell type. 
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6.3 Discussion 
Initial work for this chapter centred on the generation of the MSV over-
expressing cell lines following the discovery of LPS in our MSV preparation. To 
circumvent this problem and to produce MSV in a eukaryotic cell line, expression 
constructs were generated that harboured the predicted full length open reading 
frame of ovine MSV. Two MSV expression cassettes were developed and over-
expressed, one full length (start to stop codons) and one with sequence for C-
terminal V5 and histidine epitopes (C-MSV). The C-MSV construct was 
generated primarily to allow detection of full length MSV protein using 
commercial antibodies, directed against the tagged epitopes. This proved valuable 
in establishing the presence of MSV protein in cells expressing MSV, as our own 
MSV antibodies could not detect over-expressed MSV in these cells. An 
important point here is that the antigens used for the production of our antibodies, 
were synthetic or recombinant peptides, targeting small portions of the predicted 
MSV sequence. Thus, one possible explanation is that the expressed full length 
MSV protein may disrupt the epitope recognised by the ‘in-house’ antibodies.  
Construct specific PCR was used to confirm the expression of MSV and C-
MSV transcript in C2C12 cell lines. Western blot analysis of conditioned chemical 
media from C-MSV cell lines, confirmed that the over-expression of MSV 
transcript also resulted in the presence of MSV protein. Results from the 
expression studies demonstrated an anti-V5 reactive band close to the expected 
~40kDa size, in neomycin resistant HEK293 and CHO cells. No smaller anti-V5 
reactive bands were observed, that would indicate the presence of a cleaved C-
terminal MSV product. Interestingly, western blot analysis did not detect the 
presence of a V5 reactive band in pooled C2C12 C-MSV cells. This was surprising, 
given the presence of the C-MSV protein detected in the conditioned media from 
HEK293 and CHO cells and the readily detectable MSV message in C2C12 cells 
expressing MSV. To determine if C2C12 cells were expressing MSV, and 
translating the mRNA into protein, conditioned media from clonal cell lines, 
derived from the initial pool of neomycin resistant C2C12 cells were subjected to 
western blot analysis. This allowed closer scrutiny of C-MSV expression in these 
cells, and allowed a determination to be made on whether the absence of C-MSV 
in the parent C2C12 population was due to dilution, i.e. only a few clones 
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expressing C-MSV protein, or, if C-MSV is undetectable in C2C12 cells expressing 
MSV. Analysis of conditioned media demonstrated the presence of a V5 reactive 
band of the expected size in some clonal cell lines expressing MSV. Thus, 
confirming the presence of translated protein in this model, albeit at 
concentrations substantially lower than those seen in HEK293 and CHO cell lines. 
The presence of C-MSV is conditioned media also confirmed that as with Mstn, 
MSV mRNA is translated and secreted from these cells. The reason for the low 
abundance of C-MSV protein in C2C12 cells is unclear. However, given the readily 
detectable presence of the transcript in the C2C12 cell lines, mechanisms may exist 
to regulate the abundance of this protein in C2C12 myoblasts that are not present in 
HEK293 or CHO cells. A caveat to note here, is that the C-terminal tag of C-MSV 
(~31 amino acids) could interfere with functionality of the over-expressed protein. 
For this reason, my studies focused on the differences between MSV expressing 
and the control (pcDNA3) C2C12 cell lines, once confirmation that MSV was 
translated in these cells was obtained. This was performed using the parent C2C12 
cell pool that expressed MSV, these were chosen preferentially over clonal MSV 
expressing cells to reduce the variation that would be introduced through the use 
of individual clonal cell lines.  
Initially, the effect of MSV on the proliferation and differentiation of 
myoblasts expressing MSV was investigated. The methylene blue assay 
confirmed that C2C12 cells expressing MSV have an increased rate of proliferation 
as compared to their control counterparts. Furthermore, an independent study in 
our laboratory also confirmed that the same C2C12 cells expressing MSV display 
increased expression of nuclear cyclin E and CDK2, which provided a molecular 
basis for the increased rate of proliferation observed in MSV expressing C2C12 
cells (Jeanplong, Falconer et al. 2013).  
Under differentiation conditions, MSV expressing cultures had an increased 
abundance of the MF20 differentiation marker throughout a differentiation time-
course. Also apparent in this study, was the increased abundance of nuclei as 
assessed using DAPI fluorescence. It is important to note here, that prior to taking 
the first time-point, cells were incubated overnight in growth media. Thus, as cells 
were seeded at the same density, the differences in nuclear fluorescence (DAPI 
staining), that were observed at T0 in MSV expressing cultures is attributable to 
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an increased rate proliferation over this period. A potential explanation for the 
enhanced growth observed during the first 48 h of differentiation is the 
concentration of growth factors in the culture medium. Differentiation media 
contains horse serum (2%) as compared to growth media with foetal bovine serum 
(10%), thus, MSV may have more pronounced effect due to the reduced growth 
factor concentration in the differentiation media. The increased growth continued 
until the cells withdrew from the cell cycle to differentiate, which occurs at ~48 h 
post addition of differentiation media, as evidenced by the appearance of MF20 
and plateau in nuclear fluorescence. Interestingly, the increases in both MF20 and 
DAPI occurred without an increase in the extent of myoblast fusion, as assessed 
using the ratio of MF20:DAPI. Thus, although the C2C12 cells expressing MSV 
proliferate faster, and have more differentiated myotubes, the proportion of 
myoblasts forming myotubes remained constant.  
As the studies in ovine myoblasts had focused on changes in gene expression 
under proliferation conditions, western blot analysis was performed on whole cell 
lysates isolated from proliferating cells expressing MSV and controls. The target 
molecules investigated for this study were the same as those investigated for Mstn 
(Chapter 4). Cells expressing MSV had increased abundance of MyoD, MRF4 
and myogenin. These data indicate that the expression of MSV regulates the 
abundance of key myogenic transcription factors. In particular, the regulation of 
MyoD and myogenin are consistent with MSV functioning to block endogenous 
Mstn. Both of these factors have been implicated in the inhibition of myogenesis 
caused by Mstn in mouse and ovine myoblasts (Langley, Thomas et al. 2002; 
Joulia, Bernardi et al. 2003; Liu, Li et al. 2012). Changes in the abundance of 
myogenin and MRF4, are likely to play a role in the differentiation of the MSV 
expressing cells. However, the major focus of these studies was to gain a deeper 
understanding of the MSV-mediated mechanisms in proliferating myoblasts. 
Thus, this study confirmed that the expression of MSV can alter key myogenic 
transcription factors. Further studies will be required to understand the extent to 
which the increased expression of these factors may influence myogenesis.    
To establish if the expression of MSV influenced the signalling of canonical 
Mstn, the abundance and phosphorylation status of Smad 2 and 3 was 
investigated. Western blot analysis showed an increased abundance of total 
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Smad3 in C2C12 cells expressing MSV. No changes were observed in the 
abundance of Smad2 and no phosphorylated Smad 2 or 3 was detected in this 
study. Smad 3 has been shown to interact with binding partners such as MyoD 
and MEF2 (Liu, Black et al. 2001; Quinn, Yang et al. 2001), thus, increased Smad 
3 may play a role in the regulation of myogenic gene expression in these cells. 
Alternatively, an independent study on C2C12 cells expressing MSV that were co-
transfected with a Smad reporter construct (CAGA luciferase assay), 
demonstrated reduced ability of Mstn to induce Smad dependant reporter activity 
in these cells as compared to control cells (Jeanplong, Falconer et al. 2013). This 
implies that the expression of MSV impairs signalling through the Smads, thus, 
the increased abundance of Smad 3 may reflect a negative feedback mechanism to 
counter a reduced ability to signal through this pathway in C2C12 cells expressing 
MSV.     
MAPK signal transduction has been shown to play a role in both Mstn 
signalling (Yang, Chen et al. 2006; Elkina, von Haehling et al. 2011), and 
signalling events involved in the proliferation and differentiation of muscle 
precursors (Knight and Kothary 2011). Thus, the effect of the expression of MSV 
on the abundance and phosphorylation of components of ERK and p38 MAPK 
signalling cascades was investigated. Cells expressing MSV had a tendency for an 
increased abundance of phosphorylated ERK1, with no changes were observed in 
the abundance of ERK1 or 2, and phosphorylated ERK2. The effect of this small 
changes is unclear, but suggest that the expression of MSV may influence 
components involved in MAPK signalling, a cascade that plays a major role in the 
regulation of myogenesis.  
In numerous studies, Mstn has been shown to influence the PI3K/AKT signal 
transduction cascade. In muscle, Mstn has been shown to reduce signalling 
through this pathway, which provides a mechanism for the Mstn mediated 
inhibition of hypertrophy and protein synthesis (Trendelenburg, Meyer et al. 
2009). Thus, the effect of the expression of MSV on the abundance and 
phosphorylation of components in the PI3K signal transduction cascade was 
determined. In cells expressing MSV, western blotting showed an increase in both 
total and phosphorylated AKTS473, but not AKT phosphorylated at T308. The 
abundance and phosphorylation of PDK1 (a major upstream kinase of AKT) was 
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not affected by the expression of MSV. The increases in AKT and AKTS473 in 
cells expressing MSV could have major consequences on cellular targets and 
processes downstream of AKT, as discussed in the next section.  
As described in Chapter 1 (1.1.6.2), the cellular targets downstream of 
AKT play an important role in the control of protein synthesis. What is becoming 
more apparent is the extensive cross talk between signal transduction cascades 
that converge on common targets to regulate the activity of molecules with 
important roles in controlling the protein synthesis machinery and other metabolic 
processes (Roux, Shahbazian et al. 2007; Magnuson, Ekim et al. 2012). The 
regulation of rpS6 and 4EBP1 phosphorylation provides a good example, as the 
activity of these molecules can be targeted by PI3K or alternatively MAPK 
signalling (Nawroth, Stellwagen et al. 2011).  
It was unclear from the current study which specific upstream cascades 
control the abundance or the signalling activity (phosphorylation) of these 
molecules. In cells expressing MSV there was increased rpS6, with no change in 
the phosphorylation of rpS6. The rpS6 protein is thought to play a role in the 
synthesis of protein, although, the mechanistic details of this role have remained 
elusive. Knock-out studies in mouse embryonic fibroblasts, have shown that rpS6 
plays a role in the regulation of cell size, cell proliferation and glucose 
homeostasis (Ruvinsky, Sharon et al. 2005), implying an important metabolic role 
for rpS6.  Cells expressing MSV also showed increased abundance and 
phosphorylation of 4EBP1. The increased phosphorylation of 4EBP1 is consistent 
with the observed increase in the phosphorylation of AKTS473 in MSV expressing 
cells. The activity of 4EBP1, has also been shown to be regulated through the 
ERK dependant signalling cascade through a mechanism involving mTOR 
activity (Herbert, Tee et al. 2002). In this case this seems unlikely, given the small 
changes observed in ERK signalling in this model. Thus the increased 
phosphorylation of 4EBP1 is more likely to be a direct result of increased 
phosphorylation of AKTS473. The increases in 4EBP1 and rpS6, support a role for 
MSV in the control of cellular protein synthesis.  
Other metabolic targets investigated were AMPK and its downstream 
target ACC, both of which play a major role in the control of cellular metabolism. 
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AMPK is considered an energy sensor (see 1.2.5) and as such activation of 
AMPK can occur in response to a drop in cellular energy levels, or more precisely 
a rise in the ratio of AMP/ATP. Cytokines can also induce AMPK activation, with 
activation by IL6 providing a good example (Kelly, Gauthier et al. 2009).  Over-
expression of MSV had a tendency to increase the abundance of total AMPK but 
not its phosphorylation state. The majority of studies investigating AMPK 
function have focused on AMPK activation (phosphorylation) rather than the 
amount of total AMPK. Thus, the consequences of the increased AMPK observed 
here is unclear. Interestingly, studies using AMPK KO mice have shown that 
AMPK, in addition to its role as an energy sensor has a physiological role in the 
regulation of the activity of the 26S proteasome (Xu, Wang et al. 2012), with 
AMPK KO mice having increased 26S proteasomal activity. Thus, it could be 
speculated that increased AMPK may provide a greater signalling capacity 
through this pathway, or play a role in the synthesis versus the degradation of 
protein.  
The increases observed in both ACC and phosphorylated ACC are 
extremely interesting, as ACC plays a major role in the control of lipid synthesis 
and is important in the control of mitochondrial fatty acid oxidation (Kim 1997).  
The Phosphorylation of ACC has been shown to inhibit its activity and thus, 
reduce lipid synthesis through reduced formation of malonyl-CoA, this results in 
an increase in fatty acids available for oxidative metabolism (Kim 1997). The 
current data suggest that MSV alters signalling of this hub, and that ACC may 
represent a major target for MSV action. The increase in the phosphorylation of 
ACC appears to be independent of its upstream activator AMPK, given that there 
was no change in the phosphorylation of AMPK in the MSV expressing C2C12 
cells. What is interesting here is that the increases in total and phosphorylated 
ACC were of a similar magnitude, thus the ratio of active to inactive ACC would 
remain constant. Thus, the capacity of the processes controlled by ACC should be 
increased. In the context of MSV in ruminants, this may be extremely significant 
as the expression of MSV may alter the capacity of fatty acid metabolism in a 
digestive system that is more reliant on fatty acids derived from the fermentation 
of forage as a primary energy source.   
147 
To further establish a role for MSV in influencing cellular metabolism, the 
EZ4U assay was used to establish if the mitochondrial activity of MSV over-
expressing cultures was increased as compared to control C2C12 cells. The 
increase in EZ4U activity observed following 48 h of proliferation is most likely a 
result of the increased number of cells observed at this time-point and is 
consistent with the data from the methylene blue proliferation assay. However, the 
differences in proliferation observed at 72 h (~2.5%) are surpassed by the 
increased EZ4U activity (~9.6%) observed at this time-point. A potential 
explanation for this difference would be an increased oxidative capacity in the 
cells expressing MSV. However, experiments specifically targeting the role of 
MSV in mitochondrial metabolism would be required to firmly establish a role for 
MSV in this context.  
In summary, the over-expression of MSV in C2C12 myoblasts provided a new 
model for the investigation of MSV function and supports the increased 
proliferation observed in C2C12 myoblasts using recombinant protein produced in 
E.coli. These studies show that expression of MSV increases the rate of 
proliferation but not the extent of differentiation in C2C12 myoblasts. Furthermore, 
MSV over-expression alters the abundance and phosphorylation of a number of 
proteins with important roles in myogenesis, protein synthesis and metabolism. In 
addition, based on the EZ4U assay data MSV may also promote oxidative 
metabolism, an idea that is consistent with the increases observed in the 
abundance and phosphorylation of ACC in C2C12 cells expressing MSV. Thus, the 
data presented here support a role for MSV in promoting the proliferation of 
myoblasts. With the increased activation of AKT, the altered canonical 
components of Mstn signalling pathways and increased abundance of myogenic 
transcription factors representing some of the changes that culminate in the altered 
abundance and phosphorylation of molecules involved in intermediary metabolic 
pathways and the control of protein synthesis, and thus, provide evidence that 
support the reciprocal functions of MSV and Mstn.  
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Chapter Seven 
7 Final discussion and future perspectives 
The studies presented in this thesis investigate the effects of MSV on key 
molecules involved in signal transduction and consequently the regulation of 
myogenic and metabolic processes in myoblasts and how they relate to that of 
Mstn. Since the discovery of Mstn was published 16 years ago (McPherron, 
Lawler et al. 1997), numerous studies have focused on the mechanisms through 
which Mstn can have such a profound effect on the growth of skeletal muscle. 
The preceding research has shown that Mstn signals through the canonical TGF-β, 
MAPK and PI3K/AKT signal transduction cascades. Ultimately, the integration of 
the Mstn signal results in the regulation and control of key molecules involved in 
the control of myogenesis and in the control of cellular metabolism. Thus, 
previous studies investigating Mstn function provided a foundation for 
investigating the function of a novel Mstn splice variant (MSV). MSV is thought 
to be restricted to the Cetartiodactlya clade of mammals, with initial studies 
suggesting that MSV and Mstn may regulate myogenesis reciprocally. In support 
are the key findings that include the observation that the expression of MSV 
increases rather that decreases the proliferation of myoblasts, MSV binds to both 
Mstn and its canonical ACTR IIB receptor and that MSV inhibits canonical Mstn 
signalling (Jeanplong, Falconer et al. 2013). Therefore, the primary aim of this 
thesis was to what was to investigate the signal transduction function of MSV in 
myoblasts, and to identify how this differed from that of Mstn.  
Initially, ovine myoblasts were used to investigate the gene expression 
(microarray analysis) and signal transduction events (western blot analysis) 
following administration of recombinant Mstn and MSV. This allowed me to 
identify potential links between the initial signalling events and the subsequent 
changes in gene transcription. In addition, C2C12 cells that stably express MSV 
were developed to investigate the function of MSV. A diagrammatic 
representation of the molecules influenced by Mstn and MSV in these studies is 
presented in Figure 7.1.  
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The microarray study identified a number of transcripts that were 
differentially expressed following treatment with Mstn. Some of the findings 
supported previous studies, for example the increased abundance of the IL6 
transcript (Zhang, Rajan et al. 2011) and the decreased abundance of MyoD 
transcript (Liu, Li et al. 2012). In addition, a novel transcriptional target of Mstn, 
the β1 subunit of the Na+-K+-ATPase, was identified, and studies were carried out 
to understand the importance of regulating this complex (discussed later). The 
microarray data also had a significant impact on my approach to investigate the 
function of MSV. The IPA analysis of the microarray data, strongly suggested the 
presence of LPS in the MSV preparation. On confirmation, a method to eliminate 
LPS had to be established. Firstly, the removal off LPS from the MSV preparation 
using previously documented methods was investigated, with Triton X-114 phase 
separation (Liu, Tobias et al. 1997) proving to be the most effective method of 
removal. However, there were still doubts with regard to integrity of the 
recombinant protein, in particular with the protein folding and how the phase 
separation affected the MSV. Secondly, to circumvent the issues associated with 
the production of recombinant protein in E.coli, a C2C12 myoblast line expressing 
MSV was generated, which provided an additional model to investigate the 
function of MSV.  
Studies investigating the signal transduction events induced by Mstn and 
MSV in ovine myoblasts provided further insight into the signalling networks 
influenced by these molecules. Treatment with Mstn altered the abundance and/or 
the phosphorylation of a number of molecules in ovine myoblasts, as summarised 
in Figure 7.1. These included molecules in the canonical Smad pathway, the p38 
and ERK MAPK signalling cascades and the PI3K/AKT pathway. In addition, the 
signalling events induced by Mstn, also resulted in the altered abundance of key 
myogenic transcription factors.  These data also suggest that some of the early 
signalling events regulated following the addition of Mstn differ from those 
observed following long term exposure to Mstn. In particular, the increased 
phosphorylation of AKTS473 and p70S6KT389 observed here are at odds with 
previous studies using human and mouse myoblasts (Trendelenburg, Meyer et al. 
2009; Welle, Burgess et al. 2009). However, the increased phosphorylation of 
AKTS473 is consistent with a previous study in fibroblasts wherein Mstn 
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phosphorylates AKT through a mechanism that involves p38 MAPK, with 
increased phosphorylation of p38 also observed following Mstn treatment in this 
study. Further investigations may reveal that in fact the phosphorylation of AKT 
and p70S6K induced by Mstn may be a result of MAPK:AKT crosstalk through 
p38 or, alternatively, mTOR. In support of a p38 dependant mechanism, other 
studies have demonstrated that phosphorylation of AKTS473 is dependent on p38 
in neutrophils and vascular smooth muscle cells (Rane, Coxon et al. 2001; 
Taniyama, Ushio-Fukai et al. 2004). The specific phosphorylation of AKTS473 
following treatment with Mstn may represent a prerequisite step for the Mstn 
mediated inhibition of this pathway, which results in the specific ubiquitination 
and degradation of AKT, as described recently (Wu, Ouyang et al. 2011).  
Investigation of MSV signalling in ovine myoblasts showed that MSV 
shared common targets with Mstn. These included Smad 2 and 3, Myf5, AKT and 
4EBP1. The extent to which these were regulated by Mstn and MSV differed for 
individual molecules. The increased abundance of Smad 2 and 3 is likely to play a 
role in MSV function, with activity of the Smad pathway shown to be crucial for 
the effects of Mstn on p38, ERK and AKT activity (Yang, Chen et al. 2006; 
Trendelenburg, Meyer et al. 2009; Zhang, Rajan et al. 2011). In addition, MSV 
treatment increased the phosphorylation of AKTS473 and the abundance and 
phosphorylation of 4EBP1. Thus, canonical TGF-β signalling, the regulation of 
genes involved in protein synthesis and the myogenic regulatory factors were 
identified as points of potential convergence for the Mstn and MSV signals. This 
provided a starting point for further investigations of MSV signalling in C2C12 
myoblasts expressing MSV. 
A drawback of the approach to investigate MSV signalling in C2C12 cells 
that expressed MSV was the species difference between the cells used to 
investigate recombinant protein treatment (ovine) and MSV expression (mouse). 
In addition, alterations in the targets investigated here are the result of continuing 
exposure to over-expressed MSV, thus, comparisons to Mstn need to be made 
with this in mind. In ovine myoblasts that were treated with Mstn, the activation 
of canonical, p38 and ERK MAPK signalling demonstrated that, major aspects of 
Mstn function are conserved in these myoblasts (Yang, Chen et al. 2006; 
Trendelenburg, Meyer et al. 2009; Zhang, Rajan et al. 2011). Thus, based on 
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previous investigations showing that MSV is able to bind both Mstn, the Mstn 
receptor (Activin receptor type 2 B) and increases the rate of myoblast 
proliferation (Jeanplong, Falconer et al. 2013), it was reasoned that the majority of 
the pathways likely to be influenced by MSV, are conserved between these two 
myoblast models. Consistent with the treatment of ovine myoblasts with MSV, 
C2C12 cells expressing MSV, had an increased abundance of Smad 3, had 
increased phosphorylation of AKTS473 and an increase in the abundance and 
phosphorylation of 4EBP1. This confirmed the overlapping nature of the function 
of Mstn and MSV in the regulation of these targets.  In addition, the changes 
induced by the expression of MSV in the phosphorylation of AKT and 4EBP1 
highlight a major point of difference between the previously characterised 
function of Mstn and that of MSV. The over-expression of Mstn has been shown 
to decrease the activity of AKT and its downstream targets, and indeed genetic 
ablation of Mstn increases the activity of these pathways (Welle, Bhatt et al. 2006; 
Trendelenburg, Meyer et al. 2009), these changes underpin the reduced synthesis 
of protein associated with the long-term exposure to, or the presence of active 
Mstn. In contrast, these pathways are increased in C2C12 cells expressing MSV, 
which suggests that Mstn and MSV have reciprocal roles in the control of these 
targets and, potentially, the control of protein synthesis. Consistent with MSV 
opposing the function of Mstn, MSV expressing C2C12 cells also had an increased 
rate of proliferation, and an increased abundance of the MyoD, MRF4 and 
myogenin. 
Identifying a role for MSV in the regulation of intermediary metabolism 
represented an aim of these studies. The increased abundance and phosphorylation 
of Acetyl Co-enzyme A Carboxylase (ACC) observed in C2C12 cells expressing 
MSV is likely to have an impact on metabolism. This enzyme represents a key 
molecular hub for the regulation of fatty acid metabolism, supporting a 
physiological role for MSV, The regulation of ACC could result in an altered fatty 
acid flux and/or an increased enzymatic capacity of ACC in C2C12 cells 
expressing MSV. In addition, the increases in the mitochondrial activity assay 
(EZ4U) observed in these cells were disproportionate to the increases in 
proliferation demonstrated in these cells. This suggests that the expression of 
MSV modifies oxidative metabolism through increased mitochondrial number 
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and/or activity, which would be consistent with the increases observed in ACC. 
Based on previous studies, the full length MSV coding sequence is restricted to 
the Cetartiodactyla clade of mammals (Jeanplong, Falconer et al. 2013). Given, 
that the primary energy source for ruminants are fatty acids derived from the 
fermentation of forage, it is interesting to speculate that this splice variant may 
have evolved to promote growth in digestive systems more reliant on fatty acids 
as a source of metabolic fuel. Thus, the current data give the premise for future 
investigations centred on a role of MSV in the regulation of oxidative metabolism. 
 The microarray studies identified the Na+-K+ ATPase β1 subunit is a 
transcriptional target of Mstn. This was an unexpected finding, but is 
understandable given the significant overlap of processes regulated by the Na+-K+ 
ATPase complex and Mstn. Both play a role in the regulation of hypertrophy, 
proliferation of myocytes and the metabolism of skeletal muscle (James, Wagner 
et al. 1999; Xie and Askari 2002). In addition, a recent protein interaction study 
highlighted an interaction between Smad 2 and the Na+-K+ ATPase β1 subunit 
(Miyamoto-Sato, Fujimori et al. 2010), which supports the notion that TGF-β 
family members can signal via the Na+-K+ ATPase complex. In the current 
studies, I established that the Mstn dependant regulation of the Na+-K+ ATPase β1 
subunit requires Smad activity. It is interesting to speculate that regulation of the 
Na+-K+ ATPase β1 transcript may be of critical importance to Mstn function. In 
support of this idea, the β1 subunit transcript was sensitive to the pharmacological 
blockade of the Smad pathway and the inhibition of this pathway antagonises 
multiple facets of Mstn function including its effects on canonical, MAPK and 
PI3K signalling (Philip, Lu et al. 2005; Yang, Chen et al. 2006; Trendelenburg, 
Meyer et al. 2009)  
Data from these studies suggest that Mstn alters the function of the Na+-K+ 
ATPase on regulating the flow of ions. Interestingly, changes in the intracellular 
concentration of Na+ and K+ have recently been shown to regulate a plethora of 
transcriptional responses (Koltsova, Trushina et al. 2012) and to be important in 
the regulation of the intracellular concentration of calcium. Intracellular calcium 
plays a major role in the regulation of muscle fibre-type (Hogan, Chen et al. 
2003), the distribution and activity of critical signalling molecules such as the 
ERKs (Chuderland, Marmor et al. 2008) and the activity of myogenic 
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transcription factors with Mef2 providing a good example (McKinsey, Zhang et 
al. 2002). Thus, control of the β1 subunit by Mstn provides a means to regulate 
multiple pathways controlled through the function of Na+-K+ ATPase in skeletal 
muscle. The chances of Mstn and the ATPase sharing so many common pathways 
is unlikely to be a coincidence and, further studies will be required to define how 
their function overlaps in the control of the growth and development of skeletal 
muscle.  
7.1 Future perspectives     
The studies outlined in this thesis give premise for further investigations 
from both the Mstn and MSV perspectives. For Mstn, the discovery of the link 
between Mstn and the sodium potassium Na+-K+-ATPase is intriguing. A more 
targeted study investigating the role of Mstn in the control of Na+-K+-ATPase 
activity and signal transduction would be very interesting. Conformation of a role 
for Mstn in the regulation of Na+-K+-ATPase activity, would confirm Mstn as a 
regulator of ion flow in skeletal muscle. Furthermore, investigating the 
overlapping nature of Mstn and Na+-K+-ATPase mediated signalling may reveal a 
close relationship between the signal transduction function of these two 
molecules. Also interesting in these studies is the regulation of IL-6 by Mstn, 
presumably through p38 as previously shown in C2C12 myoblasts (Zhang, Rajan et 
al. 2011). The interest here centres around the release of IL6 released following 
bouts of exercise, with IL6 production important for glycogen repletion and the 
conservation of ATP (Pedersen, Akerstrom et al. 2007). To date there is no 
mechanism defined for the stimulation of IL-6.  Interestingly, a recent study has 
identified the Furin protease, which is known to cleave Mstn (Anderson, Goldberg 
et al. 2008), as a myokine released following exercise (Raschke, Eckardt et al. 
2013). Taking this a step further, does Mstn play a role in the post-exercise 
production of IL6, following Furin dependant extracellular cleavage. In support of 
this idea, it has been previously shown that mice with a loss of function Mstn 
mutation display decreased IL6 levels (Wilkes, Lloyd et al. 2009). Thus, a study 
in Mstn null mice, comparing IL6 production post exercise to that of wild-type 
controls could be very telling, and may reveal an important physiological 
mechanism of Mstn function.  
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In terms of MSV function, these studies highlighted a likely role for MSV 
in the control of oxidative metabolism and, in the control of protein synthesis. 
Further studies would be required to define a role for MSV in this context. Thus 
this initial study in C2C12 mouse myoblasts would be well supported by data from 
an in vivo model of MSV over expression (which has been initiated in our lab). A 
role for MSV in supporting oxidative metabolism could be confirmed in this 
model, for example exposure to diets rich in oxidative fuel sources, such as a high 
fat diet could be used. If MSV does indeed influence oxidative metabolism there 
should be clear differences in the physiological response to a high fat diet, with 
parameters such as fat deposition and skeletal muscle growth likely to be 
influenced. Finally further studies investigating the interaction between Mstn and 
MSV would be valuable, the current data support the postulate that these 
molecules signal through common as well potentially independent pathways (see 
Figure 7.1). Thus, studies in vitro or in vivo that further define their specific roles, 
for example, in the context of Na+-K+-ATPase function, the regulation of protein 
synthesis and in the control intermediary metabolism would give valuable 
information on the specific physiological function of these two Mstn transcripts 
In conclusion, the studies presented in this thesis further define the effect 
of MSV on signal transduction mechanisms that have major roles in myogenesis. 
In conjunction with the studies on Mstn signalling, they highlight specific 
signalling pathways that these molecules target and identify common targets with 
important roles in myogenesis and cellular metabolism. Furthermore, they 
establish that signalling through AKT is likely to represent a major point of 
divergence in the function and signalling of Mstn and MSV. Taking this further, it 
is interesting to speculate that MSV has evolved to permit increased growth in 
metabolic systems that rely on fatty acids derived from the fermentation of forage 
as a primary fuel source. These studies also show that in ovine myoblasts, some of 
the early signalling events induced by Mstn can differ from those imposed by 
long-term treatment or the over-expression of Mstn. In addition, these studies 
identified the β1 subunit of the Na+ K+ ATPase as a novel downstream 
transcriptional target of canonical Mstn signalling. Thus, these data extend the 
current knowledge on Mstn and MSV signalling, further highlighting the 
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conserved nature of Mstn function in ovine myoblasts and demonstrating that 
Mstn and MSV share common signalling targets to convey their distinct functions.  
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Appendix I 
 
Development of a 96 well, MF20 (Myosin Heavy Chain) fluorescence assay to 
assess the differentiation of myoblasts. 
Traditional methods for assessing the differentiation of myoblasts involve 
the immuno-histochemical staining of differentiated myotubes with antibodies 
that recognise a differentiation marker such as myosin heavy. The MF20 antibody 
provides a good example as it detects all forms of sarcomeric myosin (Bader, 
Masaki et al. 1982). A counter-stain such as haematoxylin is then used to allow 
the identification and quantification of nuclei. This method allows parameters 
such as the fusion index to be calculated through counting nuclei within myotubes 
and dividing this value by the total number of nuclei present, giving a percentage 
of the nuclei incorporated into myotubes as a fusion index. Thus, taking advantage 
of the fact that nuclei and myotubes can be stained using different fluorescent 
compounds, a fluorescence assay was established to track nuclei fluorescence 
with the 4',6-diamidino-2-phenylindole (DAPI; Life Technologies) nuclei stain, 
and MF20 immuno-fluorescence using the Alexa Fluor 488 fluorophore over a 
differentiation time course. The protocol for staining is described in materials and 
methods (2.2.22). 
Initially, confirmation that the fluorescence of the DAPI stain was 
proportional to the number of cell nuclei present. This was performed by seeding 
C2C12 myoblasts at different densities (from 0 (background) to 100000 cells per 
well) in 96 well Optilux™ (BD) plates (n=8 for each cell density). Following 
overnight attachment DAPI stain (1µg/mL in PBS) was used to stain nuclei and 
the fluorescence measured (excitation 360nm, emission 460nm) using a 
Synergy™ 2 multi-detection micro-plate reader and Gen5 software (BioTek 
Instruments). As shown below fluorescence measurements correlated well with 
the nuclei abundance, with readings reaching a plateau at about 75000 cells per 
well. 
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Following confirmation that relative abundance of nuclei could be 
quantified using this method, the MF20 immuno-staining protocol was 
standardised. This was done using a titration of the MF20 primary antibody to 
establish that the fluorescence measurements obtained using this assay were a 
result of specific antibody binding, with n=8 for each antibody dilution. Immuno-
staining was performed on C2C12 myoblasts that had been differentiated for 96 h. 
Bound MF20 antibody was detected using anti-mouse Alexa Flour 488 conjugate 
(Life Technologies) and fluorescence was measured with an excitation at 485nm 
and emission at 528nm. Shown below are the data for the MF20 antibody. The 
negative controls used were: no primary antibody (i.e. secondary only) or a non 
specific mouse IgG primary antibody (primary –ve). For subsequent experiments, 
the background values using the primary IgG negative control were subtracted 
from the MF20 fluorescent values.     
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This result gave me confidence that the fluorescence measurements 
obtained following MF20 immuno-staining were a direct result of the proportion 
of myosin heavy chains, with the 1:200 dilution was used for all further 
fluorescent assays. In addition, DAPI values were reasonably consistent across the 
titration range, consistent with the equal number of cells seeded per well.  
Although data obtained from this assay cannot be used to calculate an 
exact fusion index, the parameters could be used to indicate the extent of 
differentiation between cultures using the ratio of MF20:DAPI fluorescence. The 
reasoning here, is that as myoblasts progress through differentiation, cells exit 
from the cell cycle and the expression of myosin heavy chain increases as the 
myoblasts continue to fuse and differentiate. Thus, the ratio of myosin heavy 
chain to the amount of nuclei will increase as differentiation progresses, and 
differences in the extent of fusion would be indicated by alterations in this ratio. 
To confirm that this is indeed the case, C2C12 myoblasts were differentiated in the 
presence or absence of 3µg/mL of recombinant Mstn for 96 h (n=8 for each 
treatment).  Previous studies in our laboratory have shown that treatment of C2C12 
myoblasts with Mstn reduces the amount of fusion during myoblast differentiation 
(Langley, Thomas et al. 2002). As shown below, treatment with Mstn resulted in 
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reduced MF20 and DAPI fluorescence, consistent with Mstn inhibiting both the 
proliferation and differentiation of C2C12 myoblasts (Thomas, Langley et al. 2000; 
Langley, Thomas et al. 2002).  
Furthermore, consistent with reduced fusion of C2C12 myoblasts in the 
presence of Mstn the ratio of MF20:DAPI was decreased following Mstn 
treatment (shown below), demonstrating that this ratio in indicative of the amount 
of fusion occurring in differentiating myoblast cultures. 
Although the fluorescence measurements described here do not provide an 
actual fusion index, this method allows the high throughput screening of multiple 
cell types or treatments in a 96 well format. In addition, if the MF20:DAPI ratio 
indicates differences in the fusion between cell types or treatments, microscope 
images with good contrast (as shown in Figure 6.5) can be captured to allow the 
manual calculation  of the fusion index.   
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